date generated: 2020-09-10
Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch
Here is the first few lines of the input profile.
## x
## A1BG 2.6192564
## A1BG-AS1 0.5230655
## A1CF 0.5526173
## A2M -3.3389616
## A2M-AS1 -3.1580711
## A2ML1 -0.3535245
Here are some metrics about the input data profile:
| Profile metrics | |
|---|---|
| num_genesets | 2400 |
| num_genes_in_profile | 21907 |
| duplicated_genes_present | 0 |
| num_profile_genes_in_sets | 8459 |
| num_profile_genes_not_in_sets | 13448 |
Here is a plot of the input profiles. Note the dynamic ranges.
Here is the contour plot of the profile including all detected genes.
Here are some metrics about the gene sets used: GMT file of genesets: ReactomePathways.gmt
| Gene sets metrics | |
|---|---|
| num_genesets | 2400 |
| num_genesets_excluded | 1036 |
| num_genesets_included | 1364 |
Significance is calculated by -log10(p-value). All points shown are FDR<0.05.
Top N= 100 gene sets
| set | setSize | pANOVA | s.dist | p.adjustANOVA |
|---|---|---|---|---|
| IRAK4 deficiency (TLR2/4) | 10 | 8.37e-07 | 0.899 | 1.05e-05 |
| MyD88 deficiency (TLR2/4) | 10 | 8.37e-07 | 0.899 | 1.05e-05 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | 12 | 2.46e-06 | 0.785 | 2.62e-05 |
| alpha-linolenic acid (ALA) metabolism | 12 | 2.46e-06 | 0.785 | 2.62e-05 |
| Regulation of TLR by endogenous ligand | 11 | 1.93e-05 | 0.744 | 1.45e-04 |
| Translocation of ZAP-70 to Immunological synapse | 24 | 2.81e-10 | -0.744 | 8.52e-09 |
| Hyaluronan uptake and degradation | 12 | 8.85e-06 | 0.741 | 7.23e-05 |
| Uptake and function of anthrax toxins | 10 | 1.14e-04 | 0.705 | 6.51e-04 |
| Erythrocytes take up carbon dioxide and release oxygen | 11 | 9.46e-05 | 0.680 | 5.53e-04 |
| O2/CO2 exchange in erythrocytes | 11 | 9.46e-05 | 0.680 | 5.53e-04 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | 11 | 1.17e-04 | 0.671 | 6.57e-04 |
| p130Cas linkage to MAPK signaling for integrins | 11 | 1.32e-04 | 0.665 | 7.21e-04 |
| Advanced glycosylation endproduct receptor signaling | 12 | 9.48e-05 | 0.651 | 5.53e-04 |
| Unwinding of DNA | 12 | 1.32e-04 | -0.637 | 7.21e-04 |
| RNA Polymerase I Promoter Opening | 19 | 3.29e-06 | 0.616 | 3.27e-05 |
| RHO GTPases Activate WASPs and WAVEs | 35 | 4.57e-10 | 0.609 | 1.33e-08 |
| ROS and RNS production in phagocytes | 31 | 8.23e-09 | 0.598 | 1.75e-07 |
| Neutrophil degranulation | 458 | 0.00e+00 | 0.586 | 2.00e-100 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | 12 | 4.97e-04 | 0.580 | 2.28e-03 |
| PD-1 signaling | 28 | 1.11e-07 | -0.579 | 1.87e-06 |
| Insulin receptor recycling | 21 | 6.43e-06 | 0.569 | 5.69e-05 |
| Dissolution of Fibrin Clot | 12 | 6.70e-04 | 0.567 | 2.92e-03 |
| Retrograde neurotrophin signalling | 12 | 6.74e-04 | 0.567 | 2.93e-03 |
| Signaling by Leptin | 10 | 1.97e-03 | 0.565 | 7.06e-03 |
| COPI-independent Golgi-to-ER retrograde traffic | 33 | 2.11e-08 | 0.563 | 4.30e-07 |
| Detoxification of Reactive Oxygen Species | 32 | 3.64e-08 | 0.562 | 6.98e-07 |
| RHO GTPases Activate NADPH Oxidases | 21 | 9.01e-06 | 0.560 | 7.32e-05 |
| PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases | 13 | 5.15e-04 | 0.556 | 2.35e-03 |
| Platelet sensitization by LDL | 16 | 1.28e-04 | 0.553 | 7.07e-04 |
| Hyaluronan metabolism | 15 | 2.20e-04 | 0.551 | 1.13e-03 |
| Golgi Cisternae Pericentriolar Stack Reorganization | 14 | 3.65e-04 | 0.550 | 1.76e-03 |
| RHO GTPases Activate ROCKs | 18 | 6.85e-05 | 0.542 | 4.23e-04 |
| Phosphorylation of CD3 and TCR zeta chains | 27 | 1.38e-06 | -0.537 | 1.62e-05 |
| Diseases associated with the TLR signaling cascade | 23 | 8.79e-06 | 0.535 | 7.22e-05 |
| Diseases of Immune System | 23 | 8.79e-06 | 0.535 | 7.22e-05 |
| IRAK1 recruits IKK complex | 10 | 3.46e-03 | 0.534 | 1.14e-02 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | 10 | 3.46e-03 | 0.534 | 1.14e-02 |
| MET activates RAP1 and RAC1 | 10 | 3.66e-03 | 0.531 | 1.18e-02 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | 10 | 3.85e-03 | 0.528 | 1.23e-02 |
| Negative regulation of MET activity | 18 | 1.11e-04 | 0.526 | 6.38e-04 |
| Budding and maturation of HIV virion | 26 | 3.45e-06 | 0.526 | 3.41e-05 |
| InlB-mediated entry of Listeria monocytogenes into host cell | 12 | 1.61e-03 | 0.526 | 6.06e-03 |
| DNA strand elongation | 32 | 3.21e-07 | -0.522 | 4.91e-06 |
| Cargo concentration in the ER | 30 | 7.76e-07 | 0.521 | 1.03e-05 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | 29 | 1.25e-06 | 0.520 | 1.49e-05 |
| DNA methylation | 20 | 6.16e-05 | 0.517 | 3.85e-04 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | 21 | 4.10e-05 | 0.517 | 2.74e-04 |
| Neurodegenerative Diseases | 21 | 4.10e-05 | 0.517 | 2.74e-04 |
| MAP2K and MAPK activation | 34 | 1.81e-07 | 0.517 | 2.91e-06 |
| VLDLR internalisation and degradation | 12 | 2.16e-03 | 0.511 | 7.58e-03 |
| Transferrin endocytosis and recycling | 26 | 6.92e-06 | 0.509 | 5.97e-05 |
| EPHB-mediated forward signaling | 32 | 7.98e-07 | 0.504 | 1.03e-05 |
| Gap junction trafficking | 14 | 1.16e-03 | 0.501 | 4.59e-03 |
| Platelet Adhesion to exposed collagen | 13 | 1.76e-03 | 0.501 | 6.50e-03 |
| Signaling by high-kinase activity BRAF mutants | 31 | 1.54e-06 | 0.499 | 1.77e-05 |
| Smooth Muscle Contraction | 31 | 1.87e-06 | 0.495 | 2.09e-05 |
| Pentose phosphate pathway | 13 | 2.26e-03 | 0.489 | 7.93e-03 |
| RHO GTPases activate PAKs | 20 | 1.70e-04 | 0.486 | 8.94e-04 |
| RHO GTPases activate PKNs | 48 | 6.95e-09 | 0.483 | 1.56e-07 |
| Amyloid fiber formation | 51 | 2.44e-09 | 0.483 | 5.64e-08 |
| Activation of the pre-replicative complex | 32 | 2.43e-06 | -0.481 | 2.62e-05 |
| SHC1 events in EGFR signaling | 12 | 3.92e-03 | 0.481 | 1.25e-02 |
| Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | 12 | 4.12e-03 | 0.478 | 1.30e-02 |
| Diseases of hemostasis | 12 | 4.12e-03 | 0.478 | 1.30e-02 |
| GRB2 events in EGFR signaling | 11 | 6.02e-03 | 0.478 | 1.77e-02 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | 11 | 6.19e-03 | 0.477 | 1.81e-02 |
| Platelet Aggregation (Plug Formation) | 28 | 1.27e-05 | 0.477 | 1.00e-04 |
| Spry regulation of FGF signaling | 16 | 9.96e-04 | 0.475 | 4.06e-03 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | 22 | 1.29e-04 | 0.472 | 7.07e-04 |
| Signaling by RAF1 mutants | 34 | 1.94e-06 | 0.472 | 2.16e-05 |
| Josephin domain DUBs | 10 | 9.89e-03 | 0.471 | 2.61e-02 |
| GAB1 signalosome | 15 | 1.59e-03 | 0.471 | 5.97e-03 |
| Trafficking of GluR2-containing AMPA receptors | 12 | 4.79e-03 | 0.470 | 1.47e-02 |
| Generation of second messenger molecules | 38 | 7.20e-07 | -0.464 | 9.72e-06 |
| EGFR downregulation | 27 | 3.34e-05 | 0.461 | 2.28e-04 |
| Response of Mtb to phagocytosis | 22 | 1.91e-04 | 0.459 | 9.85e-04 |
| Antimicrobial peptides | 33 | 4.93e-06 | 0.459 | 4.51e-05 |
| Diseases of programmed cell death | 23 | 1.37e-04 | 0.459 | 7.35e-04 |
| The NLRP3 inflammasome | 15 | 2.13e-03 | 0.458 | 7.50e-03 |
| Integrin signaling | 22 | 2.08e-04 | 0.457 | 1.07e-03 |
| Response to elevated platelet cytosolic Ca2+ | 110 | 1.25e-16 | 0.457 | 1.22e-14 |
| activated TAK1 mediates p38 MAPK activation | 19 | 5.78e-04 | 0.456 | 2.59e-03 |
| Mucopolysaccharidoses | 11 | 8.83e-03 | 0.456 | 2.40e-02 |
| Platelet degranulation | 106 | 5.81e-16 | 0.455 | 5.29e-14 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | 15 | 2.30e-03 | 0.455 | 8.04e-03 |
| Lagging Strand Synthesis | 20 | 4.63e-04 | -0.452 | 2.15e-03 |
| Prolonged ERK activation events | 13 | 4.76e-03 | 0.452 | 1.47e-02 |
| Infection with Mycobacterium tuberculosis | 26 | 7.20e-05 | 0.450 | 4.42e-04 |
| WNT5A-dependent internalization of FZD4 | 13 | 5.02e-03 | 0.449 | 1.53e-02 |
| Packaging Of Telomere Ends | 20 | 5.17e-04 | 0.448 | 2.35e-03 |
| ATF6 (ATF6-alpha) activates chaperone genes | 10 | 1.44e-02 | 0.447 | 3.52e-02 |
| Membrane binding and targetting of GAG proteins | 13 | 5.40e-03 | 0.446 | 1.62e-02 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | 13 | 5.40e-03 | 0.446 | 1.62e-02 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | 24 | 1.57e-04 | -0.446 | 8.36e-04 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | 11 | 1.09e-02 | 0.443 | 2.79e-02 |
| Signal amplification | 28 | 5.41e-05 | 0.441 | 3.46e-04 |
| Biotin transport and metabolism | 11 | 1.16e-02 | -0.440 | 2.91e-02 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | 92 | 3.03e-13 | 0.440 | 1.53e-11 |
| Toll Like Receptor 2 (TLR2) Cascade | 92 | 3.03e-13 | 0.440 | 1.53e-11 |
| Toll Like Receptor TLR1:TLR2 Cascade | 92 | 3.03e-13 | 0.440 | 1.53e-11 |
| set | setSize | pANOVA | s.dist | p.adjustANOVA |
|---|---|---|---|---|
| IRAK4 deficiency (TLR2/4) | 10 | 8.37e-07 | 8.99e-01 | 1.05e-05 |
| MyD88 deficiency (TLR2/4) | 10 | 8.37e-07 | 8.99e-01 | 1.05e-05 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | 12 | 2.46e-06 | 7.85e-01 | 2.62e-05 |
| alpha-linolenic acid (ALA) metabolism | 12 | 2.46e-06 | 7.85e-01 | 2.62e-05 |
| Regulation of TLR by endogenous ligand | 11 | 1.93e-05 | 7.44e-01 | 1.45e-04 |
| Translocation of ZAP-70 to Immunological synapse | 24 | 2.81e-10 | -7.44e-01 | 8.52e-09 |
| Hyaluronan uptake and degradation | 12 | 8.85e-06 | 7.41e-01 | 7.23e-05 |
| Uptake and function of anthrax toxins | 10 | 1.14e-04 | 7.05e-01 | 6.51e-04 |
| Erythrocytes take up carbon dioxide and release oxygen | 11 | 9.46e-05 | 6.80e-01 | 5.53e-04 |
| O2/CO2 exchange in erythrocytes | 11 | 9.46e-05 | 6.80e-01 | 5.53e-04 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | 11 | 1.17e-04 | 6.71e-01 | 6.57e-04 |
| p130Cas linkage to MAPK signaling for integrins | 11 | 1.32e-04 | 6.65e-01 | 7.21e-04 |
| Advanced glycosylation endproduct receptor signaling | 12 | 9.48e-05 | 6.51e-01 | 5.53e-04 |
| Unwinding of DNA | 12 | 1.32e-04 | -6.37e-01 | 7.21e-04 |
| RNA Polymerase I Promoter Opening | 19 | 3.29e-06 | 6.16e-01 | 3.27e-05 |
| RHO GTPases Activate WASPs and WAVEs | 35 | 4.57e-10 | 6.09e-01 | 1.33e-08 |
| ROS and RNS production in phagocytes | 31 | 8.23e-09 | 5.98e-01 | 1.75e-07 |
| Neutrophil degranulation | 458 | 0.00e+00 | 5.86e-01 | 2.00e-100 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | 12 | 4.97e-04 | 5.80e-01 | 2.28e-03 |
| PD-1 signaling | 28 | 1.11e-07 | -5.79e-01 | 1.87e-06 |
| Insulin receptor recycling | 21 | 6.43e-06 | 5.69e-01 | 5.69e-05 |
| Dissolution of Fibrin Clot | 12 | 6.70e-04 | 5.67e-01 | 2.92e-03 |
| Retrograde neurotrophin signalling | 12 | 6.74e-04 | 5.67e-01 | 2.93e-03 |
| Signaling by Leptin | 10 | 1.97e-03 | 5.65e-01 | 7.06e-03 |
| COPI-independent Golgi-to-ER retrograde traffic | 33 | 2.11e-08 | 5.63e-01 | 4.30e-07 |
| Detoxification of Reactive Oxygen Species | 32 | 3.64e-08 | 5.62e-01 | 6.98e-07 |
| RHO GTPases Activate NADPH Oxidases | 21 | 9.01e-06 | 5.60e-01 | 7.32e-05 |
| PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases | 13 | 5.15e-04 | 5.56e-01 | 2.35e-03 |
| Platelet sensitization by LDL | 16 | 1.28e-04 | 5.53e-01 | 7.07e-04 |
| Hyaluronan metabolism | 15 | 2.20e-04 | 5.51e-01 | 1.13e-03 |
| Golgi Cisternae Pericentriolar Stack Reorganization | 14 | 3.65e-04 | 5.50e-01 | 1.76e-03 |
| RHO GTPases Activate ROCKs | 18 | 6.85e-05 | 5.42e-01 | 4.23e-04 |
| Phosphorylation of CD3 and TCR zeta chains | 27 | 1.38e-06 | -5.37e-01 | 1.62e-05 |
| Diseases associated with the TLR signaling cascade | 23 | 8.79e-06 | 5.35e-01 | 7.22e-05 |
| Diseases of Immune System | 23 | 8.79e-06 | 5.35e-01 | 7.22e-05 |
| IRAK1 recruits IKK complex | 10 | 3.46e-03 | 5.34e-01 | 1.14e-02 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | 10 | 3.46e-03 | 5.34e-01 | 1.14e-02 |
| MET activates RAP1 and RAC1 | 10 | 3.66e-03 | 5.31e-01 | 1.18e-02 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | 10 | 3.85e-03 | 5.28e-01 | 1.23e-02 |
| Negative regulation of MET activity | 18 | 1.11e-04 | 5.26e-01 | 6.38e-04 |
| Budding and maturation of HIV virion | 26 | 3.45e-06 | 5.26e-01 | 3.41e-05 |
| InlB-mediated entry of Listeria monocytogenes into host cell | 12 | 1.61e-03 | 5.26e-01 | 6.06e-03 |
| DNA strand elongation | 32 | 3.21e-07 | -5.22e-01 | 4.91e-06 |
| Cargo concentration in the ER | 30 | 7.76e-07 | 5.21e-01 | 1.03e-05 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | 29 | 1.25e-06 | 5.20e-01 | 1.49e-05 |
| DNA methylation | 20 | 6.16e-05 | 5.17e-01 | 3.85e-04 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | 21 | 4.10e-05 | 5.17e-01 | 2.74e-04 |
| Neurodegenerative Diseases | 21 | 4.10e-05 | 5.17e-01 | 2.74e-04 |
| MAP2K and MAPK activation | 34 | 1.81e-07 | 5.17e-01 | 2.91e-06 |
| VLDLR internalisation and degradation | 12 | 2.16e-03 | 5.11e-01 | 7.58e-03 |
| Transferrin endocytosis and recycling | 26 | 6.92e-06 | 5.09e-01 | 5.97e-05 |
| EPHB-mediated forward signaling | 32 | 7.98e-07 | 5.04e-01 | 1.03e-05 |
| Gap junction trafficking | 14 | 1.16e-03 | 5.01e-01 | 4.59e-03 |
| Platelet Adhesion to exposed collagen | 13 | 1.76e-03 | 5.01e-01 | 6.50e-03 |
| Signaling by high-kinase activity BRAF mutants | 31 | 1.54e-06 | 4.99e-01 | 1.77e-05 |
| Smooth Muscle Contraction | 31 | 1.87e-06 | 4.95e-01 | 2.09e-05 |
| Pentose phosphate pathway | 13 | 2.26e-03 | 4.89e-01 | 7.93e-03 |
| RHO GTPases activate PAKs | 20 | 1.70e-04 | 4.86e-01 | 8.94e-04 |
| RHO GTPases activate PKNs | 48 | 6.95e-09 | 4.83e-01 | 1.56e-07 |
| Amyloid fiber formation | 51 | 2.44e-09 | 4.83e-01 | 5.64e-08 |
| Activation of the pre-replicative complex | 32 | 2.43e-06 | -4.81e-01 | 2.62e-05 |
| SHC1 events in EGFR signaling | 12 | 3.92e-03 | 4.81e-01 | 1.25e-02 |
| Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | 12 | 4.12e-03 | 4.78e-01 | 1.30e-02 |
| Diseases of hemostasis | 12 | 4.12e-03 | 4.78e-01 | 1.30e-02 |
| GRB2 events in EGFR signaling | 11 | 6.02e-03 | 4.78e-01 | 1.77e-02 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | 11 | 6.19e-03 | 4.77e-01 | 1.81e-02 |
| Platelet Aggregation (Plug Formation) | 28 | 1.27e-05 | 4.77e-01 | 1.00e-04 |
| Spry regulation of FGF signaling | 16 | 9.96e-04 | 4.75e-01 | 4.06e-03 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | 22 | 1.29e-04 | 4.72e-01 | 7.07e-04 |
| Signaling by RAF1 mutants | 34 | 1.94e-06 | 4.72e-01 | 2.16e-05 |
| Josephin domain DUBs | 10 | 9.89e-03 | 4.71e-01 | 2.61e-02 |
| GAB1 signalosome | 15 | 1.59e-03 | 4.71e-01 | 5.97e-03 |
| Trafficking of GluR2-containing AMPA receptors | 12 | 4.79e-03 | 4.70e-01 | 1.47e-02 |
| Generation of second messenger molecules | 38 | 7.20e-07 | -4.64e-01 | 9.72e-06 |
| EGFR downregulation | 27 | 3.34e-05 | 4.61e-01 | 2.28e-04 |
| Response of Mtb to phagocytosis | 22 | 1.91e-04 | 4.59e-01 | 9.85e-04 |
| Antimicrobial peptides | 33 | 4.93e-06 | 4.59e-01 | 4.51e-05 |
| Diseases of programmed cell death | 23 | 1.37e-04 | 4.59e-01 | 7.35e-04 |
| The NLRP3 inflammasome | 15 | 2.13e-03 | 4.58e-01 | 7.50e-03 |
| Integrin signaling | 22 | 2.08e-04 | 4.57e-01 | 1.07e-03 |
| Response to elevated platelet cytosolic Ca2+ | 110 | 1.25e-16 | 4.57e-01 | 1.22e-14 |
| activated TAK1 mediates p38 MAPK activation | 19 | 5.78e-04 | 4.56e-01 | 2.59e-03 |
| Mucopolysaccharidoses | 11 | 8.83e-03 | 4.56e-01 | 2.40e-02 |
| Platelet degranulation | 106 | 5.81e-16 | 4.55e-01 | 5.29e-14 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | 15 | 2.30e-03 | 4.55e-01 | 8.04e-03 |
| Lagging Strand Synthesis | 20 | 4.63e-04 | -4.52e-01 | 2.15e-03 |
| Prolonged ERK activation events | 13 | 4.76e-03 | 4.52e-01 | 1.47e-02 |
| Infection with Mycobacterium tuberculosis | 26 | 7.20e-05 | 4.50e-01 | 4.42e-04 |
| WNT5A-dependent internalization of FZD4 | 13 | 5.02e-03 | 4.49e-01 | 1.53e-02 |
| Packaging Of Telomere Ends | 20 | 5.17e-04 | 4.48e-01 | 2.35e-03 |
| ATF6 (ATF6-alpha) activates chaperone genes | 10 | 1.44e-02 | 4.47e-01 | 3.52e-02 |
| Membrane binding and targetting of GAG proteins | 13 | 5.40e-03 | 4.46e-01 | 1.62e-02 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | 13 | 5.40e-03 | 4.46e-01 | 1.62e-02 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | 24 | 1.57e-04 | -4.46e-01 | 8.36e-04 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | 11 | 1.09e-02 | 4.43e-01 | 2.79e-02 |
| Signal amplification | 28 | 5.41e-05 | 4.41e-01 | 3.46e-04 |
| Biotin transport and metabolism | 11 | 1.16e-02 | -4.40e-01 | 2.91e-02 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | 92 | 3.03e-13 | 4.40e-01 | 1.53e-11 |
| Toll Like Receptor 2 (TLR2) Cascade | 92 | 3.03e-13 | 4.40e-01 | 1.53e-11 |
| Toll Like Receptor TLR1:TLR2 Cascade | 92 | 3.03e-13 | 4.40e-01 | 1.53e-11 |
| Toll Like Receptor TLR6:TLR2 Cascade | 92 | 3.03e-13 | 4.40e-01 | 1.53e-11 |
| Signal transduction by L1 | 20 | 6.81e-04 | 4.39e-01 | 2.95e-03 |
| Suppression of phagosomal maturation | 12 | 8.51e-03 | 4.39e-01 | 2.33e-02 |
| Alpha-protein kinase 1 signaling pathway | 11 | 1.19e-02 | 4.38e-01 | 2.99e-02 |
| RHO GTPases activate IQGAPs | 11 | 1.26e-02 | 4.34e-01 | 3.13e-02 |
| ERKs are inactivated | 13 | 6.71e-03 | 4.34e-01 | 1.93e-02 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | 38 | 3.90e-06 | 4.33e-01 | 3.64e-05 |
| Signaling by RAS mutants | 38 | 3.90e-06 | 4.33e-01 | 3.64e-05 |
| Signaling by moderate kinase activity BRAF mutants | 38 | 3.90e-06 | 4.33e-01 | 3.64e-05 |
| Signaling downstream of RAS mutants | 38 | 3.90e-06 | 4.33e-01 | 3.64e-05 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | 25 | 1.86e-04 | 4.32e-01 | 9.67e-04 |
| Processive synthesis on the lagging strand | 15 | 3.88e-03 | -4.31e-01 | 1.24e-02 |
| HDR through MMEJ (alt-NHEJ) | 10 | 1.89e-02 | -4.29e-01 | 4.36e-02 |
| AKT phosphorylates targets in the cytosol | 14 | 5.54e-03 | 4.28e-01 | 1.65e-02 |
| Formation of ATP by chemiosmotic coupling | 18 | 1.67e-03 | 4.28e-01 | 6.24e-03 |
| Recycling pathway of L1 | 26 | 1.68e-04 | 4.26e-01 | 8.84e-04 |
| Erythropoietin activates RAS | 13 | 8.13e-03 | 4.24e-01 | 2.26e-02 |
| Late endosomal microautophagy | 30 | 6.00e-05 | 4.23e-01 | 3.79e-04 |
| Butyrophilin (BTN) family interactions | 10 | 2.05e-02 | -4.23e-01 | 4.67e-02 |
| Activation of ATR in response to replication stress | 37 | 8.43e-06 | -4.23e-01 | 7.05e-05 |
| Interleukin-1 signaling | 98 | 5.37e-13 | 4.22e-01 | 2.44e-11 |
| Growth hormone receptor signaling | 20 | 1.10e-03 | 4.21e-01 | 4.42e-03 |
| PCNA-Dependent Long Patch Base Excision Repair | 21 | 8.48e-04 | -4.21e-01 | 3.59e-03 |
| Transcriptional regulation of granulopoiesis | 46 | 8.63e-07 | 4.19e-01 | 1.07e-05 |
| Assembly Of The HIV Virion | 15 | 5.09e-03 | 4.18e-01 | 1.55e-02 |
| Regulated proteolysis of p75NTR | 11 | 1.65e-02 | 4.18e-01 | 3.92e-02 |
| ATF6 (ATF6-alpha) activates chaperones | 12 | 1.23e-02 | 4.17e-01 | 3.07e-02 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | 88 | 1.49e-11 | 4.16e-01 | 5.49e-10 |
| Glycogen breakdown (glycogenolysis) | 13 | 1.01e-02 | 4.12e-01 | 2.64e-02 |
| Pre-NOTCH Processing in Golgi | 18 | 2.51e-03 | 4.11e-01 | 8.74e-03 |
| HuR (ELAVL1) binds and stabilizes mRNA | 10 | 2.45e-02 | 4.11e-01 | 5.46e-02 |
| SUMOylation of immune response proteins | 11 | 1.84e-02 | 4.11e-01 | 4.26e-02 |
| Gastrin-CREB signalling pathway via PKC and MAPK | 14 | 7.84e-03 | 4.10e-01 | 2.20e-02 |
| ERK/MAPK targets | 22 | 8.93e-04 | 4.09e-01 | 3.72e-03 |
| Notch-HLH transcription pathway | 28 | 1.86e-04 | 4.08e-01 | 9.66e-04 |
| Signal regulatory protein family interactions | 12 | 1.44e-02 | 4.08e-01 | 3.51e-02 |
| ADP signalling through P2Y purinoceptor 1 | 21 | 1.25e-03 | 4.07e-01 | 4.82e-03 |
| Lysosome Vesicle Biogenesis | 32 | 7.32e-05 | 4.05e-01 | 4.48e-04 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) | 36 | 2.62e-05 | 4.05e-01 | 1.85e-04 |
| Glycogen synthesis | 13 | 1.16e-02 | 4.04e-01 | 2.91e-02 |
| MyD88 dependent cascade initiated on endosome | 89 | 4.41e-11 | 4.04e-01 | 1.43e-09 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | 89 | 4.41e-11 | 4.04e-01 | 1.43e-09 |
| Heme degradation | 10 | 2.73e-02 | 4.03e-01 | 5.99e-02 |
| DARPP-32 events | 22 | 1.08e-03 | 4.02e-01 | 4.35e-03 |
| Signalling to ERKs | 32 | 8.47e-05 | 4.01e-01 | 5.02e-04 |
| Interleukin-6 signaling | 10 | 2.81e-02 | 4.01e-01 | 6.13e-02 |
| Inflammasomes | 20 | 1.92e-03 | 4.01e-01 | 6.91e-03 |
| Toll Like Receptor 4 (TLR4) Cascade | 121 | 3.21e-14 | 3.99e-01 | 2.08e-12 |
| Removal of the Flap Intermediate | 14 | 9.82e-03 | -3.99e-01 | 2.60e-02 |
| MyD88 cascade initiated on plasma membrane | 82 | 5.31e-10 | 3.97e-01 | 1.42e-08 |
| Toll Like Receptor 10 (TLR10) Cascade | 82 | 5.31e-10 | 3.97e-01 | 1.42e-08 |
| Toll Like Receptor 5 (TLR5) Cascade | 82 | 5.31e-10 | 3.97e-01 | 1.42e-08 |
| rRNA modification in the nucleus and cytosol | 59 | 1.39e-07 | -3.96e-01 | 2.32e-06 |
| Regulation of IFNG signaling | 14 | 1.04e-02 | 3.96e-01 | 2.71e-02 |
| Collagen degradation | 28 | 3.05e-04 | 3.94e-01 | 1.50e-03 |
| COPI-mediated anterograde transport | 78 | 1.90e-09 | 3.93e-01 | 4.80e-08 |
| Antigen processing-Cross presentation | 98 | 1.88e-11 | 3.92e-01 | 6.58e-10 |
| Metabolism of Angiotensinogen to Angiotensins | 11 | 2.43e-02 | 3.92e-01 | 5.41e-02 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | 30 | 2.11e-04 | 3.91e-01 | 1.08e-03 |
| Signaling by BRAF and RAF fusions | 57 | 3.30e-07 | 3.91e-01 | 4.98e-06 |
| RHO GTPases activate KTN1 | 11 | 2.49e-02 | 3.91e-01 | 5.51e-02 |
| Activation of the AP-1 family of transcription factors | 10 | 3.25e-02 | 3.90e-01 | 6.90e-02 |
| COPII-mediated vesicle transport | 65 | 5.29e-08 | 3.90e-01 | 9.67e-07 |
| Toll Like Receptor 9 (TLR9) Cascade | 93 | 7.92e-11 | 3.90e-01 | 2.51e-09 |
| EPH-Ephrin signaling | 79 | 2.31e-09 | 3.89e-01 | 5.44e-08 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | 12 | 1.98e-02 | 3.88e-01 | 4.55e-02 |
| Energy dependent regulation of mTOR by LKB1-AMPK | 27 | 5.03e-04 | 3.87e-01 | 2.30e-03 |
| Telomere C-strand (Lagging Strand) Synthesis | 34 | 9.64e-05 | -3.86e-01 | 5.59e-04 |
| Formation of apoptosome | 11 | 2.75e-02 | 3.84e-01 | 6.00e-02 |
| Regulation of the apoptosome activity | 11 | 2.75e-02 | 3.84e-01 | 6.00e-02 |
| Toll-like Receptor Cascades | 143 | 2.29e-15 | 3.84e-01 | 1.96e-13 |
| LDL clearance | 18 | 5.19e-03 | 3.81e-01 | 1.57e-02 |
| Sema4D in semaphorin signaling | 22 | 2.00e-03 | 3.80e-01 | 7.16e-03 |
| Apoptosis induced DNA fragmentation | 10 | 3.79e-02 | 3.79e-01 | 7.80e-02 |
| Cross-presentation of soluble exogenous antigens (endosomes) | 48 | 5.62e-06 | 3.79e-01 | 5.07e-05 |
| Frs2-mediated activation | 11 | 3.00e-02 | 3.78e-01 | 6.44e-02 |
| Signaling by Erythropoietin | 24 | 1.35e-03 | 3.78e-01 | 5.19e-03 |
| ADP signalling through P2Y purinoceptor 12 | 18 | 5.56e-03 | 3.77e-01 | 1.66e-02 |
| G-protein beta:gamma signalling | 29 | 4.44e-04 | 3.77e-01 | 2.07e-03 |
| Sema4D induced cell migration and growth-cone collapse | 19 | 4.48e-03 | 3.77e-01 | 1.40e-02 |
| Iron uptake and transport | 52 | 2.62e-06 | 3.77e-01 | 2.71e-05 |
| Cellular response to hypoxia | 72 | 3.43e-08 | 3.76e-01 | 6.69e-07 |
| Thromboxane signalling through TP receptor | 20 | 3.68e-03 | 3.75e-01 | 1.19e-02 |
| Formation of the cornified envelope | 21 | 3.06e-03 | 3.73e-01 | 1.02e-02 |
| mTORC1-mediated signalling | 23 | 1.96e-03 | 3.73e-01 | 7.04e-03 |
| ER to Golgi Anterograde Transport | 129 | 2.87e-13 | 3.72e-01 | 1.53e-11 |
| trans-Golgi Network Vesicle Budding | 69 | 9.29e-08 | 3.72e-01 | 1.60e-06 |
| Hh mutants that don't undergo autocatalytic processing are degraded by ERAD | 54 | 2.48e-06 | 3.70e-01 | 2.63e-05 |
| Signaling by NTRK1 (TRKA) | 101 | 1.31e-10 | 3.70e-01 | 4.06e-09 |
| RHO GTPases activate CIT | 18 | 6.61e-03 | 3.70e-01 | 1.92e-02 |
| Response of EIF2AK1 (HRI) to heme deficiency | 14 | 1.68e-02 | 3.69e-01 | 4.00e-02 |
| Gap junction trafficking and regulation | 16 | 1.08e-02 | 3.68e-01 | 2.76e-02 |
| Golgi Associated Vesicle Biogenesis | 55 | 2.33e-06 | 3.68e-01 | 2.55e-05 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | 22 | 2.81e-03 | 3.68e-01 | 9.50e-03 |
| Regulation of ornithine decarboxylase (ODC) | 50 | 6.72e-06 | 3.68e-01 | 5.88e-05 |
| Cell-extracellular matrix interactions | 14 | 1.73e-02 | 3.68e-01 | 4.07e-02 |
| MAP kinase activation | 63 | 4.52e-07 | 3.67e-01 | 6.43e-06 |
| Innate Immune System | 968 | 5.83e-84 | 3.67e-01 | 3.97e-81 |
| Signaling by MET | 61 | 7.13e-07 | 3.67e-01 | 9.72e-06 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | 16 | 1.11e-02 | 3.67e-01 | 2.83e-02 |
| Calnexin/calreticulin cycle | 26 | 1.22e-03 | 3.66e-01 | 4.75e-03 |
| RAF activation | 32 | 3.35e-04 | 3.66e-01 | 1.64e-03 |
| Signaling by NTRKs | 116 | 9.74e-12 | 3.66e-01 | 3.69e-10 |
| Diseases of DNA repair | 10 | 4.55e-02 | -3.65e-01 | 9.13e-02 |
| Beta-catenin phosphorylation cascade | 17 | 9.11e-03 | 3.65e-01 | 2.45e-02 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | 16 | 1.15e-02 | 3.65e-01 | 2.89e-02 |
| Leading Strand Synthesis | 14 | 1.83e-02 | -3.64e-01 | 4.26e-02 |
| Polymerase switching | 14 | 1.83e-02 | -3.64e-01 | 4.26e-02 |
| Platelet activation, signaling and aggregation | 221 | 1.35e-20 | 3.63e-01 | 2.05e-18 |
| Endogenous sterols | 17 | 1.00e-02 | 3.61e-01 | 2.64e-02 |
| Telomere C-strand synthesis initiation | 13 | 2.45e-02 | -3.60e-01 | 5.46e-02 |
| G beta:gamma signalling through CDC42 | 17 | 1.02e-02 | 3.60e-01 | 2.66e-02 |
| Cell recruitment (pro-inflammatory response) | 22 | 3.47e-03 | 3.60e-01 | 1.14e-02 |
| Purinergic signaling in leishmaniasis infection | 22 | 3.47e-03 | 3.60e-01 | 1.14e-02 |
| HDACs deacetylate histones | 47 | 2.04e-05 | 3.59e-01 | 1.51e-04 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | 49 | 1.37e-05 | 3.59e-01 | 1.05e-04 |
| Glycogen metabolism | 23 | 2.91e-03 | 3.59e-01 | 9.79e-03 |
| Clathrin-mediated endocytosis | 127 | 3.15e-12 | 3.58e-01 | 1.30e-10 |
| IKK complex recruitment mediated by RIP1 | 23 | 2.99e-03 | 3.58e-01 | 9.99e-03 |
| GP1b-IX-V activation signalling | 10 | 5.04e-02 | 3.57e-01 | 9.97e-02 |
| Pexophagy | 11 | 4.02e-02 | 3.57e-01 | 8.22e-02 |
| RAB geranylgeranylation | 61 | 1.46e-06 | 3.57e-01 | 1.68e-05 |
| MET activates RAS signaling | 10 | 5.12e-02 | 3.56e-01 | 1.01e-01 |
| Nucleobase biosynthesis | 13 | 2.64e-02 | -3.56e-01 | 5.82e-02 |
| MTOR signalling | 38 | 1.50e-04 | 3.55e-01 | 7.98e-04 |
| ER-Phagosome pathway | 83 | 2.17e-08 | 3.55e-01 | 4.35e-07 |
| Thrombin signalling through proteinase activated receptors (PARs) | 27 | 1.42e-03 | 3.55e-01 | 5.42e-03 |
| Post-translational protein phosphorylation | 70 | 2.94e-07 | 3.54e-01 | 4.61e-06 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | 65 | 8.07e-07 | 3.54e-01 | 1.03e-05 |
| Interleukin-1 family signaling | 125 | 8.55e-12 | 3.53e-01 | 3.33e-10 |
| Negative regulation of NOTCH4 signaling | 54 | 7.02e-06 | 3.53e-01 | 6.02e-05 |
| Fanconi Anemia Pathway | 36 | 2.43e-04 | -3.53e-01 | 1.23e-03 |
| Cleavage of the damaged purine | 24 | 2.75e-03 | 3.53e-01 | 9.32e-03 |
| Depurination | 24 | 2.75e-03 | 3.53e-01 | 9.32e-03 |
| Recognition and association of DNA glycosylase with site containing an affected purine | 24 | 2.75e-03 | 3.53e-01 | 9.32e-03 |
| Syndecan interactions | 19 | 7.70e-03 | 3.53e-01 | 2.16e-02 |
| Homologous DNA Pairing and Strand Exchange | 42 | 7.63e-05 | -3.53e-01 | 4.62e-04 |
| Pre-NOTCH Transcription and Translation | 49 | 1.95e-05 | 3.53e-01 | 1.46e-04 |
| Defective CFTR causes cystic fibrosis | 60 | 2.57e-06 | 3.51e-01 | 2.70e-05 |
| Hh mutants abrogate ligand secretion | 55 | 6.85e-06 | 3.51e-01 | 5.95e-05 |
| MAPK targets/ Nuclear events mediated by MAP kinases | 31 | 7.33e-04 | 3.50e-01 | 3.17e-03 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | 54 | 8.71e-06 | 3.50e-01 | 7.22e-05 |
| Pre-NOTCH Expression and Processing | 65 | 1.18e-06 | 3.48e-01 | 1.43e-05 |
| Resolution of Abasic Sites (AP sites) | 37 | 2.48e-04 | -3.48e-01 | 1.25e-03 |
| PKA activation in glucagon signalling | 14 | 2.47e-02 | 3.47e-01 | 5.48e-02 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | 83 | 5.32e-08 | 3.45e-01 | 9.67e-07 |
| Pyrimidine salvage | 10 | 5.91e-02 | 3.45e-01 | 1.13e-01 |
| Signaling by EGFR in Cancer | 23 | 4.22e-03 | 3.45e-01 | 1.33e-02 |
| Inhibition of DNA recombination at telomere | 35 | 4.21e-04 | 3.44e-01 | 1.98e-03 |
| Degradation of DVL | 55 | 1.03e-05 | 3.44e-01 | 8.33e-05 |
| Hedgehog ligand biogenesis | 59 | 5.69e-06 | 3.41e-01 | 5.10e-05 |
| G beta:gamma signalling through PLC beta | 17 | 1.48e-02 | 3.41e-01 | 3.60e-02 |
| Vif-mediated degradation of APOBEC3G | 53 | 1.73e-05 | 3.41e-01 | 1.31e-04 |
| Cytochrome c-mediated apoptotic response | 13 | 3.33e-02 | 3.41e-01 | 7.02e-02 |
| MyD88-independent TLR4 cascade | 96 | 7.99e-09 | 3.41e-01 | 1.73e-07 |
| TRIF(TICAM1)-mediated TLR4 signaling | 96 | 7.99e-09 | 3.41e-01 | 1.73e-07 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | 48 | 4.45e-05 | 3.41e-01 | 2.95e-04 |
| Regulation of Apoptosis | 52 | 2.18e-05 | 3.40e-01 | 1.60e-04 |
| Negative regulation of FGFR3 signaling | 20 | 8.81e-03 | 3.38e-01 | 2.40e-02 |
| TAK1 activates NFkB by phosphorylation and activation of IKKs complex | 27 | 2.38e-03 | 3.38e-01 | 8.29e-03 |
| Interleukin-17 signaling | 68 | 1.45e-06 | 3.38e-01 | 1.68e-05 |
| Common Pathway of Fibrin Clot Formation | 14 | 2.97e-02 | 3.36e-01 | 6.41e-02 |
| Signaling by EGFR | 46 | 8.37e-05 | 3.35e-01 | 4.99e-04 |
| Glucagon signaling in metabolic regulation | 27 | 2.63e-03 | 3.34e-01 | 9.00e-03 |
| Oncogenic MAPK signaling | 73 | 7.76e-07 | 3.34e-01 | 1.03e-05 |
| ER Quality Control Compartment (ERQC) | 21 | 7.99e-03 | 3.34e-01 | 2.22e-02 |
| Degradation of GLI2 by the proteasome | 57 | 1.28e-05 | 3.34e-01 | 1.00e-04 |
| Cargo recognition for clathrin-mediated endocytosis | 90 | 4.34e-08 | 3.34e-01 | 8.21e-07 |
| Diseases of carbohydrate metabolism | 29 | 1.86e-03 | 3.34e-01 | 6.81e-03 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | 53 | 2.62e-05 | 3.34e-01 | 1.85e-04 |
| Rev-mediated nuclear export of HIV RNA | 35 | 6.35e-04 | -3.34e-01 | 2.81e-03 |
| SHC1 events in ERBB4 signaling | 10 | 6.80e-02 | 3.33e-01 | 1.26e-01 |
| FOXO-mediated transcription of cell death genes | 16 | 2.16e-02 | 3.32e-01 | 4.89e-02 |
| Golgi-to-ER retrograde transport | 111 | 1.79e-09 | 3.30e-01 | 4.60e-08 |
| GPVI-mediated activation cascade | 31 | 1.48e-03 | 3.30e-01 | 5.64e-03 |
| Degradation of GLI1 by the proteasome | 58 | 1.42e-05 | 3.29e-01 | 1.08e-04 |
| Regulation of PTEN stability and activity | 67 | 3.28e-06 | 3.29e-01 | 3.27e-05 |
| Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | 51 | 4.97e-05 | 3.28e-01 | 3.23e-04 |
| p53-Independent DNA Damage Response | 51 | 4.97e-05 | 3.28e-01 | 3.23e-04 |
| p53-Independent G1/S DNA damage checkpoint | 51 | 4.97e-05 | 3.28e-01 | 3.23e-04 |
| Presynaptic phase of homologous DNA pairing and strand exchange | 39 | 4.00e-04 | -3.28e-01 | 1.89e-03 |
| G-protein activation | 23 | 6.68e-03 | 3.27e-01 | 1.93e-02 |
| Interactions of Rev with host cellular proteins | 37 | 5.97e-04 | -3.26e-01 | 2.65e-03 |
| VxPx cargo-targeting to cilium | 19 | 1.40e-02 | 3.25e-01 | 3.44e-02 |
| Vpu mediated degradation of CD4 | 51 | 6.08e-05 | 3.25e-01 | 3.82e-04 |
| NIK-->noncanonical NF-kB signaling | 58 | 1.99e-05 | 3.24e-01 | 1.47e-04 |
| RAB GEFs exchange GTP for GDP on RABs | 88 | 1.51e-07 | 3.24e-01 | 2.48e-06 |
| Synthesis of PC | 23 | 7.24e-03 | 3.23e-01 | 2.05e-02 |
| G beta:gamma signalling through BTK | 15 | 3.01e-02 | 3.23e-01 | 6.45e-02 |
| E3 ubiquitin ligases ubiquitinate target proteins | 52 | 5.50e-05 | 3.23e-01 | 3.51e-04 |
| Activation of Matrix Metalloproteinases | 23 | 7.33e-03 | 3.23e-01 | 2.08e-02 |
| Signaling by NOTCH4 | 79 | 6.95e-07 | 3.23e-01 | 9.57e-06 |
| Presynaptic function of Kainate receptors | 18 | 1.80e-02 | 3.22e-01 | 4.21e-02 |
| Nuclear Events (kinase and transcription factor activation) | 53 | 5.25e-05 | 3.21e-01 | 3.38e-04 |
| NEP/NS2 Interacts with the Cellular Export Machinery | 32 | 1.67e-03 | -3.21e-01 | 6.24e-03 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | 29 | 2.94e-03 | 3.19e-01 | 9.84e-03 |
| GLI3 is processed to GLI3R by the proteasome | 58 | 2.78e-05 | 3.18e-01 | 1.96e-04 |
| Protein ubiquitination | 72 | 3.07e-06 | 3.18e-01 | 3.14e-05 |
| Dectin-1 mediated noncanonical NF-kB signaling | 59 | 2.42e-05 | 3.18e-01 | 1.75e-04 |
| Triglyceride catabolism | 16 | 2.79e-02 | 3.17e-01 | 6.09e-02 |
| ERBB2 Regulates Cell Motility | 10 | 8.23e-02 | 3.17e-01 | 1.47e-01 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | 59 | 2.58e-05 | 3.17e-01 | 1.84e-04 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 80 | 9.74e-07 | 3.17e-01 | 1.19e-05 |
| Nucleotide salvage | 21 | 1.20e-02 | 3.17e-01 | 3.00e-02 |
| TNFR1-induced proapoptotic signaling | 12 | 5.78e-02 | -3.16e-01 | 1.11e-01 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | 35 | 1.23e-03 | 3.16e-01 | 4.77e-03 |
| Amino acids regulate mTORC1 | 50 | 1.16e-04 | 3.15e-01 | 6.56e-04 |
| Metabolism of polyamines | 58 | 3.35e-05 | 3.15e-01 | 2.28e-04 |
| Ubiquitin-dependent degradation of Cyclin D | 51 | 1.02e-04 | 3.15e-01 | 5.87e-04 |
| Apoptotic factor-mediated response | 18 | 2.10e-02 | 3.14e-01 | 4.77e-02 |
| Negative regulation of FGFR4 signaling | 21 | 1.27e-02 | 3.14e-01 | 3.15e-02 |
| Transport to the Golgi and subsequent modification | 155 | 1.60e-11 | 3.13e-01 | 5.73e-10 |
| RORA activates gene expression | 18 | 2.17e-02 | 3.12e-01 | 4.91e-02 |
| Metabolism of steroid hormones | 21 | 1.32e-02 | 3.12e-01 | 3.27e-02 |
| Metabolism of porphyrins | 22 | 1.15e-02 | 3.11e-01 | 2.90e-02 |
| Autophagy | 124 | 2.12e-09 | 3.11e-01 | 5.16e-08 |
| Activation of BAD and translocation to mitochondria | 15 | 3.69e-02 | 3.11e-01 | 7.60e-02 |
| Signaling by NOTCH | 183 | 3.84e-13 | 3.11e-01 | 1.81e-11 |
| Extension of Telomeres | 51 | 1.26e-04 | -3.10e-01 | 6.99e-04 |
| Mitochondrial tRNA aminoacylation | 21 | 1.39e-02 | -3.10e-01 | 3.40e-02 |
| Membrane Trafficking | 559 | 5.33e-36 | 3.09e-01 | 1.82e-33 |
| Vpr-mediated nuclear import of PICs | 34 | 1.87e-03 | -3.08e-01 | 6.81e-03 |
| Uptake and actions of bacterial toxins | 27 | 5.68e-03 | 3.07e-01 | 1.68e-02 |
| Regulation of RUNX3 expression and activity | 55 | 8.07e-05 | 3.07e-01 | 4.85e-04 |
| Effects of PIP2 hydrolysis | 24 | 9.24e-03 | -3.07e-01 | 2.48e-02 |
| ABC transporter disorders | 71 | 7.90e-06 | 3.07e-01 | 6.69e-05 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | 16 | 3.42e-02 | 3.06e-01 | 7.17e-02 |
| rRNA processing in the nucleus and cytosol | 190 | 3.58e-13 | -3.06e-01 | 1.75e-11 |
| Nuclear import of Rev protein | 34 | 2.04e-03 | -3.06e-01 | 7.25e-03 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | 14 | 4.78e-02 | -3.06e-01 | 9.53e-02 |
| VEGFA-VEGFR2 Pathway | 92 | 4.27e-07 | 3.05e-01 | 6.13e-06 |
| Major pathway of rRNA processing in the nucleolus and cytosol | 180 | 1.68e-12 | -3.05e-01 | 7.17e-11 |
| NS1 Mediated Effects on Host Pathways | 40 | 8.53e-04 | -3.05e-01 | 3.59e-03 |
| Caspase activation via extrinsic apoptotic signalling pathway | 25 | 8.38e-03 | 3.05e-01 | 2.31e-02 |
| Polymerase switching on the C-strand of the telomere | 26 | 7.19e-03 | -3.05e-01 | 2.04e-02 |
| Condensation of Prophase Chromosomes | 29 | 4.54e-03 | 3.04e-01 | 1.41e-02 |
| L1CAM interactions | 85 | 1.26e-06 | 3.04e-01 | 1.49e-05 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | 22 | 1.37e-02 | 3.03e-01 | 3.38e-02 |
| Plasma lipoprotein clearance | 29 | 4.75e-03 | 3.03e-01 | 1.47e-02 |
| Acyl chain remodelling of PI | 10 | 9.74e-02 | 3.03e-01 | 1.67e-01 |
| Trafficking and processing of endosomal TLR | 13 | 5.88e-02 | 3.03e-01 | 1.12e-01 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | 29 | 4.82e-03 | 3.02e-01 | 1.47e-02 |
| Rap1 signalling | 13 | 5.95e-02 | 3.02e-01 | 1.13e-01 |
| Glycogen storage diseases | 13 | 6.01e-02 | 3.01e-01 | 1.14e-01 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | 13 | 6.05e-02 | 3.01e-01 | 1.15e-01 |
| CLEC7A (Dectin-1) signaling | 97 | 3.16e-07 | 3.00e-01 | 4.90e-06 |
| Senescence-Associated Secretory Phenotype (SASP) | 66 | 2.52e-05 | 3.00e-01 | 1.81e-04 |
| Activation of G protein gated Potassium channels | 20 | 2.03e-02 | 3.00e-01 | 4.62e-02 |
| G protein gated Potassium channels | 20 | 2.03e-02 | 3.00e-01 | 4.62e-02 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | 20 | 2.03e-02 | 3.00e-01 | 4.62e-02 |
| Toll Like Receptor 3 (TLR3) Cascade | 92 | 6.70e-07 | 3.00e-01 | 9.33e-06 |
| Negative regulation of FGFR1 signaling | 24 | 1.12e-02 | 2.99e-01 | 2.83e-02 |
| Autodegradation of the E3 ubiquitin ligase COP1 | 50 | 2.53e-04 | 2.99e-01 | 1.27e-03 |
| p38MAPK events | 13 | 6.19e-02 | 2.99e-01 | 1.17e-01 |
| Selenocysteine synthesis | 92 | 8.72e-07 | -2.97e-01 | 1.07e-05 |
| cGMP effects | 13 | 6.42e-02 | 2.96e-01 | 1.20e-01 |
| Signaling by Insulin receptor | 59 | 8.38e-05 | 2.96e-01 | 4.99e-04 |
| MET promotes cell motility | 26 | 9.05e-03 | 2.96e-01 | 2.44e-02 |
| Chondroitin sulfate biosynthesis | 12 | 7.62e-02 | 2.96e-01 | 1.39e-01 |
| CD28 dependent PI3K/Akt signaling | 22 | 1.64e-02 | -2.96e-01 | 3.92e-02 |
| PCP/CE pathway | 87 | 1.87e-06 | 2.96e-01 | 2.09e-05 |
| Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon | 17 | 3.50e-02 | 2.95e-01 | 7.30e-02 |
| Translesion synthesis by REV1 | 16 | 4.13e-02 | -2.95e-01 | 8.40e-02 |
| Activation of NF-kappaB in B cells | 66 | 3.57e-05 | 2.94e-01 | 2.41e-04 |
| Aquaporin-mediated transport | 38 | 1.72e-03 | 2.94e-01 | 6.38e-03 |
| p75NTR signals via NF-kB | 15 | 4.88e-02 | 2.94e-01 | 9.68e-02 |
| Vasopressin regulates renal water homeostasis via Aquaporins | 34 | 3.22e-03 | 2.92e-01 | 1.07e-02 |
| MASTL Facilitates Mitotic Progression | 10 | 1.10e-01 | 2.92e-01 | 1.83e-01 |
| Diseases associated with glycosylation precursor biosynthesis | 18 | 3.27e-02 | 2.91e-01 | 6.91e-02 |
| tRNA processing in the nucleus | 59 | 1.15e-04 | -2.90e-01 | 6.51e-04 |
| Prefoldin mediated transfer of substrate to CCT/TriC | 26 | 1.04e-02 | 2.90e-01 | 2.71e-02 |
| Receptor Mediated Mitophagy | 11 | 9.58e-02 | 2.90e-01 | 1.65e-01 |
| TBC/RABGAPs | 45 | 7.61e-04 | 2.90e-01 | 3.26e-03 |
| Formation of tubulin folding intermediates by CCT/TriC | 22 | 1.87e-02 | 2.90e-01 | 4.32e-02 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | 51 | 3.51e-04 | 2.89e-01 | 1.71e-03 |
| Opioid Signalling | 75 | 1.55e-05 | 2.89e-01 | 1.17e-04 |
| Constitutive Signaling by EGFRvIII | 14 | 6.17e-02 | 2.88e-01 | 1.16e-01 |
| Signaling by EGFRvIII in Cancer | 14 | 6.17e-02 | 2.88e-01 | 1.16e-01 |
| Integration of energy metabolism | 86 | 3.84e-06 | 2.88e-01 | 3.64e-05 |
| Misspliced GSK3beta mutants stabilize beta-catenin | 15 | 5.33e-02 | 2.88e-01 | 1.04e-01 |
| S33 mutants of beta-catenin aren't phosphorylated | 15 | 5.33e-02 | 2.88e-01 | 1.04e-01 |
| S37 mutants of beta-catenin aren't phosphorylated | 15 | 5.33e-02 | 2.88e-01 | 1.04e-01 |
| S45 mutants of beta-catenin aren't phosphorylated | 15 | 5.33e-02 | 2.88e-01 | 1.04e-01 |
| T41 mutants of beta-catenin aren't phosphorylated | 15 | 5.33e-02 | 2.88e-01 | 1.04e-01 |
| phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex | 15 | 5.33e-02 | 2.88e-01 | 1.04e-01 |
| G beta:gamma signalling through PI3Kgamma | 22 | 1.93e-02 | 2.88e-01 | 4.46e-02 |
| Signaling by PDGFRA extracellular domain mutants | 12 | 8.43e-02 | 2.88e-01 | 1.49e-01 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | 12 | 8.43e-02 | 2.88e-01 | 1.49e-01 |
| Transport of Ribonucleoproteins into the Host Nucleus | 32 | 4.86e-03 | -2.88e-01 | 1.48e-02 |
| Biosynthesis of specialized proresolving mediators (SPMs) | 16 | 4.64e-02 | 2.88e-01 | 9.30e-02 |
| Formation of Fibrin Clot (Clotting Cascade) | 26 | 1.12e-02 | 2.87e-01 | 2.84e-02 |
| EPHA-mediated growth cone collapse | 13 | 7.31e-02 | 2.87e-01 | 1.34e-01 |
| rRNA processing | 219 | 2.40e-13 | -2.87e-01 | 1.49e-11 |
| SCF-beta-TrCP mediated degradation of Emi1 | 54 | 2.64e-04 | 2.87e-01 | 1.32e-03 |
| Export of Viral Ribonucleoproteins from Nucleus | 33 | 4.60e-03 | -2.85e-01 | 1.43e-02 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | 88 | 3.93e-06 | 2.85e-01 | 3.64e-05 |
| Interactions of Vpr with host cellular proteins | 37 | 2.75e-03 | -2.84e-01 | 9.32e-03 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | 15 | 5.77e-02 | 2.83e-01 | 1.11e-01 |
| Signalling to RAS | 19 | 3.27e-02 | 2.83e-01 | 6.91e-02 |
| Interferon alpha/beta signaling | 57 | 2.25e-04 | -2.82e-01 | 1.14e-03 |
| Carnitine metabolism | 10 | 1.23e-01 | 2.82e-01 | 1.98e-01 |
| Post-chaperonin tubulin folding pathway | 19 | 3.43e-02 | 2.80e-01 | 7.18e-02 |
| SHC1 events in ERBB2 signaling | 17 | 4.54e-02 | 2.80e-01 | 9.13e-02 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | 18 | 3.97e-02 | 2.80e-01 | 8.13e-02 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | 18 | 3.97e-02 | 2.80e-01 | 8.13e-02 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | 11 | 1.08e-01 | 2.80e-01 | 1.80e-01 |
| XBP1(S) activates chaperone genes | 47 | 9.11e-04 | 2.80e-01 | 3.77e-03 |
| SIRT1 negatively regulates rRNA expression | 24 | 1.78e-02 | 2.79e-01 | 4.18e-02 |
| Peptide chain elongation | 88 | 5.95e-06 | -2.79e-01 | 5.31e-05 |
| Interleukin-4 and Interleukin-13 signaling | 92 | 3.68e-06 | 2.79e-01 | 3.58e-05 |
| Beta-oxidation of very long chain fatty acids | 10 | 1.28e-01 | 2.78e-01 | 2.04e-01 |
| Signaling by Non-Receptor Tyrosine Kinases | 48 | 8.53e-04 | 2.78e-01 | 3.59e-03 |
| Signaling by PTK6 | 48 | 8.53e-04 | 2.78e-01 | 3.59e-03 |
| Asparagine N-linked glycosylation | 269 | 5.32e-15 | 2.77e-01 | 4.27e-13 |
| Interleukin-27 signaling | 11 | 1.12e-01 | 2.77e-01 | 1.84e-01 |
| Autodegradation of Cdh1 by Cdh1:APC/C | 64 | 1.28e-04 | 2.77e-01 | 7.07e-04 |
| G alpha (z) signalling events | 36 | 4.07e-03 | 2.77e-01 | 1.29e-02 |
| HDR through Single Strand Annealing (SSA) | 37 | 3.61e-03 | -2.76e-01 | 1.17e-02 |
| Mitotic Telophase/Cytokinesis | 13 | 8.47e-02 | 2.76e-01 | 1.50e-01 |
| Metabolism of nitric oxide: NOS3 activation and regulation | 12 | 9.79e-02 | 2.76e-01 | 1.67e-01 |
| Rab regulation of trafficking | 121 | 1.59e-07 | 2.76e-01 | 2.59e-06 |
| Cleavage of the damaged pyrimidine | 29 | 1.04e-02 | 2.75e-01 | 2.71e-02 |
| Depyrimidination | 29 | 1.04e-02 | 2.75e-01 | 2.71e-02 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | 29 | 1.04e-02 | 2.75e-01 | 2.71e-02 |
| Degradation of AXIN | 54 | 4.87e-04 | 2.74e-01 | 2.25e-03 |
| NOTCH1 Intracellular Domain Regulates Transcription | 45 | 1.45e-03 | 2.74e-01 | 5.53e-03 |
| Signaling by FGFR3 | 31 | 8.41e-03 | 2.73e-01 | 2.31e-02 |
| tRNA modification in the nucleus and cytosol | 43 | 1.92e-03 | -2.73e-01 | 6.91e-03 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | 32 | 7.55e-03 | 2.73e-01 | 2.13e-02 |
| Macroautophagy | 110 | 7.88e-07 | 2.72e-01 | 1.03e-05 |
| TRAF6 mediated NF-kB activation | 23 | 2.38e-02 | 2.72e-01 | 5.34e-02 |
| Myogenesis | 21 | 3.11e-02 | 2.72e-01 | 6.64e-02 |
| Platelet homeostasis | 70 | 8.63e-05 | 2.71e-01 | 5.09e-04 |
| PLC beta mediated events | 43 | 2.09e-03 | 2.71e-01 | 7.41e-03 |
| Activation of GABAB receptors | 31 | 8.98e-03 | 2.71e-01 | 2.42e-02 |
| GABA B receptor activation | 31 | 8.98e-03 | 2.71e-01 | 2.42e-02 |
| Class C/3 (Metabotropic glutamate/pheromone receptors) | 11 | 1.19e-01 | -2.71e-01 | 1.94e-01 |
| TGF-beta receptor signaling activates SMADs | 32 | 7.94e-03 | 2.71e-01 | 2.22e-02 |
| PPARA activates gene expression | 104 | 1.84e-06 | 2.71e-01 | 2.09e-05 |
| Eukaryotic Translation Elongation | 93 | 6.47e-06 | -2.71e-01 | 5.69e-05 |
| Oxidative Stress Induced Senescence | 79 | 3.24e-05 | 2.70e-01 | 2.22e-04 |
| Transport of the SLBP independent Mature mRNA | 35 | 5.65e-03 | -2.70e-01 | 1.68e-02 |
| Interleukin-10 signaling | 35 | 5.66e-03 | 2.70e-01 | 1.68e-02 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | 32 | 8.22e-03 | -2.70e-01 | 2.27e-02 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | 32 | 8.22e-03 | -2.70e-01 | 2.27e-02 |
| Stabilization of p53 | 55 | 5.37e-04 | 2.70e-01 | 2.43e-03 |
| Intrinsic Pathway of Fibrin Clot Formation | 16 | 6.18e-02 | 2.70e-01 | 1.16e-01 |
| Citric acid cycle (TCA cycle) | 22 | 2.86e-02 | 2.70e-01 | 6.20e-02 |
| Signaling by NOTCH1 | 67 | 1.37e-04 | 2.69e-01 | 7.35e-04 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | 179 | 5.04e-10 | 2.69e-01 | 1.42e-08 |
| Signaling by VEGF | 100 | 3.27e-06 | 2.69e-01 | 3.27e-05 |
| IRE1alpha activates chaperones | 49 | 1.13e-03 | 2.69e-01 | 4.49e-03 |
| Activated NOTCH1 Transmits Signal to the Nucleus | 27 | 1.58e-02 | 2.68e-01 | 3.79e-02 |
| Metalloprotease DUBs | 21 | 3.33e-02 | 2.68e-01 | 7.02e-02 |
| Vesicle-mediated transport | 650 | 1.64e-31 | 2.68e-01 | 4.48e-29 |
| Apoptosis | 168 | 2.16e-09 | 2.68e-01 | 5.16e-08 |
| Signaling by Interleukins | 386 | 1.71e-19 | 2.68e-01 | 2.12e-17 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | 36 | 5.50e-03 | 2.67e-01 | 1.65e-02 |
| PKA activation | 15 | 7.31e-02 | 2.67e-01 | 1.34e-01 |
| Respiratory electron transport | 101 | 3.58e-06 | 2.67e-01 | 3.52e-05 |
| NF-kB is activated and signals survival | 12 | 1.11e-01 | 2.66e-01 | 1.83e-01 |
| Signaling by Receptor Tyrosine Kinases | 414 | 1.68e-20 | 2.66e-01 | 2.29e-18 |
| Programmed Cell Death | 171 | 2.10e-09 | 2.65e-01 | 5.16e-08 |
| Purine ribonucleoside monophosphate biosynthesis | 10 | 1.47e-01 | -2.65e-01 | 2.31e-01 |
| Plasma lipoprotein assembly, remodeling, and clearance | 53 | 8.47e-04 | 2.65e-01 | 3.59e-03 |
| MAPK6/MAPK4 signaling | 83 | 3.05e-05 | 2.65e-01 | 2.11e-04 |
| Cristae formation | 31 | 1.08e-02 | 2.65e-01 | 2.76e-02 |
| Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. | 124 | 3.67e-07 | 2.64e-01 | 5.45e-06 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | 23 | 2.83e-02 | 2.64e-01 | 6.14e-02 |
| Prostacyclin signalling through prostacyclin receptor | 16 | 6.82e-02 | 2.63e-01 | 1.26e-01 |
| Eukaryotic Translation Termination | 92 | 1.32e-05 | -2.63e-01 | 1.02e-04 |
| Postmitotic nuclear pore complex (NPC) reformation | 27 | 1.83e-02 | -2.62e-01 | 4.26e-02 |
| Translesion synthesis by POLI | 17 | 6.22e-02 | -2.61e-01 | 1.17e-01 |
| Tie2 Signaling | 16 | 7.05e-02 | 2.61e-01 | 1.30e-01 |
| Regulation of signaling by CBL | 18 | 5.52e-02 | 2.61e-01 | 1.06e-01 |
| Scavenging by Class A Receptors | 12 | 1.18e-01 | 2.61e-01 | 1.93e-01 |
| Viral mRNA Translation | 88 | 2.47e-05 | -2.60e-01 | 1.78e-04 |
| Amine ligand-binding receptors | 10 | 1.55e-01 | -2.60e-01 | 2.40e-01 |
| Caspase activation via Death Receptors in the presence of ligand | 16 | 7.20e-02 | 2.60e-01 | 1.33e-01 |
| Potential therapeutics for SARS | 36 | 7.10e-03 | 2.59e-01 | 2.03e-02 |
| GABA receptor activation | 36 | 7.11e-03 | 2.59e-01 | 2.03e-02 |
| C-type lectin receptors (CLRs) | 129 | 3.78e-07 | 2.59e-01 | 5.54e-06 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | 28 | 1.78e-02 | -2.59e-01 | 4.18e-02 |
| Signaling by FGFR4 | 31 | 1.28e-02 | 2.58e-01 | 3.16e-02 |
| APC/C:Cdc20 mediated degradation of Securin | 67 | 2.63e-04 | 2.58e-01 | 1.32e-03 |
| AMER1 mutants destabilize the destruction complex | 14 | 9.52e-02 | 2.58e-01 | 1.64e-01 |
| APC truncation mutants have impaired AXIN binding | 14 | 9.52e-02 | 2.58e-01 | 1.64e-01 |
| AXIN missense mutants destabilize the destruction complex | 14 | 9.52e-02 | 2.58e-01 | 1.64e-01 |
| AXIN mutants destabilize the destruction complex, activating WNT signaling | 14 | 9.52e-02 | 2.58e-01 | 1.64e-01 |
| Truncations of AMER1 destabilize the destruction complex | 14 | 9.52e-02 | 2.58e-01 | 1.64e-01 |
| truncated APC mutants destabilize the destruction complex | 14 | 9.52e-02 | 2.58e-01 | 1.64e-01 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | 53 | 1.21e-03 | 2.57e-01 | 4.72e-03 |
| Hedgehog 'on' state | 76 | 1.08e-04 | 2.57e-01 | 6.23e-04 |
| Initiation of Nuclear Envelope (NE) Reformation | 19 | 5.27e-02 | 2.57e-01 | 1.04e-01 |
| Defects in vitamin and cofactor metabolism | 21 | 4.23e-02 | -2.56e-01 | 8.58e-02 |
| Regulation of lipid metabolism by PPARalpha | 106 | 5.54e-06 | 2.55e-01 | 5.04e-05 |
| IRAK2 mediated activation of TAK1 complex | 10 | 1.62e-01 | 2.55e-01 | 2.49e-01 |
| Mitochondrial iron-sulfur cluster biogenesis | 13 | 1.11e-01 | 2.55e-01 | 1.84e-01 |
| tRNA processing | 136 | 2.88e-07 | -2.55e-01 | 4.57e-06 |
| Metabolism of non-coding RNA | 53 | 1.35e-03 | -2.54e-01 | 5.19e-03 |
| snRNP Assembly | 53 | 1.35e-03 | -2.54e-01 | 5.19e-03 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | 73 | 1.73e-04 | 2.54e-01 | 9.06e-04 |
| Processive synthesis on the C-strand of the telomere | 19 | 5.52e-02 | -2.54e-01 | 1.06e-01 |
| Regulation of insulin secretion | 60 | 6.70e-04 | 2.54e-01 | 2.92e-03 |
| Glycosphingolipid metabolism | 36 | 8.40e-03 | 2.54e-01 | 2.31e-02 |
| Semaphorin interactions | 57 | 9.23e-04 | 2.54e-01 | 3.79e-03 |
| G-protein mediated events | 44 | 3.65e-03 | 2.53e-01 | 1.18e-02 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | 14 | 1.01e-01 | -2.53e-01 | 1.70e-01 |
| Intraflagellar transport | 39 | 6.22e-03 | -2.53e-01 | 1.82e-02 |
| Base-Excision Repair, AP Site Formation | 31 | 1.50e-02 | 2.52e-01 | 3.62e-02 |
| Complex I biogenesis | 55 | 1.21e-03 | 2.52e-01 | 4.72e-03 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | 36 | 8.91e-03 | 2.52e-01 | 2.42e-02 |
| Degradation of beta-catenin by the destruction complex | 84 | 6.67e-05 | 2.52e-01 | 4.15e-04 |
| Transcriptional regulation of white adipocyte differentiation | 77 | 1.36e-04 | 2.51e-01 | 7.35e-04 |
| SARS-CoV Infections | 83 | 7.53e-05 | 2.51e-01 | 4.58e-04 |
| NGF-stimulated transcription | 31 | 1.64e-02 | 2.49e-01 | 3.92e-02 |
| PI3K events in ERBB2 signaling | 11 | 1.53e-01 | 2.49e-01 | 2.38e-01 |
| p75NTR recruits signalling complexes | 12 | 1.36e-01 | 2.49e-01 | 2.16e-01 |
| TICAM1, RIP1-mediated IKK complex recruitment | 19 | 6.09e-02 | 2.48e-01 | 1.15e-01 |
| Transport of Mature mRNA Derived from an Intronless Transcript | 42 | 5.36e-03 | -2.48e-01 | 1.62e-02 |
| Signaling by ERBB4 | 44 | 4.37e-03 | 2.48e-01 | 1.37e-02 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | 27 | 2.59e-02 | -2.48e-01 | 5.72e-02 |
| Nucleobase catabolism | 28 | 2.33e-02 | 2.48e-01 | 5.23e-02 |
| Constitutive Signaling by Overexpressed ERBB2 | 11 | 1.55e-01 | 2.48e-01 | 2.40e-01 |
| Ca-dependent events | 29 | 2.11e-02 | 2.47e-01 | 4.79e-02 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | 16 | 8.67e-02 | 2.47e-01 | 1.52e-01 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | 55 | 1.56e-03 | 2.47e-01 | 5.90e-03 |
| Asymmetric localization of PCP proteins | 61 | 8.66e-04 | 2.47e-01 | 3.64e-03 |
| CDT1 association with the CDC6:ORC:origin complex | 58 | 1.18e-03 | 2.46e-01 | 4.65e-03 |
| SCF(Skp2)-mediated degradation of p27/p21 | 60 | 9.73e-04 | 2.46e-01 | 3.98e-03 |
| Hemostasis | 550 | 5.25e-23 | 2.46e-01 | 1.02e-20 |
| GRB2 events in ERBB2 signaling | 11 | 1.58e-01 | 2.46e-01 | 2.44e-01 |
| Signaling by SCF-KIT | 40 | 7.17e-03 | 2.46e-01 | 2.04e-02 |
| Transport of the SLBP Dependant Mature mRNA | 36 | 1.08e-02 | -2.46e-01 | 2.76e-02 |
| HDMs demethylate histones | 22 | 4.64e-02 | 2.45e-01 | 9.30e-02 |
| Aggrephagy | 22 | 4.66e-02 | 2.45e-01 | 9.32e-02 |
| Pyruvate metabolism | 28 | 2.48e-02 | 2.45e-01 | 5.51e-02 |
| Signaling by cytosolic FGFR1 fusion mutants | 18 | 7.23e-02 | 2.45e-01 | 1.33e-01 |
| SARS-CoV-1 Infection | 47 | 3.74e-03 | 2.44e-01 | 1.20e-02 |
| RHO GTPase Effectors | 250 | 2.78e-11 | 2.44e-01 | 9.48e-10 |
| O-glycosylation of TSR domain-containing proteins | 27 | 2.83e-02 | -2.44e-01 | 6.14e-02 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | 32 | 1.70e-02 | 2.44e-01 | 4.04e-02 |
| Surfactant metabolism | 22 | 4.79e-02 | 2.44e-01 | 9.53e-02 |
| Nuclear signaling by ERBB4 | 24 | 3.90e-02 | 2.43e-01 | 8.01e-02 |
| Listeria monocytogenes entry into host cells | 17 | 8.25e-02 | 2.43e-01 | 1.47e-01 |
| Apoptotic execution phase | 45 | 4.77e-03 | 2.43e-01 | 1.47e-02 |
| Heme biosynthesis | 14 | 1.15e-01 | 2.43e-01 | 1.89e-01 |
| Gluconeogenesis | 28 | 2.62e-02 | 2.43e-01 | 5.77e-02 |
| ESR-mediated signaling | 161 | 1.07e-07 | 2.43e-01 | 1.83e-06 |
| Laminin interactions | 21 | 5.43e-02 | 2.43e-01 | 1.05e-01 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 94 | 4.84e-05 | -2.42e-01 | 3.19e-04 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | 26 | 3.26e-02 | -2.42e-01 | 6.90e-02 |
| tRNA Aminoacylation | 42 | 6.78e-03 | -2.41e-01 | 1.95e-02 |
| Mismatch Repair | 15 | 1.06e-01 | -2.41e-01 | 1.78e-01 |
| Translesion synthesis by POLK | 17 | 8.56e-02 | -2.41e-01 | 1.51e-01 |
| Regulation of RAS by GAPs | 67 | 6.68e-04 | 2.40e-01 | 2.92e-03 |
| The citric acid (TCA) cycle and respiratory electron transport | 172 | 5.61e-08 | 2.40e-01 | 9.93e-07 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | 40 | 8.86e-03 | 2.39e-01 | 2.41e-02 |
| Interleukin-15 signaling | 14 | 1.22e-01 | 2.38e-01 | 1.98e-01 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | 54 | 2.55e-03 | 2.37e-01 | 8.77e-03 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | 54 | 2.55e-03 | 2.37e-01 | 8.77e-03 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | 54 | 2.55e-03 | 2.37e-01 | 8.77e-03 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | 54 | 2.55e-03 | 2.37e-01 | 8.77e-03 |
| Signaling by NOTCH1 in Cancer | 54 | 2.55e-03 | 2.37e-01 | 8.77e-03 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | 18 | 8.14e-02 | 2.37e-01 | 1.46e-01 |
| Signaling by Hippo | 18 | 8.17e-02 | 2.37e-01 | 1.46e-01 |
| Activation of gene expression by SREBF (SREBP) | 42 | 7.92e-03 | 2.37e-01 | 2.21e-02 |
| Plasma lipoprotein assembly | 10 | 1.97e-01 | 2.36e-01 | 2.96e-01 |
| Extra-nuclear estrogen signaling | 66 | 9.28e-04 | 2.36e-01 | 3.80e-03 |
| Glycerophospholipid biosynthesis | 106 | 2.89e-05 | 2.35e-01 | 2.02e-04 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | 72 | 5.71e-04 | 2.35e-01 | 2.57e-03 |
| CDK-mediated phosphorylation and removal of Cdc6 | 72 | 5.83e-04 | 2.34e-01 | 2.60e-03 |
| Acyl chain remodelling of PC | 19 | 7.71e-02 | 2.34e-01 | 1.39e-01 |
| Downstream signaling events of B Cell Receptor (BCR) | 80 | 2.96e-04 | 2.34e-01 | 1.46e-03 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | 73 | 5.49e-04 | 2.34e-01 | 2.48e-03 |
| Keratinization | 33 | 2.01e-02 | 2.34e-01 | 4.62e-02 |
| Sphingolipid metabolism | 77 | 4.07e-04 | 2.33e-01 | 1.92e-03 |
| Nitric oxide stimulates guanylate cyclase | 16 | 1.07e-01 | 2.32e-01 | 1.80e-01 |
| Depolymerisation of the Nuclear Lamina | 15 | 1.19e-01 | 2.32e-01 | 1.93e-01 |
| mRNA decay by 3' to 5' exoribonuclease | 16 | 1.07e-01 | -2.32e-01 | 1.80e-01 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | 76 | 4.70e-04 | 2.32e-01 | 2.17e-03 |
| HDR through Homologous Recombination (HRR) | 66 | 1.15e-03 | -2.31e-01 | 4.56e-03 |
| COPI-dependent Golgi-to-ER retrograde traffic | 78 | 4.28e-04 | 2.31e-01 | 2.01e-03 |
| RA biosynthesis pathway | 13 | 1.50e-01 | -2.30e-01 | 2.34e-01 |
| Chaperonin-mediated protein folding | 84 | 2.68e-04 | 2.30e-01 | 1.33e-03 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | 75 | 5.83e-04 | 2.30e-01 | 2.60e-03 |
| The role of Nef in HIV-1 replication and disease pathogenesis | 28 | 3.58e-02 | 2.29e-01 | 7.43e-02 |
| Intra-Golgi traffic | 43 | 9.48e-03 | 2.29e-01 | 2.52e-02 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | 43 | 9.62e-03 | -2.28e-01 | 2.55e-02 |
| Oncogene Induced Senescence | 33 | 2.40e-02 | 2.27e-01 | 5.37e-02 |
| Beta-catenin independent WNT signaling | 137 | 4.52e-06 | 2.27e-01 | 4.16e-05 |
| Selenoamino acid metabolism | 114 | 2.96e-05 | -2.26e-01 | 2.06e-04 |
| NOD1/2 Signaling Pathway | 32 | 2.68e-02 | 2.26e-01 | 5.88e-02 |
| Tryptophan catabolism | 12 | 1.75e-01 | 2.26e-01 | 2.67e-01 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | 14 | 1.44e-01 | 2.26e-01 | 2.27e-01 |
| UCH proteinases | 87 | 2.83e-04 | 2.25e-01 | 1.40e-03 |
| ABC-family proteins mediated transport | 94 | 1.66e-04 | 2.25e-01 | 8.76e-04 |
| p53-Dependent G1 DNA Damage Response | 64 | 1.89e-03 | 2.25e-01 | 6.84e-03 |
| p53-Dependent G1/S DNA damage checkpoint | 64 | 1.89e-03 | 2.25e-01 | 6.84e-03 |
| Diseases of signal transduction by growth factor receptors and second messengers | 343 | 9.13e-13 | 2.24e-01 | 4.02e-11 |
| Plasma lipoprotein remodeling | 18 | 9.94e-02 | 2.24e-01 | 1.69e-01 |
| Signaling by NOTCH3 | 43 | 1.11e-02 | 2.24e-01 | 2.83e-02 |
| Costimulation by the CD28 family | 74 | 8.86e-04 | -2.23e-01 | 3.71e-03 |
| Degradation of the extracellular matrix | 78 | 6.48e-04 | 2.23e-01 | 2.86e-03 |
| Influenza Viral RNA Transcription and Replication | 135 | 7.53e-06 | -2.23e-01 | 6.42e-05 |
| TP53 Regulates Metabolic Genes | 85 | 3.76e-04 | 2.23e-01 | 1.80e-03 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | 25 | 5.39e-02 | -2.23e-01 | 1.05e-01 |
| G1/S DNA Damage Checkpoints | 66 | 1.79e-03 | 2.22e-01 | 6.57e-03 |
| Estrogen-dependent gene expression | 99 | 1.33e-04 | 2.22e-01 | 7.21e-04 |
| EPH-ephrin mediated repulsion of cells | 40 | 1.52e-02 | 2.22e-01 | 3.66e-02 |
| Regulation of RUNX2 expression and activity | 67 | 1.71e-03 | 2.22e-01 | 6.34e-03 |
| Defective B3GALTL causes Peters-plus syndrome (PpS) | 26 | 5.11e-02 | -2.21e-01 | 1.01e-01 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | 100 | 1.46e-04 | -2.20e-01 | 7.80e-04 |
| Selective autophagy | 58 | 3.80e-03 | 2.20e-01 | 1.22e-02 |
| Signaling by ERBB2 in Cancer | 21 | 8.27e-02 | 2.19e-01 | 1.47e-01 |
| Adenylate cyclase inhibitory pathway | 11 | 2.10e-01 | 2.19e-01 | 3.12e-01 |
| Downregulation of ERBB2 signaling | 24 | 6.39e-02 | 2.18e-01 | 1.20e-01 |
| FGFR1 mutant receptor activation | 24 | 6.47e-02 | 2.18e-01 | 1.21e-01 |
| NRIF signals cell death from the nucleus | 15 | 1.45e-01 | 2.18e-01 | 2.28e-01 |
| Chaperone Mediated Autophagy | 20 | 9.61e-02 | 2.15e-01 | 1.65e-01 |
| Removal of the Flap Intermediate from the C-strand | 17 | 1.25e-01 | -2.15e-01 | 2.01e-01 |
| Signaling by Nuclear Receptors | 217 | 5.11e-08 | 2.15e-01 | 9.54e-07 |
| Signaling by WNT | 254 | 4.05e-09 | 2.14e-01 | 9.21e-08 |
| PTEN Regulation | 139 | 1.30e-05 | 2.14e-01 | 1.01e-04 |
| Sphingolipid de novo biosynthesis | 41 | 1.78e-02 | 2.14e-01 | 4.18e-02 |
| Negative regulation of FGFR2 signaling | 23 | 7.66e-02 | 2.13e-01 | 1.39e-01 |
| Formation of the beta-catenin:TCF transactivating complex | 46 | 1.26e-02 | 2.13e-01 | 3.13e-02 |
| Transport of bile salts and organic acids, metal ions and amine compounds | 55 | 6.53e-03 | 2.12e-01 | 1.89e-02 |
| Interleukin-12 family signaling | 53 | 7.67e-03 | 2.12e-01 | 2.16e-02 |
| SUMOylation of SUMOylation proteins | 35 | 3.02e-02 | -2.12e-01 | 6.47e-02 |
| Interleukin-12 signaling | 44 | 1.54e-02 | 2.11e-01 | 3.71e-02 |
| Sialic acid metabolism | 28 | 5.34e-02 | 2.11e-01 | 1.04e-01 |
| Purine salvage | 12 | 2.06e-01 | 2.11e-01 | 3.08e-01 |
| Retinoid metabolism and transport | 24 | 7.37e-02 | 2.11e-01 | 1.35e-01 |
| Signaling by Rho GTPases | 367 | 4.57e-12 | 2.10e-01 | 1.83e-10 |
| TCF dependent signaling in response to WNT | 166 | 3.21e-06 | 2.09e-01 | 3.27e-05 |
| NOTCH3 Intracellular Domain Regulates Transcription | 21 | 9.74e-02 | 2.09e-01 | 1.67e-01 |
| Attenuation phase | 23 | 8.28e-02 | 2.09e-01 | 1.47e-01 |
| Integrin cell surface interactions | 52 | 9.18e-03 | 2.09e-01 | 2.46e-02 |
| Transcriptional Regulation by E2F6 | 34 | 3.52e-02 | -2.09e-01 | 7.32e-02 |
| Striated Muscle Contraction | 24 | 7.76e-02 | 2.08e-01 | 1.40e-01 |
| Metabolism of fat-soluble vitamins | 28 | 5.67e-02 | 2.08e-01 | 1.09e-01 |
| Synthesis of PIPs at the late endosome membrane | 11 | 2.32e-01 | 2.08e-01 | 3.36e-01 |
| Inwardly rectifying K+ channels | 24 | 7.79e-02 | 2.08e-01 | 1.41e-01 |
| Protein folding | 90 | 6.57e-04 | 2.08e-01 | 2.89e-03 |
| MHC class II antigen presentation | 101 | 3.09e-04 | 2.08e-01 | 1.52e-03 |
| RNA Polymerase I Transcription Initiation | 47 | 1.38e-02 | -2.07e-01 | 3.40e-02 |
| Interleukin-6 family signaling | 18 | 1.30e-01 | 2.06e-01 | 2.09e-01 |
| Termination of translesion DNA synthesis | 32 | 4.40e-02 | -2.06e-01 | 8.89e-02 |
| Formation of a pool of free 40S subunits | 100 | 3.77e-04 | -2.06e-01 | 1.80e-03 |
| Assembly of active LPL and LIPC lipase complexes | 10 | 2.60e-01 | 2.06e-01 | 3.68e-01 |
| RUNX3 regulates NOTCH signaling | 14 | 1.85e-01 | 2.05e-01 | 2.81e-01 |
| ABC transporters in lipid homeostasis | 14 | 1.86e-01 | -2.04e-01 | 2.81e-01 |
| BMAL1:CLOCK,NPAS2 activates circadian gene expression | 25 | 7.71e-02 | 2.04e-01 | 1.39e-01 |
| p75 NTR receptor-mediated signalling | 89 | 9.07e-04 | 2.03e-01 | 3.76e-03 |
| Insulin processing | 21 | 1.09e-01 | 2.02e-01 | 1.82e-01 |
| Pyruvate metabolism and Citric Acid (TCA) cycle | 52 | 1.19e-02 | 2.02e-01 | 2.98e-02 |
| Elastic fibre formation | 32 | 4.85e-02 | 2.01e-01 | 9.64e-02 |
| Transcriptional regulation by RUNX3 | 90 | 1.01e-03 | 2.01e-01 | 4.08e-03 |
| SUMOylation of intracellular receptors | 26 | 7.68e-02 | 2.00e-01 | 1.39e-01 |
| CaM pathway | 27 | 7.26e-02 | 2.00e-01 | 1.33e-01 |
| Calmodulin induced events | 27 | 7.26e-02 | 2.00e-01 | 1.33e-01 |
| Biosynthesis of DHA-derived SPMs | 14 | 1.97e-01 | 1.99e-01 | 2.97e-01 |
| Signaling by FGFR1 | 38 | 3.40e-02 | 1.99e-01 | 7.13e-02 |
| RET signaling | 32 | 5.21e-02 | 1.98e-01 | 1.03e-01 |
| Immune System | 1894 | 3.07e-46 | 1.98e-01 | 1.40e-43 |
| RIP-mediated NFkB activation via ZBP1 | 17 | 1.60e-01 | 1.97e-01 | 2.46e-01 |
| Regulation of TP53 Activity through Acetylation | 29 | 6.76e-02 | -1.96e-01 | 1.25e-01 |
| Cohesin Loading onto Chromatin | 10 | 2.84e-01 | 1.96e-01 | 3.94e-01 |
| Unblocking of NMDA receptors, glutamate binding and activation | 12 | 2.42e-01 | -1.95e-01 | 3.47e-01 |
| Signaling by TGF-beta Receptor Complex | 72 | 4.29e-03 | 1.95e-01 | 1.35e-02 |
| BBSome-mediated cargo-targeting to cilium | 22 | 1.14e-01 | -1.94e-01 | 1.88e-01 |
| DAP12 interactions | 39 | 3.59e-02 | 1.94e-01 | 7.44e-02 |
| NR1H2 and NR1H3-mediated signaling | 39 | 3.61e-02 | 1.94e-01 | 7.47e-02 |
| Downregulation of TGF-beta receptor signaling | 26 | 8.73e-02 | 1.94e-01 | 1.53e-01 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | 114 | 3.56e-04 | -1.94e-01 | 1.72e-03 |
| Nonsense-Mediated Decay (NMD) | 114 | 3.56e-04 | -1.94e-01 | 1.72e-03 |
| Negative regulation of MAPK pathway | 42 | 3.02e-02 | 1.93e-01 | 6.47e-02 |
| Regulation of APC/C activators between G1/S and early anaphase | 80 | 2.83e-03 | 1.93e-01 | 9.55e-03 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | 21 | 1.26e-01 | 1.93e-01 | 2.03e-01 |
| Cellular Senescence | 144 | 6.80e-05 | 1.92e-01 | 4.22e-04 |
| Arachidonic acid metabolism | 43 | 2.93e-02 | 1.92e-01 | 6.33e-02 |
| PRC2 methylates histones and DNA | 29 | 7.36e-02 | 1.92e-01 | 1.35e-01 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | 14 | 2.14e-01 | -1.92e-01 | 3.17e-01 |
| Ion channel transport | 135 | 1.22e-04 | 1.92e-01 | 6.83e-04 |
| Metabolism of cofactors | 19 | 1.49e-01 | 1.91e-01 | 2.33e-01 |
| Signaling by ERBB2 TMD/JMD mutants | 17 | 1.72e-01 | 1.91e-01 | 2.62e-01 |
| ZBP1(DAI) mediated induction of type I IFNs | 20 | 1.39e-01 | 1.91e-01 | 2.21e-01 |
| DNA Damage/Telomere Stress Induced Senescence | 44 | 2.85e-02 | 1.91e-01 | 6.18e-02 |
| Metabolism of amine-derived hormones | 10 | 2.99e-01 | -1.90e-01 | 4.10e-01 |
| Transport of small molecules | 561 | 1.57e-14 | 1.90e-01 | 1.07e-12 |
| Activation of HOX genes during differentiation | 69 | 6.52e-03 | 1.89e-01 | 1.89e-02 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | 69 | 6.52e-03 | 1.89e-01 | 1.89e-02 |
| Metabolism of steroids | 120 | 3.42e-04 | 1.89e-01 | 1.67e-03 |
| FRS-mediated FGFR3 signaling | 11 | 2.78e-01 | 1.89e-01 | 3.89e-01 |
| RNA Polymerase III Chain Elongation | 18 | 1.66e-01 | -1.89e-01 | 2.54e-01 |
| PINK1-PRKN Mediated Mitophagy | 21 | 1.35e-01 | 1.88e-01 | 2.16e-01 |
| Acyl chain remodelling of PE | 20 | 1.45e-01 | 1.88e-01 | 2.29e-01 |
| PKA-mediated phosphorylation of CREB | 17 | 1.80e-01 | 1.88e-01 | 2.74e-01 |
| Triglyceride metabolism | 25 | 1.05e-01 | 1.87e-01 | 1.76e-01 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | 33 | 6.33e-02 | 1.87e-01 | 1.19e-01 |
| PIP3 activates AKT signaling | 241 | 6.02e-07 | 1.87e-01 | 8.46e-06 |
| Phospholipid metabolism | 185 | 1.23e-05 | 1.86e-01 | 9.84e-05 |
| CD209 (DC-SIGN) signaling | 20 | 1.50e-01 | 1.86e-01 | 2.34e-01 |
| Nuclear Pore Complex (NPC) Disassembly | 36 | 5.36e-02 | -1.86e-01 | 1.04e-01 |
| Signaling by ERBB2 KD Mutants | 20 | 1.50e-01 | 1.86e-01 | 2.34e-01 |
| Cytosolic iron-sulfur cluster assembly | 13 | 2.46e-01 | -1.86e-01 | 3.53e-01 |
| Transcriptional regulation by RUNX2 | 103 | 1.14e-03 | 1.86e-01 | 4.52e-03 |
| Extracellular matrix organization | 219 | 2.25e-06 | 1.85e-01 | 2.47e-05 |
| Mitophagy | 28 | 8.99e-02 | 1.85e-01 | 1.57e-01 |
| Regulation of IFNA signaling | 12 | 2.67e-01 | 1.85e-01 | 3.77e-01 |
| Antiviral mechanism by IFN-stimulated genes | 80 | 4.28e-03 | -1.85e-01 | 1.35e-02 |
| Collagen formation | 66 | 9.52e-03 | 1.85e-01 | 2.53e-02 |
| Regulation of localization of FOXO transcription factors | 12 | 2.71e-01 | 1.84e-01 | 3.81e-01 |
| Peroxisomal protein import | 57 | 1.71e-02 | 1.83e-01 | 4.04e-02 |
| Activation of kainate receptors upon glutamate binding | 26 | 1.08e-01 | 1.82e-01 | 1.80e-01 |
| Assembly of the pre-replicative complex | 67 | 9.99e-03 | 1.82e-01 | 2.63e-02 |
| Stimuli-sensing channels | 74 | 6.87e-03 | 1.82e-01 | 1.97e-02 |
| Disorders of developmental biology | 12 | 2.76e-01 | 1.82e-01 | 3.87e-01 |
| Loss of function of MECP2 in Rett syndrome | 12 | 2.76e-01 | 1.82e-01 | 3.87e-01 |
| Pervasive developmental disorders | 12 | 2.76e-01 | 1.82e-01 | 3.87e-01 |
| Metabolism of lipids | 625 | 9.17e-15 | 1.81e-01 | 6.95e-13 |
| Signaling by TGFB family members | 91 | 2.84e-03 | 1.81e-01 | 9.58e-03 |
| APC/C-mediated degradation of cell cycle proteins | 87 | 3.52e-03 | 1.81e-01 | 1.15e-02 |
| Regulation of mitotic cell cycle | 87 | 3.52e-03 | 1.81e-01 | 1.15e-02 |
| SUMOylation of RNA binding proteins | 47 | 3.20e-02 | -1.81e-01 | 6.79e-02 |
| Synthesis of PE | 12 | 2.79e-01 | -1.81e-01 | 3.89e-01 |
| Intracellular signaling by second messengers | 273 | 3.32e-07 | 1.79e-01 | 4.98e-06 |
| Diseases associated with O-glycosylation of proteins | 49 | 2.98e-02 | -1.79e-01 | 6.41e-02 |
| Influenza Infection | 154 | 1.22e-04 | -1.79e-01 | 6.83e-04 |
| Ub-specific processing proteases | 171 | 5.65e-05 | 1.78e-01 | 3.58e-04 |
| NCAM1 interactions | 23 | 1.39e-01 | -1.78e-01 | 2.20e-01 |
| Factors involved in megakaryocyte development and platelet production | 117 | 8.93e-04 | 1.78e-01 | 3.72e-03 |
| SUMOylation of ubiquitinylation proteins | 39 | 5.48e-02 | -1.78e-01 | 1.06e-01 |
| Retrograde transport at the Trans-Golgi-Network | 49 | 3.17e-02 | 1.77e-01 | 6.74e-02 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | 12 | 2.87e-01 | 1.77e-01 | 3.98e-01 |
| Glutathione conjugation | 26 | 1.18e-01 | 1.77e-01 | 1.93e-01 |
| Resolution of D-Loop Structures | 33 | 7.85e-02 | -1.77e-01 | 1.41e-01 |
| Acyl chain remodelling of PG | 11 | 3.12e-01 | 1.76e-01 | 4.24e-01 |
| Cyclin E associated events during G1/S transition | 83 | 5.53e-03 | 1.76e-01 | 1.65e-02 |
| Peptide hormone metabolism | 50 | 3.13e-02 | 1.76e-01 | 6.66e-02 |
| Cell junction organization | 60 | 1.85e-02 | 1.76e-01 | 4.28e-02 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | 17 | 2.11e-01 | -1.75e-01 | 3.13e-01 |
| Synthesis of very long-chain fatty acyl-CoAs | 22 | 1.56e-01 | 1.75e-01 | 2.42e-01 |
| Apoptotic cleavage of cellular proteins | 34 | 7.85e-02 | 1.74e-01 | 1.41e-01 |
| Circadian Clock | 67 | 1.37e-02 | 1.74e-01 | 3.37e-02 |
| Nef mediated downregulation of MHC class I complex cell surface expression | 10 | 3.41e-01 | 1.74e-01 | 4.52e-01 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | 32 | 8.89e-02 | -1.74e-01 | 1.55e-01 |
| Peroxisomal lipid metabolism | 27 | 1.19e-01 | 1.74e-01 | 1.93e-01 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | 80 | 7.44e-03 | 1.73e-01 | 2.10e-02 |
| Meiotic synapsis | 45 | 4.48e-02 | 1.73e-01 | 9.03e-02 |
| Deubiquitination | 242 | 3.70e-06 | 1.73e-01 | 3.58e-05 |
| Class I MHC mediated antigen processing & presentation | 350 | 2.99e-08 | 1.72e-01 | 5.91e-07 |
| Regulation of PTEN gene transcription | 59 | 2.23e-02 | 1.72e-01 | 5.03e-02 |
| Signaling by FGFR1 in disease | 31 | 9.76e-02 | 1.72e-01 | 1.67e-01 |
| Signaling by Hedgehog | 121 | 1.10e-03 | 1.72e-01 | 4.42e-03 |
| Unfolded Protein Response (UPR) | 87 | 5.84e-03 | 1.71e-01 | 1.73e-02 |
| RNA Polymerase III Transcription Initiation | 36 | 7.66e-02 | -1.71e-01 | 1.39e-01 |
| Neurotransmitter receptors and postsynaptic signal transmission | 124 | 1.06e-03 | 1.70e-01 | 4.26e-03 |
| HS-GAG biosynthesis | 20 | 1.88e-01 | 1.70e-01 | 2.85e-01 |
| CD28 dependent Vav1 pathway | 12 | 3.08e-01 | 1.70e-01 | 4.20e-01 |
| Signaling by PDGFR in disease | 19 | 2.02e-01 | 1.69e-01 | 3.04e-01 |
| Pausing and recovery of Tat-mediated HIV elongation | 30 | 1.10e-01 | 1.69e-01 | 1.82e-01 |
| Tat-mediated HIV elongation arrest and recovery | 30 | 1.10e-01 | 1.69e-01 | 1.82e-01 |
| HCMV Late Events | 69 | 1.53e-02 | 1.69e-01 | 3.70e-02 |
| Maturation of nucleoprotein | 10 | 3.55e-01 | -1.69e-01 | 4.66e-01 |
| MAPK1/MAPK3 signaling | 236 | 8.18e-06 | 1.69e-01 | 6.89e-05 |
| Signaling by ERBB2 | 44 | 5.38e-02 | 1.68e-01 | 1.05e-01 |
| G alpha (12/13) signalling events | 69 | 1.67e-02 | 1.67e-01 | 3.98e-02 |
| Mitochondrial biogenesis | 88 | 7.05e-03 | 1.66e-01 | 2.02e-02 |
| MAPK family signaling cascades | 270 | 2.63e-06 | 1.66e-01 | 2.71e-05 |
| VEGFR2 mediated cell proliferation | 18 | 2.23e-01 | 1.66e-01 | 3.27e-01 |
| Other semaphorin interactions | 16 | 2.52e-01 | 1.65e-01 | 3.59e-01 |
| Carboxyterminal post-translational modifications of tubulin | 27 | 1.37e-01 | 1.65e-01 | 2.18e-01 |
| Defects in cobalamin (B12) metabolism | 13 | 3.03e-01 | -1.65e-01 | 4.15e-01 |
| Recognition of DNA damage by PCNA-containing replication complex | 30 | 1.19e-01 | -1.65e-01 | 1.93e-01 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | 18 | 2.27e-01 | 1.64e-01 | 3.32e-01 |
| Dual Incision in GG-NER | 41 | 6.86e-02 | -1.64e-01 | 1.27e-01 |
| mitochondrial fatty acid beta-oxidation of saturated fatty acids | 11 | 3.45e-01 | 1.64e-01 | 4.57e-01 |
| Glycosaminoglycan metabolism | 94 | 5.91e-03 | 1.64e-01 | 1.74e-02 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | 20 | 2.05e-01 | 1.64e-01 | 3.07e-01 |
| Trafficking of AMPA receptors | 20 | 2.05e-01 | 1.64e-01 | 3.07e-01 |
| Insulin receptor signalling cascade | 39 | 7.68e-02 | 1.64e-01 | 1.39e-01 |
| Incretin synthesis, secretion, and inactivation | 10 | 3.71e-01 | 1.63e-01 | 4.81e-01 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | 10 | 3.71e-01 | 1.63e-01 | 4.81e-01 |
| Metabolism of carbohydrates | 244 | 1.10e-05 | 1.63e-01 | 8.83e-05 |
| Rho GTPase cycle | 126 | 1.57e-03 | 1.63e-01 | 5.92e-03 |
| Downstream signal transduction | 27 | 1.42e-01 | 1.63e-01 | 2.25e-01 |
| Activation of RAC1 | 11 | 3.49e-01 | 1.63e-01 | 4.61e-01 |
| Intrinsic Pathway for Apoptosis | 53 | 4.03e-02 | 1.63e-01 | 8.24e-02 |
| Regulation of actin dynamics for phagocytic cup formation | 123 | 1.85e-03 | 1.62e-01 | 6.79e-03 |
| Dectin-2 family | 19 | 2.22e-01 | 1.62e-01 | 3.26e-01 |
| FLT3 Signaling | 245 | 1.28e-05 | 1.62e-01 | 1.00e-04 |
| Constitutive Signaling by AKT1 E17K in Cancer | 26 | 1.55e-01 | 1.61e-01 | 2.40e-01 |
| rRNA processing in the mitochondrion | 29 | 1.34e-01 | -1.61e-01 | 2.14e-01 |
| SUMOylation of DNA damage response and repair proteins | 77 | 1.48e-02 | -1.61e-01 | 3.61e-02 |
| Aflatoxin activation and detoxification | 14 | 2.99e-01 | 1.60e-01 | 4.10e-01 |
| Neddylation | 219 | 4.38e-05 | 1.60e-01 | 2.91e-04 |
| HIV elongation arrest and recovery | 32 | 1.18e-01 | 1.60e-01 | 1.93e-01 |
| Pausing and recovery of HIV elongation | 32 | 1.18e-01 | 1.60e-01 | 1.93e-01 |
| Cyclin A:Cdk2-associated events at S phase entry | 85 | 1.09e-02 | 1.60e-01 | 2.79e-02 |
| FRS-mediated FGFR4 signaling | 12 | 3.40e-01 | 1.59e-01 | 4.52e-01 |
| RAF/MAP kinase cascade | 231 | 3.18e-05 | 1.59e-01 | 2.19e-04 |
| Phase 0 - rapid depolarisation | 28 | 1.46e-01 | -1.59e-01 | 2.30e-01 |
| Bile acid and bile salt metabolism | 28 | 1.49e-01 | 1.58e-01 | 2.33e-01 |
| Hedgehog 'off' state | 93 | 8.83e-03 | 1.57e-01 | 2.40e-02 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | 23 | 1.92e-01 | 1.57e-01 | 2.91e-01 |
| A tetrasaccharide linker sequence is required for GAG synthesis | 17 | 2.65e-01 | -1.56e-01 | 3.74e-01 |
| Metabolic disorders of biological oxidation enzymes | 26 | 1.68e-01 | 1.56e-01 | 2.58e-01 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | 72 | 2.30e-02 | -1.55e-01 | 5.19e-02 |
| Downregulation of ERBB2:ERBB3 signaling | 12 | 3.53e-01 | 1.55e-01 | 4.64e-01 |
| Deadenylation of mRNA | 22 | 2.09e-01 | 1.55e-01 | 3.11e-01 |
| Interferon Signaling | 177 | 3.85e-04 | -1.55e-01 | 1.83e-03 |
| Signaling by ERBB2 ECD mutants | 15 | 3.03e-01 | 1.54e-01 | 4.14e-01 |
| Degradation of cysteine and homocysteine | 12 | 3.57e-01 | 1.54e-01 | 4.67e-01 |
| Post-translational protein modification | 1194 | 5.60e-19 | 1.53e-01 | 5.87e-17 |
| Fatty acid metabolism | 153 | 1.16e-03 | 1.52e-01 | 4.59e-03 |
| Signal Transduction | 1894 | 7.04e-28 | 1.52e-01 | 1.60e-25 |
| ISG15 antiviral mechanism | 72 | 2.60e-02 | -1.52e-01 | 5.75e-02 |
| Formation of RNA Pol II elongation complex | 57 | 4.80e-02 | 1.51e-01 | 9.53e-02 |
| RNA Polymerase II Transcription Elongation | 57 | 4.80e-02 | 1.51e-01 | 9.53e-02 |
| Fatty acyl-CoA biosynthesis | 35 | 1.21e-01 | 1.51e-01 | 1.96e-01 |
| Blood group systems biosynthesis | 17 | 2.81e-01 | 1.51e-01 | 3.91e-01 |
| TNFR2 non-canonical NF-kB pathway | 96 | 1.06e-02 | 1.51e-01 | 2.74e-02 |
| HCMV Infection | 96 | 1.07e-02 | 1.51e-01 | 2.74e-02 |
| Chemokine receptors bind chemokines | 39 | 1.03e-01 | -1.51e-01 | 1.74e-01 |
| SLBP independent Processing of Histone Pre-mRNAs | 10 | 4.10e-01 | -1.51e-01 | 5.23e-01 |
| Leishmania infection | 245 | 5.06e-05 | 1.50e-01 | 3.27e-04 |
| Disorders of transmembrane transporters | 148 | 1.67e-03 | 1.50e-01 | 6.24e-03 |
| Signaling by NTRK2 (TRKB) | 20 | 2.47e-01 | 1.50e-01 | 3.53e-01 |
| Transcriptional regulation by RUNX1 | 185 | 4.54e-04 | 1.49e-01 | 2.11e-03 |
| Early Phase of HIV Life Cycle | 14 | 3.34e-01 | -1.49e-01 | 4.47e-01 |
| Transmission across Chemical Synapses | 172 | 7.60e-04 | 1.49e-01 | 3.26e-03 |
| Repression of WNT target genes | 14 | 3.36e-01 | -1.48e-01 | 4.49e-01 |
| Transport of vitamins, nucleosides, and related molecules | 33 | 1.41e-01 | 1.48e-01 | 2.23e-01 |
| NOTCH2 intracellular domain regulates transcription | 11 | 3.95e-01 | 1.48e-01 | 5.10e-01 |
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | 17 | 2.93e-01 | -1.47e-01 | 4.04e-01 |
| Miscellaneous transport and binding events | 20 | 2.54e-01 | 1.47e-01 | 3.61e-01 |
| Death Receptor Signalling | 132 | 3.50e-03 | 1.47e-01 | 1.15e-02 |
| Cell death signalling via NRAGE, NRIF and NADE | 70 | 3.34e-02 | 1.47e-01 | 7.02e-02 |
| Transcriptional Regulation by MECP2 | 47 | 8.13e-02 | 1.47e-01 | 1.46e-01 |
| Fcgamma receptor (FCGR) dependent phagocytosis | 147 | 2.11e-03 | 1.47e-01 | 7.47e-03 |
| MET activates PTK2 signaling | 15 | 3.25e-01 | 1.47e-01 | 4.39e-01 |
| Cell-Cell communication | 89 | 1.71e-02 | 1.46e-01 | 4.05e-02 |
| RAF-independent MAPK1/3 activation | 21 | 2.47e-01 | 1.46e-01 | 3.53e-01 |
| Cellular responses to external stimuli | 506 | 1.91e-08 | 1.46e-01 | 3.95e-07 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | 111 | 8.23e-03 | -1.45e-01 | 2.27e-02 |
| tRNA processing in the mitochondrion | 32 | 1.55e-01 | -1.45e-01 | 2.40e-01 |
| Synthesis of bile acids and bile salts | 24 | 2.21e-01 | 1.44e-01 | 3.25e-01 |
| Interferon gamma signaling | 83 | 2.32e-02 | -1.44e-01 | 5.23e-02 |
| Adrenaline,noradrenaline inhibits insulin secretion | 24 | 2.22e-01 | 1.44e-01 | 3.26e-01 |
| SUMOylation of DNA replication proteins | 46 | 9.14e-02 | -1.44e-01 | 1.59e-01 |
| FRS-mediated FGFR1 signaling | 14 | 3.52e-01 | 1.44e-01 | 4.63e-01 |
| Vitamin B5 (pantothenate) metabolism | 17 | 3.05e-01 | 1.44e-01 | 4.16e-01 |
| Cytosolic sulfonation of small molecules | 19 | 2.81e-01 | 1.43e-01 | 3.91e-01 |
| Signaling by FGFR2 IIIa TM | 18 | 2.95e-01 | 1.43e-01 | 4.06e-01 |
| HS-GAG degradation | 16 | 3.25e-01 | 1.42e-01 | 4.39e-01 |
| Cellular responses to stress | 500 | 5.60e-08 | 1.42e-01 | 9.93e-07 |
| HIV Transcription Initiation | 45 | 9.99e-02 | 1.42e-01 | 1.69e-01 |
| RNA Polymerase II HIV Promoter Escape | 45 | 9.99e-02 | 1.42e-01 | 1.69e-01 |
| RNA Polymerase II Promoter Escape | 45 | 9.99e-02 | 1.42e-01 | 1.69e-01 |
| RNA Polymerase II Transcription Initiation | 45 | 9.99e-02 | 1.42e-01 | 1.69e-01 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | 45 | 9.99e-02 | 1.42e-01 | 1.69e-01 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | 45 | 9.99e-02 | 1.42e-01 | 1.69e-01 |
| Metabolism of folate and pterines | 16 | 3.26e-01 | 1.42e-01 | 4.40e-01 |
| B-WICH complex positively regulates rRNA expression | 47 | 9.33e-02 | 1.41e-01 | 1.62e-01 |
| L13a-mediated translational silencing of Ceruloplasmin expression | 110 | 1.05e-02 | -1.41e-01 | 2.73e-02 |
| Signaling by Activin | 10 | 4.40e-01 | -1.41e-01 | 5.52e-01 |
| SUMOylation of chromatin organization proteins | 57 | 6.56e-02 | -1.41e-01 | 1.22e-01 |
| Collagen biosynthesis and modifying enzymes | 48 | 9.20e-02 | 1.41e-01 | 1.60e-01 |
| FCGR activation | 76 | 3.45e-02 | -1.40e-01 | 7.20e-02 |
| Negative regulation of the PI3K/AKT network | 87 | 2.39e-02 | 1.40e-01 | 5.36e-02 |
| RNA Pol II CTD phosphorylation and interaction with CE | 27 | 2.08e-01 | 1.40e-01 | 3.11e-01 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | 27 | 2.08e-01 | 1.40e-01 | 3.11e-01 |
| Polo-like kinase mediated events | 16 | 3.33e-01 | 1.40e-01 | 4.46e-01 |
| NoRC negatively regulates rRNA expression | 62 | 5.70e-02 | 1.40e-01 | 1.10e-01 |
| RNA Polymerase I Transcription Termination | 30 | 1.85e-01 | -1.40e-01 | 2.81e-01 |
| Cyclin A/B1/B2 associated events during G2/M transition | 25 | 2.27e-01 | 1.40e-01 | 3.32e-01 |
| Metabolism | 1772 | 1.78e-22 | 1.39e-01 | 3.04e-20 |
| Translation of structural proteins | 28 | 2.02e-01 | 1.39e-01 | 3.04e-01 |
| Assembly of collagen fibrils and other multimeric structures | 42 | 1.20e-01 | 1.39e-01 | 1.94e-01 |
| Signaling by PDGF | 44 | 1.12e-01 | 1.39e-01 | 1.84e-01 |
| FOXO-mediated transcription | 59 | 6.72e-02 | 1.38e-01 | 1.25e-01 |
| Regulation of TP53 Activity through Association with Co-factors | 12 | 4.09e-01 | -1.38e-01 | 5.23e-01 |
| Muscle contraction | 142 | 4.62e-03 | 1.38e-01 | 1.43e-02 |
| TP53 Regulates Transcription of Cell Death Genes | 43 | 1.20e-01 | 1.37e-01 | 1.94e-01 |
| Folding of actin by CCT/TriC | 10 | 4.53e-01 | 1.37e-01 | 5.65e-01 |
| FCGR3A-mediated phagocytosis | 121 | 9.35e-03 | 1.37e-01 | 2.49e-02 |
| Leishmania phagocytosis | 121 | 9.35e-03 | 1.37e-01 | 2.49e-02 |
| Parasite infection | 121 | 9.35e-03 | 1.37e-01 | 2.49e-02 |
| Regulation of MECP2 expression and activity | 28 | 2.10e-01 | 1.37e-01 | 3.12e-01 |
| Synthesis of PIPs at the plasma membrane | 52 | 8.98e-02 | 1.36e-01 | 1.57e-01 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | 10 | 4.57e-01 | 1.36e-01 | 5.69e-01 |
| Downstream signaling of activated FGFR3 | 16 | 3.48e-01 | 1.35e-01 | 4.61e-01 |
| Transport of Mature Transcript to Cytoplasm | 81 | 3.56e-02 | -1.35e-01 | 7.40e-02 |
| Phase 4 - resting membrane potential | 10 | 4.63e-01 | 1.34e-01 | 5.75e-01 |
| Metal ion SLC transporters | 21 | 2.88e-01 | 1.34e-01 | 3.99e-01 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 182 | 1.89e-03 | -1.34e-01 | 6.84e-03 |
| SUMOylation of transcription factors | 16 | 3.57e-01 | 1.33e-01 | 4.67e-01 |
| Developmental Biology | 732 | 1.07e-09 | 1.32e-01 | 2.80e-08 |
| SRP-dependent cotranslational protein targeting to membrane | 111 | 1.62e-02 | -1.32e-01 | 3.88e-02 |
| RNA Polymerase II Pre-transcription Events | 78 | 4.41e-02 | 1.32e-01 | 8.89e-02 |
| Zinc transporters | 14 | 3.93e-01 | 1.32e-01 | 5.08e-01 |
| RNA Polymerase I Promoter Escape | 47 | 1.18e-01 | 1.32e-01 | 1.93e-01 |
| Orc1 removal from chromatin | 70 | 5.76e-02 | 1.31e-01 | 1.11e-01 |
| Fc epsilon receptor (FCERI) signaling | 191 | 1.77e-03 | 1.31e-01 | 6.52e-03 |
| Classical antibody-mediated complement activation | 69 | 5.97e-02 | -1.31e-01 | 1.14e-01 |
| O-linked glycosylation of mucins | 47 | 1.21e-01 | 1.31e-01 | 1.96e-01 |
| Metabolism of proteins | 1719 | 1.86e-19 | 1.31e-01 | 2.12e-17 |
| CD22 mediated BCR regulation | 59 | 8.26e-02 | -1.31e-01 | 1.47e-01 |
| Protein methylation | 15 | 3.83e-01 | 1.30e-01 | 4.95e-01 |
| The canonical retinoid cycle in rods (twilight vision) | 10 | 4.76e-01 | 1.30e-01 | 5.87e-01 |
| Cap-dependent Translation Initiation | 118 | 1.50e-02 | -1.30e-01 | 3.62e-02 |
| Eukaryotic Translation Initiation | 118 | 1.50e-02 | -1.30e-01 | 3.62e-02 |
| Synthesis of substrates in N-glycan biosythesis | 58 | 8.82e-02 | 1.29e-01 | 1.54e-01 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | 13 | 4.21e-01 | 1.29e-01 | 5.36e-01 |
| Long-term potentiation | 14 | 4.04e-01 | -1.29e-01 | 5.19e-01 |
| RAS processing | 19 | 3.32e-01 | 1.28e-01 | 4.46e-01 |
| HIV Infection | 225 | 9.21e-04 | 1.28e-01 | 3.79e-03 |
| Viral Messenger RNA Synthesis | 44 | 1.42e-01 | -1.28e-01 | 2.24e-01 |
| Cytosolic tRNA aminoacylation | 24 | 2.78e-01 | -1.28e-01 | 3.89e-01 |
| Amino acid transport across the plasma membrane | 24 | 2.81e-01 | 1.27e-01 | 3.91e-01 |
| Disease | 1303 | 1.32e-14 | 1.27e-01 | 9.50e-13 |
| Transcriptional regulation of pluripotent stem cells | 20 | 3.26e-01 | 1.27e-01 | 4.39e-01 |
| Formation of the Early Elongation Complex | 33 | 2.09e-01 | 1.26e-01 | 3.11e-01 |
| Formation of the HIV-1 Early Elongation Complex | 33 | 2.09e-01 | 1.26e-01 | 3.11e-01 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | 28 | 2.48e-01 | -1.26e-01 | 3.54e-01 |
| Translesion Synthesis by POLH | 18 | 3.56e-01 | -1.26e-01 | 4.66e-01 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | 25 | 2.80e-01 | 1.25e-01 | 3.90e-01 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | 20 | 3.35e-01 | 1.25e-01 | 4.48e-01 |
| Telomere Extension By Telomerase | 23 | 3.01e-01 | -1.24e-01 | 4.14e-01 |
| Signaling by FGFR in disease | 51 | 1.25e-01 | 1.24e-01 | 2.01e-01 |
| Ephrin signaling | 18 | 3.62e-01 | 1.24e-01 | 4.72e-01 |
| RUNX3 regulates p14-ARF | 10 | 4.97e-01 | 1.24e-01 | 6.05e-01 |
| HSF1-dependent transactivation | 29 | 2.49e-01 | 1.24e-01 | 3.54e-01 |
| Regulation of beta-cell development | 19 | 3.52e-01 | 1.23e-01 | 4.63e-01 |
| Cell surface interactions at the vascular wall | 174 | 5.36e-03 | 1.22e-01 | 1.62e-02 |
| Meiotic recombination | 38 | 1.94e-01 | 1.22e-01 | 2.92e-01 |
| Class I peroxisomal membrane protein import | 20 | 3.49e-01 | -1.21e-01 | 4.61e-01 |
| E2F mediated regulation of DNA replication | 22 | 3.32e-01 | -1.20e-01 | 4.46e-01 |
| Potassium Channels | 64 | 9.86e-02 | 1.19e-01 | 1.68e-01 |
| Axon guidance | 457 | 1.28e-05 | 1.19e-01 | 1.00e-04 |
| Creation of C4 and C2 activators | 71 | 8.33e-02 | -1.19e-01 | 1.48e-01 |
| Regulation of TP53 Activity through Methylation | 19 | 3.70e-01 | -1.19e-01 | 4.81e-01 |
| DAG and IP3 signaling | 33 | 2.39e-01 | 1.18e-01 | 3.43e-01 |
| SHC-mediated cascade:FGFR4 | 10 | 5.17e-01 | 1.18e-01 | 6.27e-01 |
| Mitotic Prophase | 98 | 4.33e-02 | 1.18e-01 | 8.77e-02 |
| Protein localization | 157 | 1.07e-02 | 1.18e-01 | 2.74e-02 |
| Platelet calcium homeostasis | 22 | 3.38e-01 | 1.18e-01 | 4.51e-01 |
| Downstream signaling of activated FGFR4 | 17 | 4.02e-01 | 1.17e-01 | 5.17e-01 |
| Infectious disease | 724 | 7.34e-08 | 1.17e-01 | 1.28e-06 |
| Keratan sulfate/keratin metabolism | 27 | 2.91e-01 | 1.17e-01 | 4.02e-01 |
| Signaling by NOTCH2 | 30 | 2.68e-01 | 1.17e-01 | 3.77e-01 |
| Neuronal System | 259 | 1.19e-03 | 1.17e-01 | 4.67e-03 |
| Heparan sulfate/heparin (HS-GAG) metabolism | 37 | 2.18e-01 | 1.17e-01 | 3.22e-01 |
| ECM proteoglycans | 35 | 2.32e-01 | 1.17e-01 | 3.36e-01 |
| Nuclear Envelope (NE) Reassembly | 69 | 9.41e-02 | 1.17e-01 | 1.63e-01 |
| Regulation of FOXO transcriptional activity by acetylation | 10 | 5.27e-01 | 1.16e-01 | 6.37e-01 |
| Mitotic Anaphase | 224 | 3.35e-03 | 1.14e-01 | 1.11e-02 |
| MECP2 regulates neuronal receptors and channels | 13 | 4.78e-01 | 1.14e-01 | 5.88e-01 |
| VEGFR2 mediated vascular permeability | 27 | 3.08e-01 | 1.13e-01 | 4.20e-01 |
| Nervous system development | 476 | 2.40e-05 | 1.13e-01 | 1.75e-04 |
| Antigen processing: Ubiquitination & Proteasome degradation | 289 | 1.01e-03 | 1.12e-01 | 4.11e-03 |
| Non-integrin membrane-ECM interactions | 37 | 2.38e-01 | 1.12e-01 | 3.42e-01 |
| Initial triggering of complement | 78 | 8.68e-02 | -1.12e-01 | 1.52e-01 |
| Molecules associated with elastic fibres | 22 | 3.63e-01 | 1.12e-01 | 4.73e-01 |
| RNA polymerase II transcribes snRNA genes | 72 | 1.01e-01 | 1.12e-01 | 1.70e-01 |
| Formation of TC-NER Pre-Incision Complex | 53 | 1.61e-01 | 1.11e-01 | 2.48e-01 |
| PI Metabolism | 80 | 8.53e-02 | 1.11e-01 | 1.51e-01 |
| Phase II - Conjugation of compounds | 68 | 1.13e-01 | 1.11e-01 | 1.86e-01 |
| Regulation of pyruvate dehydrogenase (PDH) complex | 15 | 4.56e-01 | 1.11e-01 | 5.68e-01 |
| Interleukin-20 family signaling | 17 | 4.30e-01 | 1.11e-01 | 5.45e-01 |
| Ca2+ pathway | 57 | 1.50e-01 | 1.10e-01 | 2.34e-01 |
| Phase I - Functionalization of compounds | 65 | 1.24e-01 | 1.10e-01 | 2.00e-01 |
| Metabolism of nucleotides | 86 | 7.90e-02 | 1.10e-01 | 1.42e-01 |
| Regulation of TNFR1 signaling | 32 | 2.84e-01 | -1.09e-01 | 3.94e-01 |
| Mitotic Metaphase and Anaphase | 225 | 4.82e-03 | 1.09e-01 | 1.47e-02 |
| Adherens junctions interactions | 19 | 4.11e-01 | 1.09e-01 | 5.25e-01 |
| Glucose metabolism | 84 | 8.62e-02 | 1.08e-01 | 1.52e-01 |
| Ras activation upon Ca2+ influx through NMDA receptor | 15 | 4.70e-01 | -1.08e-01 | 5.81e-01 |
| Assembly and cell surface presentation of NMDA receptors | 18 | 4.29e-01 | -1.08e-01 | 5.45e-01 |
| SHC-mediated cascade:FGFR1 | 12 | 5.19e-01 | 1.07e-01 | 6.29e-01 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | 38 | 2.54e-01 | -1.07e-01 | 3.61e-01 |
| Cytokine Signaling in Immune system | 736 | 8.01e-07 | 1.07e-01 | 1.03e-05 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | 42 | 2.32e-01 | 1.07e-01 | 3.36e-01 |
| HIV Transcription Elongation | 42 | 2.32e-01 | 1.07e-01 | 3.36e-01 |
| Tat-mediated elongation of the HIV-1 transcript | 42 | 2.32e-01 | 1.07e-01 | 3.36e-01 |
| Chromosome Maintenance | 105 | 5.92e-02 | -1.07e-01 | 1.13e-01 |
| Glycolysis | 67 | 1.32e-01 | 1.06e-01 | 2.11e-01 |
| Role of phospholipids in phagocytosis | 88 | 8.64e-02 | -1.06e-01 | 1.52e-01 |
| The phototransduction cascade | 26 | 3.54e-01 | -1.05e-01 | 4.65e-01 |
| PI-3K cascade:FGFR4 | 10 | 5.65e-01 | 1.05e-01 | 6.69e-01 |
| Activation of NMDA receptors and postsynaptic events | 58 | 1.69e-01 | 1.04e-01 | 2.58e-01 |
| Cellular hexose transport | 15 | 4.86e-01 | -1.04e-01 | 5.95e-01 |
| FCERI mediated NF-kB activation | 138 | 3.53e-02 | 1.04e-01 | 7.35e-02 |
| Signaling by FGFR2 | 60 | 1.65e-01 | 1.04e-01 | 2.54e-01 |
| PI3K/AKT Signaling in Cancer | 81 | 1.08e-01 | 1.03e-01 | 1.80e-01 |
| RUNX2 regulates osteoblast differentiation | 19 | 4.36e-01 | -1.03e-01 | 5.48e-01 |
| Formation of HIV elongation complex in the absence of HIV Tat | 44 | 2.38e-01 | 1.03e-01 | 3.42e-01 |
| Acetylcholine Neurotransmitter Release Cycle | 11 | 5.55e-01 | -1.03e-01 | 6.61e-01 |
| Generic Transcription Pathway | 1085 | 1.09e-08 | -1.03e-01 | 2.28e-07 |
| Negative epigenetic regulation of rRNA expression | 65 | 1.52e-01 | 1.03e-01 | 2.37e-01 |
| Mitochondrial calcium ion transport | 22 | 4.05e-01 | 1.03e-01 | 5.19e-01 |
| Regulation of TP53 Activity | 152 | 2.96e-02 | -1.02e-01 | 6.39e-02 |
| G alpha (i) signalling events | 246 | 5.89e-03 | 1.02e-01 | 1.73e-02 |
| Gene expression (Transcription) | 1335 | 4.00e-10 | -1.02e-01 | 1.19e-08 |
| SLC-mediated transmembrane transport | 180 | 1.84e-02 | 1.02e-01 | 4.26e-02 |
| DNA Double-Strand Break Repair | 135 | 4.22e-02 | -1.01e-01 | 8.58e-02 |
| Biological oxidations | 138 | 4.10e-02 | 1.01e-01 | 8.37e-02 |
| Cilium Assembly | 181 | 1.95e-02 | -1.01e-01 | 4.48e-02 |
| Caspase-mediated cleavage of cytoskeletal proteins | 12 | 5.47e-01 | 1.01e-01 | 6.54e-01 |
| Interleukin receptor SHC signaling | 23 | 4.04e-01 | 1.00e-01 | 5.19e-01 |
| Transcriptional activation of mitochondrial biogenesis | 51 | 2.20e-01 | 9.92e-02 | 3.24e-01 |
| Post NMDA receptor activation events | 48 | 2.36e-01 | 9.88e-02 | 3.41e-01 |
| Interconversion of nucleotide di- and triphosphates | 27 | 3.75e-01 | 9.87e-02 | 4.86e-01 |
| Switching of origins to a post-replicative state | 90 | 1.07e-01 | 9.84e-02 | 1.79e-01 |
| Condensation of Prometaphase Chromosomes | 11 | 5.73e-01 | 9.81e-02 | 6.78e-01 |
| Regulation of KIT signaling | 15 | 5.12e-01 | 9.79e-02 | 6.21e-01 |
| Glutamate and glutamine metabolism | 12 | 5.61e-01 | -9.69e-02 | 6.67e-01 |
| Nicotinamide salvaging | 14 | 5.31e-01 | -9.67e-02 | 6.40e-01 |
| PI-3K cascade:FGFR1 | 12 | 5.63e-01 | 9.63e-02 | 6.68e-01 |
| Endosomal/Vacuolar pathway | 12 | 5.63e-01 | -9.63e-02 | 6.68e-01 |
| Downstream signaling of activated FGFR1 | 20 | 4.62e-01 | 9.49e-02 | 5.74e-01 |
| IGF1R signaling cascade | 36 | 3.24e-01 | 9.49e-02 | 4.39e-01 |
| N-Glycan antennae elongation | 13 | 5.54e-01 | -9.48e-02 | 6.61e-01 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | 73 | 1.62e-01 | 9.47e-02 | 2.49e-01 |
| Cytochrome P450 - arranged by substrate type | 36 | 3.28e-01 | 9.43e-02 | 4.41e-01 |
| Diseases associated with glycosaminoglycan metabolism | 26 | 4.08e-01 | 9.38e-02 | 5.22e-01 |
| Separation of Sister Chromatids | 168 | 3.62e-02 | 9.36e-02 | 7.48e-02 |
| Interleukin-2 family signaling | 38 | 3.19e-01 | 9.35e-02 | 4.32e-01 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | 46 | 2.74e-01 | 9.31e-02 | 3.85e-01 |
| Cholesterol biosynthesis | 24 | 4.30e-01 | 9.30e-02 | 5.45e-01 |
| HSF1 activation | 26 | 4.12e-01 | 9.30e-02 | 5.25e-01 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | 23 | 4.43e-01 | 9.25e-02 | 5.54e-01 |
| G alpha (q) signalling events | 134 | 6.48e-02 | 9.24e-02 | 1.21e-01 |
| Signaling by FGFR | 69 | 1.85e-01 | 9.23e-02 | 2.81e-01 |
| Regulation of TP53 Activity through Phosphorylation | 88 | 1.35e-01 | -9.21e-02 | 2.16e-01 |
| Nuclear Envelope Breakdown | 53 | 2.46e-01 | -9.20e-02 | 3.53e-01 |
| Synthesis of IP3 and IP4 in the cytosol | 22 | 4.56e-01 | 9.17e-02 | 5.68e-01 |
| mRNA Capping | 29 | 3.97e-01 | 9.08e-02 | 5.12e-01 |
| DNA Damage Bypass | 47 | 2.82e-01 | -9.07e-02 | 3.92e-01 |
| RNA Polymerase III Abortive And Retractive Initiation | 41 | 3.15e-01 | -9.06e-02 | 4.28e-01 |
| RNA Polymerase III Transcription | 41 | 3.15e-01 | -9.06e-02 | 4.28e-01 |
| Acyl chain remodelling of PS | 14 | 5.59e-01 | 9.02e-02 | 6.65e-01 |
| STING mediated induction of host immune responses | 15 | 5.48e-01 | 8.96e-02 | 6.55e-01 |
| Homology Directed Repair | 110 | 1.07e-01 | -8.89e-02 | 1.80e-01 |
| Lysine catabolism | 11 | 6.10e-01 | 8.87e-02 | 7.10e-01 |
| Metabolism of RNA | 688 | 7.82e-05 | -8.83e-02 | 4.72e-04 |
| Purine catabolism | 16 | 5.42e-01 | 8.80e-02 | 6.49e-01 |
| Phase 2 - plateau phase | 17 | 5.30e-01 | -8.80e-02 | 6.39e-01 |
| M Phase | 361 | 4.44e-03 | 8.72e-02 | 1.39e-02 |
| Mitotic G2-G2/M phases | 183 | 4.27e-02 | 8.69e-02 | 8.65e-02 |
| RNA Polymerase II Transcription | 1204 | 4.09e-07 | -8.67e-02 | 5.94e-06 |
| NCAM signaling for neurite out-growth | 43 | 3.26e-01 | -8.66e-02 | 4.39e-01 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | 36 | 3.69e-01 | 8.65e-02 | 4.80e-01 |
| Nonhomologous End-Joining (NHEJ) | 42 | 3.36e-01 | 8.58e-02 | 4.49e-01 |
| Inositol phosphate metabolism | 42 | 3.38e-01 | 8.54e-02 | 4.51e-01 |
| Signaling by the B Cell Receptor (BCR) | 163 | 6.05e-02 | 8.52e-02 | 1.15e-01 |
| Peptide ligand-binding receptors | 97 | 1.47e-01 | 8.52e-02 | 2.31e-01 |
| Transcription of the HIV genome | 67 | 2.28e-01 | 8.51e-02 | 3.33e-01 |
| Activation of BH3-only proteins | 30 | 4.22e-01 | 8.48e-02 | 5.37e-01 |
| APC/C:Cdc20 mediated degradation of Cyclin B | 24 | 4.76e-01 | 8.40e-02 | 5.87e-01 |
| Processing of Intronless Pre-mRNAs | 19 | 5.28e-01 | -8.37e-02 | 6.37e-01 |
| Nephrin family interactions | 18 | 5.40e-01 | -8.33e-02 | 6.48e-01 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | 23 | 4.90e-01 | 8.31e-02 | 5.98e-01 |
| Synthesis of IP2, IP, and Ins in the cytosol | 13 | 6.04e-01 | 8.31e-02 | 7.04e-01 |
| Signaling by WNT in cancer | 30 | 4.31e-01 | 8.30e-02 | 5.45e-01 |
| Prolactin receptor signaling | 11 | 6.33e-01 | 8.30e-02 | 7.29e-01 |
| IRS-related events triggered by IGF1R | 35 | 3.95e-01 | 8.30e-02 | 5.10e-01 |
| Fertilization | 12 | 6.19e-01 | 8.29e-02 | 7.16e-01 |
| G1/S-Specific Transcription | 29 | 4.40e-01 | -8.28e-02 | 5.52e-01 |
| Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS) | 10 | 6.50e-01 | -8.28e-02 | 7.45e-01 |
| NRAGE signals death through JNK | 53 | 3.03e-01 | 8.19e-02 | 4.14e-01 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | 17 | 5.60e-01 | -8.16e-02 | 6.66e-01 |
| DNA Repair | 289 | 1.71e-02 | -8.15e-02 | 4.04e-02 |
| Elevation of cytosolic Ca2+ levels | 13 | 6.11e-01 | 8.15e-02 | 7.10e-01 |
| Formation of the ternary complex, and subsequently, the 43S complex | 51 | 3.16e-01 | -8.11e-02 | 4.29e-01 |
| Recruitment of NuMA to mitotic centrosomes | 80 | 2.10e-01 | -8.10e-02 | 3.12e-01 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | 11 | 6.43e-01 | -8.08e-02 | 7.38e-01 |
| Host Interactions of HIV factors | 130 | 1.12e-01 | 8.07e-02 | 1.84e-01 |
| TNFs bind their physiological receptors | 25 | 4.86e-01 | -8.06e-02 | 5.95e-01 |
| DNA Double Strand Break Response | 47 | 3.40e-01 | 8.05e-02 | 4.52e-01 |
| Chondroitin sulfate/dermatan sulfate metabolism | 38 | 3.91e-01 | 8.04e-02 | 5.06e-01 |
| G2/M Transition | 181 | 6.42e-02 | 7.98e-02 | 1.20e-01 |
| Regulation of HSF1-mediated heat shock response | 79 | 2.22e-01 | -7.94e-02 | 3.26e-01 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | 17 | 5.71e-01 | -7.93e-02 | 6.76e-01 |
| PKMTs methylate histone lysines | 45 | 3.58e-01 | -7.92e-02 | 4.68e-01 |
| Olfactory Signaling Pathway | 60 | 2.89e-01 | 7.91e-02 | 4.00e-01 |
| Interleukin-7 signaling | 21 | 5.38e-01 | 7.76e-02 | 6.46e-01 |
| Signaling by GPCR | 545 | 2.12e-03 | 7.69e-02 | 7.50e-03 |
| Centrosome maturation | 81 | 2.32e-01 | -7.69e-02 | 3.36e-01 |
| Recruitment of mitotic centrosome proteins and complexes | 81 | 2.32e-01 | -7.69e-02 | 3.36e-01 |
| GPCR downstream signalling | 501 | 3.26e-03 | 7.68e-02 | 1.08e-02 |
| Sema3A PAK dependent Axon repulsion | 16 | 5.96e-01 | 7.66e-02 | 6.97e-01 |
| ADORA2B mediated anti-inflammatory cytokines production | 73 | 2.62e-01 | 7.60e-02 | 3.70e-01 |
| Synthesis of glycosylphosphatidylinositol (GPI) | 17 | 5.89e-01 | -7.56e-02 | 6.93e-01 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | 25 | 5.13e-01 | 7.56e-02 | 6.23e-01 |
| TICAM1-dependent activation of IRF3/IRF7 | 12 | 6.52e-01 | 7.51e-02 | 7.47e-01 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | 11 | 6.66e-01 | -7.51e-02 | 7.57e-01 |
| Transcriptional regulation by small RNAs | 63 | 3.04e-01 | 7.49e-02 | 4.15e-01 |
| TP53 Regulates Transcription of Death Receptors and Ligands | 12 | 6.55e-01 | 7.46e-02 | 7.49e-01 |
| FCERI mediated Ca+2 mobilization | 89 | 2.26e-01 | -7.42e-02 | 3.31e-01 |
| Inactivation, recovery and regulation of the phototransduction cascade | 25 | 5.22e-01 | -7.40e-02 | 6.31e-01 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | 37 | 4.36e-01 | 7.39e-02 | 5.48e-01 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | 19 | 5.78e-01 | -7.36e-02 | 6.83e-01 |
| Signaling by NTRK3 (TRKC) | 16 | 6.13e-01 | 7.29e-02 | 7.12e-01 |
| Neurotransmitter release cycle | 39 | 4.31e-01 | 7.29e-02 | 5.45e-01 |
| Cell-cell junction organization | 39 | 4.31e-01 | 7.29e-02 | 5.45e-01 |
| TCR signaling | 122 | 1.65e-01 | 7.28e-02 | 2.53e-01 |
| TRP channels | 19 | 5.83e-01 | -7.28e-02 | 6.87e-01 |
| Anchoring of the basal body to the plasma membrane | 97 | 2.17e-01 | -7.26e-02 | 3.20e-01 |
| Positive epigenetic regulation of rRNA expression | 62 | 3.26e-01 | 7.21e-02 | 4.39e-01 |
| Regulation of RUNX1 Expression and Activity | 18 | 5.97e-01 | -7.20e-02 | 6.98e-01 |
| Adaptive Immune System | 757 | 7.74e-04 | 7.18e-02 | 3.31e-03 |
| Ovarian tumor domain proteases | 37 | 4.53e-01 | 7.13e-02 | 5.65e-01 |
| Downstream TCR signaling | 101 | 2.16e-01 | 7.12e-02 | 3.20e-01 |
| RIPK1-mediated regulated necrosis | 16 | 6.23e-01 | 7.11e-02 | 7.18e-01 |
| Regulated Necrosis | 16 | 6.23e-01 | 7.11e-02 | 7.18e-01 |
| MicroRNA (miRNA) biogenesis | 24 | 5.54e-01 | 6.97e-02 | 6.61e-01 |
| FCGR3A-mediated IL10 synthesis | 99 | 2.34e-01 | -6.92e-02 | 3.38e-01 |
| Cellular response to heat stress | 93 | 2.59e-01 | -6.78e-02 | 3.67e-01 |
| Establishment of Sister Chromatid Cohesion | 11 | 6.97e-01 | 6.78e-02 | 7.87e-01 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | 63 | 3.59e-01 | 6.68e-02 | 4.69e-01 |
| G alpha (s) signalling events | 143 | 1.69e-01 | 6.66e-02 | 2.59e-01 |
| Cyclin D associated events in G1 | 47 | 4.33e-01 | 6.61e-02 | 5.46e-01 |
| G1 Phase | 47 | 4.33e-01 | 6.61e-02 | 5.46e-01 |
| Signaling by FGFR4 in disease | 11 | 7.05e-01 | 6.59e-02 | 7.94e-01 |
| TRAF6 mediated IRF7 activation | 15 | 6.59e-01 | 6.59e-02 | 7.52e-01 |
| IRS-mediated signalling | 34 | 5.09e-01 | 6.55e-02 | 6.18e-01 |
| Scavenging of heme from plasma | 71 | 3.41e-01 | -6.53e-02 | 4.52e-01 |
| Pregnenolone biosynthesis | 10 | 7.23e-01 | 6.47e-02 | 8.06e-01 |
| SUMOylation of transcription cofactors | 44 | 4.59e-01 | 6.45e-02 | 5.70e-01 |
| WNT ligand biogenesis and trafficking | 21 | 6.10e-01 | 6.42e-02 | 7.10e-01 |
| FGFR2 alternative splicing | 25 | 5.82e-01 | 6.37e-02 | 6.86e-01 |
| Interleukin-37 signaling | 19 | 6.31e-01 | 6.36e-02 | 7.26e-01 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | 104 | 2.63e-01 | -6.36e-02 | 3.71e-01 |
| Xenobiotics | 12 | 7.03e-01 | -6.35e-02 | 7.93e-01 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | 43 | 4.72e-01 | 6.34e-02 | 5.84e-01 |
| Synthesis, secretion, and deacylation of Ghrelin | 11 | 7.16e-01 | -6.33e-02 | 8.01e-01 |
| Base Excision Repair | 58 | 4.05e-01 | -6.32e-02 | 5.19e-01 |
| Basigin interactions | 23 | 6.01e-01 | 6.31e-02 | 7.01e-01 |
| Late Phase of HIV Life Cycle | 131 | 2.13e-01 | 6.30e-02 | 3.16e-01 |
| Processing and activation of SUMO | 10 | 7.35e-01 | 6.17e-02 | 8.16e-01 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | 12 | 7.13e-01 | -6.13e-02 | 8.00e-01 |
| Post-translational modification: synthesis of GPI-anchored proteins | 57 | 4.25e-01 | 6.11e-02 | 5.40e-01 |
| Constitutive Signaling by Aberrant PI3K in Cancer | 54 | 4.44e-01 | 6.02e-02 | 5.56e-01 |
| TP53 Regulates Transcription of Cell Cycle Genes | 48 | 4.74e-01 | 5.97e-02 | 5.86e-01 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | 27 | 5.92e-01 | 5.96e-02 | 6.95e-01 |
| Receptor-type tyrosine-protein phosphatases | 12 | 7.24e-01 | 5.89e-02 | 8.06e-01 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | 84 | 3.51e-01 | -5.89e-02 | 4.63e-01 |
| NOTCH4 Intracellular Domain Regulates Transcription | 18 | 6.67e-01 | 5.87e-02 | 7.57e-01 |
| Transcriptional Regulation by VENTX | 38 | 5.38e-01 | -5.77e-02 | 6.46e-01 |
| Diseases associated with N-glycosylation of proteins | 17 | 6.85e-01 | 5.69e-02 | 7.76e-01 |
| PI3K Cascade | 30 | 5.90e-01 | 5.69e-02 | 6.93e-01 |
| Regulation of PTEN mRNA translation | 13 | 7.23e-01 | -5.67e-02 | 8.06e-01 |
| PERK regulates gene expression | 31 | 5.86e-01 | 5.66e-02 | 6.89e-01 |
| Branched-chain amino acid catabolism | 21 | 6.58e-01 | -5.57e-02 | 7.52e-01 |
| Loss of Nlp from mitotic centrosomes | 69 | 4.32e-01 | -5.47e-02 | 5.45e-01 |
| Loss of proteins required for interphase microtubule organization from the centrosome | 69 | 4.32e-01 | -5.47e-02 | 5.45e-01 |
| G2/M Checkpoints | 140 | 2.68e-01 | 5.42e-02 | 3.77e-01 |
| Translation | 295 | 1.10e-01 | -5.41e-02 | 1.83e-01 |
| Transport of inorganic cations/anions and amino acids/oligopeptides | 80 | 4.08e-01 | 5.35e-02 | 5.22e-01 |
| Other interleukin signaling | 18 | 6.95e-01 | 5.34e-02 | 7.85e-01 |
| PI-3K cascade:FGFR2 | 12 | 7.50e-01 | -5.32e-02 | 8.28e-01 |
| SUMOylation | 166 | 2.45e-01 | -5.23e-02 | 3.52e-01 |
| Synthesis of PIPs at the Golgi membrane | 16 | 7.21e-01 | 5.16e-02 | 8.05e-01 |
| Gamma carboxylation, hypusine formation and arylsulfatase activation | 34 | 6.03e-01 | 5.15e-02 | 7.04e-01 |
| Processing of SMDT1 | 15 | 7.30e-01 | 5.14e-02 | 8.12e-01 |
| Eicosanoid ligand-binding receptors | 13 | 7.48e-01 | -5.14e-02 | 8.28e-01 |
| RNA Polymerase I Promoter Clearance | 66 | 4.78e-01 | 5.05e-02 | 5.88e-01 |
| RNA Polymerase I Transcription | 66 | 4.78e-01 | 5.05e-02 | 5.88e-01 |
| CD28 co-stimulation | 33 | 6.17e-01 | -5.03e-02 | 7.15e-01 |
| Cargo trafficking to the periciliary membrane | 47 | 5.63e-01 | 4.88e-02 | 6.68e-01 |
| Role of LAT2/NTAL/LAB on calcium mobilization | 74 | 4.69e-01 | -4.87e-02 | 5.81e-01 |
| Signaling by NODAL | 13 | 7.62e-01 | -4.86e-02 | 8.37e-01 |
| Mitotic Prometaphase | 185 | 2.57e-01 | -4.83e-02 | 3.65e-01 |
| Association of TriC/CCT with target proteins during biosynthesis | 37 | 6.11e-01 | 4.83e-02 | 7.10e-01 |
| TRAF3-dependent IRF activation pathway | 13 | 7.63e-01 | 4.82e-02 | 8.38e-01 |
| TP53 Regulates Transcription of DNA Repair Genes | 61 | 5.20e-01 | -4.76e-02 | 6.29e-01 |
| Processing of Capped Intronless Pre-mRNA | 28 | 6.63e-01 | -4.76e-02 | 7.55e-01 |
| mRNA Splicing - Minor Pathway | 52 | 5.56e-01 | 4.72e-02 | 6.63e-01 |
| Neurexins and neuroligins | 37 | 6.21e-01 | -4.70e-02 | 7.17e-01 |
| Chromatin modifying enzymes | 218 | 2.34e-01 | 4.67e-02 | 3.38e-01 |
| Chromatin organization | 218 | 2.34e-01 | 4.67e-02 | 3.38e-01 |
| HIV Life Cycle | 144 | 3.39e-01 | 4.61e-02 | 4.51e-01 |
| Phosphorylation of the APC/C | 20 | 7.21e-01 | 4.61e-02 | 8.05e-01 |
| Telomere Maintenance | 80 | 4.88e-01 | -4.48e-02 | 5.96e-01 |
| Ion transport by P-type ATPases | 43 | 6.12e-01 | 4.47e-02 | 7.11e-01 |
| SUMO E3 ligases SUMOylate target proteins | 160 | 3.33e-01 | -4.44e-02 | 4.46e-01 |
| Reproduction | 80 | 4.93e-01 | 4.43e-02 | 6.01e-01 |
| Glucagon-type ligand receptors | 20 | 7.32e-01 | 4.42e-02 | 8.13e-01 |
| DNA Replication Pre-Initiation | 83 | 4.87e-01 | 4.42e-02 | 5.95e-01 |
| O-linked glycosylation | 84 | 4.86e-01 | -4.40e-02 | 5.95e-01 |
| Global Genome Nucleotide Excision Repair (GG-NER) | 84 | 4.86e-01 | -4.40e-02 | 5.95e-01 |
| Signaling by FGFR2 in disease | 32 | 6.67e-01 | 4.39e-02 | 7.57e-01 |
| Defective B4GALT7 causes EDS, progeroid type | 11 | 8.02e-01 | -4.37e-02 | 8.67e-01 |
| Diseases of metabolism | 191 | 2.99e-01 | 4.36e-02 | 4.10e-01 |
| Netrin-1 signaling | 40 | 6.38e-01 | 4.30e-02 | 7.33e-01 |
| RNA Polymerase III Transcription Termination | 23 | 7.25e-01 | -4.24e-02 | 8.06e-01 |
| DAP12 signaling | 28 | 6.98e-01 | 4.23e-02 | 7.88e-01 |
| Regulation of expression of SLITs and ROBOs | 161 | 3.55e-01 | -4.22e-02 | 4.66e-01 |
| SHC-mediated cascade:FGFR2 | 12 | 8.01e-01 | -4.21e-02 | 8.67e-01 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | 20 | 7.45e-01 | -4.20e-02 | 8.25e-01 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | 12 | 8.02e-01 | 4.18e-02 | 8.67e-01 |
| Transcriptional Regulation by TP53 | 352 | 1.82e-01 | 4.14e-02 | 2.77e-01 |
| Norepinephrine Neurotransmitter Release Cycle | 14 | 7.92e-01 | 4.07e-02 | 8.63e-01 |
| Signaling by KIT in disease | 20 | 7.56e-01 | -4.01e-02 | 8.33e-01 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | 20 | 7.56e-01 | -4.01e-02 | 8.33e-01 |
| Glutamate Neurotransmitter Release Cycle | 20 | 7.57e-01 | -4.00e-02 | 8.33e-01 |
| IL-6-type cytokine receptor ligand interactions | 12 | 8.11e-01 | 3.98e-02 | 8.75e-01 |
| Lewis blood group biosynthesis | 13 | 8.04e-01 | 3.97e-02 | 8.69e-01 |
| CDC6 association with the ORC:origin complex | 11 | 8.20e-01 | -3.95e-02 | 8.83e-01 |
| Formation of Incision Complex in GG-NER | 43 | 6.56e-01 | 3.93e-02 | 7.50e-01 |
| SUMOylation of DNA methylation proteins | 16 | 7.86e-01 | -3.91e-02 | 8.59e-01 |
| Sulfur amino acid metabolism | 22 | 7.53e-01 | 3.88e-02 | 8.30e-01 |
| Interleukin-2 signaling | 11 | 8.25e-01 | 3.84e-02 | 8.88e-01 |
| Meiosis | 68 | 5.93e-01 | 3.75e-02 | 6.95e-01 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | 91 | 5.38e-01 | -3.74e-02 | 6.46e-01 |
| Amplification of signal from the kinetochores | 91 | 5.38e-01 | -3.74e-02 | 6.46e-01 |
| mRNA 3'-end processing | 56 | 6.29e-01 | -3.73e-02 | 7.25e-01 |
| TNFR1-induced NFkappaB signaling pathway | 25 | 7.50e-01 | -3.68e-02 | 8.28e-01 |
| Cytosolic sensors of pathogen-associated DNA | 62 | 6.19e-01 | 3.65e-02 | 7.16e-01 |
| Termination of O-glycan biosynthesis | 16 | 8.02e-01 | 3.63e-02 | 8.67e-01 |
| AURKA Activation by TPX2 | 72 | 5.98e-01 | -3.60e-02 | 6.99e-01 |
| Mitochondrial protein import | 64 | 6.19e-01 | 3.59e-02 | 7.16e-01 |
| Deactivation of the beta-catenin transactivating complex | 36 | 7.10e-01 | 3.58e-02 | 7.97e-01 |
| Synthesis of DNA | 119 | 5.06e-01 | -3.53e-02 | 6.16e-01 |
| CLEC7A (Dectin-1) induces NFAT activation | 11 | 8.40e-01 | -3.52e-02 | 8.98e-01 |
| S Phase | 161 | 4.47e-01 | -3.48e-02 | 5.58e-01 |
| Class A/1 (Rhodopsin-like receptors) | 169 | 4.36e-01 | 3.47e-02 | 5.48e-01 |
| Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane | 11 | 8.42e-01 | 3.47e-02 | 9.00e-01 |
| Metabolism of water-soluble vitamins and cofactors | 110 | 5.37e-01 | -3.41e-02 | 6.46e-01 |
| Processing of Capped Intron-Containing Pre-mRNA | 238 | 3.66e-01 | -3.40e-02 | 4.76e-01 |
| Mitotic G1 phase and G1/S transition | 148 | 4.86e-01 | 3.32e-02 | 5.95e-01 |
| Metabolism of vitamins and cofactors | 156 | 4.76e-01 | 3.31e-02 | 5.87e-01 |
| Vitamin D (calciferol) metabolism | 10 | 8.57e-01 | 3.29e-02 | 9.05e-01 |
| IRF3-mediated induction of type I IFN | 12 | 8.44e-01 | -3.29e-02 | 9.00e-01 |
| PIWI-interacting RNA (piRNA) biogenesis | 24 | 7.81e-01 | 3.28e-02 | 8.55e-01 |
| Visual phototransduction | 60 | 6.65e-01 | 3.23e-02 | 7.57e-01 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | 14 | 8.38e-01 | -3.16e-02 | 8.97e-01 |
| Nucleotide-like (purinergic) receptors | 13 | 8.44e-01 | 3.15e-02 | 9.00e-01 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | 36 | 7.45e-01 | -3.13e-02 | 8.25e-01 |
| Diseases of mitotic cell cycle | 36 | 7.45e-01 | -3.13e-02 | 8.25e-01 |
| Mitotic Spindle Checkpoint | 108 | 5.80e-01 | -3.08e-02 | 6.84e-01 |
| Processing of DNA double-strand break ends | 71 | 6.59e-01 | -3.03e-02 | 7.52e-01 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | 14 | 8.45e-01 | -3.02e-02 | 9.01e-01 |
| Signaling by Retinoic Acid | 31 | 7.73e-01 | 3.00e-02 | 8.47e-01 |
| GABA synthesis, release, reuptake and degradation | 13 | 8.52e-01 | -2.98e-02 | 9.02e-01 |
| Voltage gated Potassium channels | 25 | 7.97e-01 | 2.97e-02 | 8.66e-01 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | 17 | 8.34e-01 | -2.94e-02 | 8.94e-01 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | 17 | 8.34e-01 | -2.94e-02 | 8.94e-01 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | 14 | 8.54e-01 | 2.85e-02 | 9.02e-01 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | 14 | 8.54e-01 | 2.85e-02 | 9.02e-01 |
| G2/M DNA damage checkpoint | 68 | 6.86e-01 | -2.84e-02 | 7.77e-01 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | 64 | 6.95e-01 | -2.84e-02 | 7.85e-01 |
| RNA Polymerase II Transcription Termination | 65 | 6.95e-01 | -2.81e-02 | 7.85e-01 |
| Serotonin Neurotransmitter Release Cycle | 15 | 8.50e-01 | 2.81e-02 | 9.02e-01 |
| Activation of SMO | 13 | 8.65e-01 | 2.73e-02 | 9.12e-01 |
| Mitochondrial Fatty Acid Beta-Oxidation | 36 | 7.77e-01 | 2.73e-02 | 8.52e-01 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | 21 | 8.32e-01 | -2.68e-02 | 8.93e-01 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | 21 | 8.32e-01 | -2.68e-02 | 8.93e-01 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | 16 | 8.58e-01 | -2.59e-02 | 9.05e-01 |
| N-glycan antennae elongation in the medial/trans-Golgi | 21 | 8.40e-01 | -2.54e-02 | 8.98e-01 |
| APC-Cdc20 mediated degradation of Nek2A | 26 | 8.37e-01 | 2.34e-02 | 8.96e-01 |
| Ribosomal scanning and start codon recognition | 58 | 7.59e-01 | -2.33e-02 | 8.34e-01 |
| Interaction between L1 and Ankyrins | 22 | 8.50e-01 | 2.33e-02 | 9.02e-01 |
| Deposition of new CENPA-containing nucleosomes at the centromere | 40 | 8.00e-01 | 2.32e-02 | 8.67e-01 |
| Nucleosome assembly | 40 | 8.00e-01 | 2.32e-02 | 8.67e-01 |
| KSRP (KHSRP) binds and destabilizes mRNA | 17 | 8.69e-01 | -2.32e-02 | 9.14e-01 |
| FGFR2 mutant receptor activation | 22 | 8.51e-01 | 2.31e-02 | 9.02e-01 |
| Interleukin-35 Signalling | 12 | 8.91e-01 | -2.29e-02 | 9.33e-01 |
| DNA Replication | 126 | 6.64e-01 | -2.24e-02 | 7.56e-01 |
| Binding and Uptake of Ligands by Scavenger Receptors | 93 | 7.09e-01 | 2.24e-02 | 7.97e-01 |
| Regulation of Complement cascade | 95 | 7.15e-01 | -2.17e-02 | 8.01e-01 |
| Complement cascade | 99 | 7.15e-01 | -2.12e-02 | 8.01e-01 |
| Class B/2 (Secretin family receptors) | 56 | 7.84e-01 | 2.11e-02 | 8.57e-01 |
| Methylation | 12 | 8.99e-01 | -2.11e-02 | 9.38e-01 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | 22 | 8.65e-01 | 2.10e-02 | 9.12e-01 |
| G0 and Early G1 | 27 | 8.52e-01 | 2.08e-02 | 9.02e-01 |
| GPCR ligand binding | 235 | 5.92e-01 | 2.03e-02 | 6.95e-01 |
| RHO GTPases Activate Formins | 117 | 7.09e-01 | 2.00e-02 | 7.97e-01 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | 14 | 8.98e-01 | 1.99e-02 | 9.38e-01 |
| Cell Cycle, Mitotic | 503 | 4.49e-01 | 1.97e-02 | 5.61e-01 |
| Defective B3GALT6 causes EDSP2 and SEMDJL1 | 11 | 9.10e-01 | -1.97e-02 | 9.44e-01 |
| Regulation of innate immune responses to cytosolic DNA | 14 | 8.99e-01 | 1.96e-02 | 9.38e-01 |
| Synthesis of PA | 32 | 8.50e-01 | 1.94e-02 | 9.02e-01 |
| Signaling by BMP | 21 | 8.81e-01 | -1.89e-02 | 9.25e-01 |
| EML4 and NUDC in mitotic spindle formation | 95 | 7.52e-01 | -1.87e-02 | 8.30e-01 |
| RUNX2 regulates bone development | 24 | 8.75e-01 | -1.85e-02 | 9.20e-01 |
| Signaling by FGFR3 in disease | 13 | 9.08e-01 | 1.84e-02 | 9.44e-01 |
| Signaling by FGFR3 point mutants in cancer | 13 | 9.08e-01 | 1.84e-02 | 9.44e-01 |
| Translation initiation complex formation | 58 | 8.09e-01 | -1.83e-02 | 8.74e-01 |
| HCMV Early Events | 74 | 7.91e-01 | 1.78e-02 | 8.62e-01 |
| Regulation of PLK1 Activity at G2/M Transition | 87 | 7.83e-01 | -1.71e-02 | 8.56e-01 |
| Dual incision in TC-NER | 65 | 8.15e-01 | -1.67e-02 | 8.79e-01 |
| Cell Cycle Checkpoints | 260 | 6.48e-01 | 1.65e-02 | 7.43e-01 |
| Downstream signaling of activated FGFR2 | 19 | 9.03e-01 | 1.62e-02 | 9.41e-01 |
| HATs acetylate histones | 93 | 7.88e-01 | -1.61e-02 | 8.60e-01 |
| AKT phosphorylates targets in the nucleus | 10 | 9.31e-01 | -1.58e-02 | 9.55e-01 |
| FCERI mediated MAPK activation | 90 | 7.97e-01 | 1.57e-02 | 8.66e-01 |
| CRMPs in Sema3A signaling | 14 | 9.19e-01 | -1.56e-02 | 9.50e-01 |
| FRS-mediated FGFR2 signaling | 14 | 9.20e-01 | 1.56e-02 | 9.50e-01 |
| Lysosphingolipid and LPA receptors | 11 | 9.30e-01 | -1.52e-02 | 9.55e-01 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | 20 | 9.08e-01 | -1.50e-02 | 9.44e-01 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | 20 | 9.08e-01 | 1.49e-02 | 9.44e-01 |
| Keratan sulfate biosynthesis | 22 | 9.04e-01 | -1.49e-02 | 9.42e-01 |
| Epigenetic regulation of gene expression | 103 | 7.96e-01 | 1.47e-02 | 8.66e-01 |
| Negative regulators of DDX58/IFIH1 signaling | 34 | 8.90e-01 | -1.37e-02 | 9.33e-01 |
| Organelle biogenesis and maintenance | 269 | 7.09e-01 | -1.32e-02 | 7.97e-01 |
| Regulation of TP53 Expression and Degradation | 36 | 8.93e-01 | -1.30e-02 | 9.34e-01 |
| CTLA4 inhibitory signaling | 21 | 9.19e-01 | -1.29e-02 | 9.50e-01 |
| Defective EXT1 causes exostoses 1, TRPS2 and CHDS | 10 | 9.44e-01 | 1.29e-02 | 9.62e-01 |
| Defective EXT2 causes exostoses 2 | 10 | 9.44e-01 | 1.29e-02 | 9.62e-01 |
| Regulation of necroptotic cell death | 14 | 9.35e-01 | -1.27e-02 | 9.57e-01 |
| Transcription of E2F targets under negative control by DREAM complex | 19 | 9.26e-01 | 1.23e-02 | 9.54e-01 |
| FOXO-mediated transcription of cell cycle genes | 15 | 9.36e-01 | 1.19e-02 | 9.58e-01 |
| Cardiac conduction | 92 | 8.48e-01 | 1.16e-02 | 9.02e-01 |
| Dopamine Neurotransmitter Release Cycle | 20 | 9.29e-01 | 1.15e-02 | 9.54e-01 |
| Nicotinate metabolism | 25 | 9.21e-01 | -1.15e-02 | 9.50e-01 |
| TNF signaling | 42 | 8.99e-01 | 1.13e-02 | 9.38e-01 |
| Signaling by ROBO receptors | 201 | 7.93e-01 | -1.07e-02 | 8.63e-01 |
| Mitochondrial translation termination | 91 | 8.68e-01 | -1.01e-02 | 9.14e-01 |
| CASP8 activity is inhibited | 11 | 9.55e-01 | -9.91e-03 | 9.67e-01 |
| Dimerization of procaspase-8 | 11 | 9.55e-01 | -9.91e-03 | 9.67e-01 |
| Regulation by c-FLIP | 11 | 9.55e-01 | -9.91e-03 | 9.67e-01 |
| DNA Damage Recognition in GG-NER | 38 | 9.16e-01 | -9.86e-03 | 9.48e-01 |
| Mitochondrial translation elongation | 91 | 8.78e-01 | -9.27e-03 | 9.23e-01 |
| mRNA decay by 5' to 3' exoribonuclease | 15 | 9.54e-01 | -8.64e-03 | 9.67e-01 |
| Cell Cycle | 625 | 7.16e-01 | -8.52e-03 | 8.01e-01 |
| Deadenylation-dependent mRNA decay | 53 | 9.16e-01 | -8.41e-03 | 9.48e-01 |
| Synthesis of PIPs at the early endosome membrane | 16 | 9.54e-01 | -8.25e-03 | 9.67e-01 |
| Regulation of FZD by ubiquitination | 15 | 9.56e-01 | -8.14e-03 | 9.68e-01 |
| Nucleotide Excision Repair | 110 | 8.85e-01 | -8.00e-03 | 9.28e-01 |
| PECAM1 interactions | 12 | 9.62e-01 | -7.90e-03 | 9.71e-01 |
| RMTs methylate histone arginines | 37 | 9.37e-01 | 7.53e-03 | 9.58e-01 |
| Tight junction interactions | 18 | 9.57e-01 | 7.28e-03 | 9.68e-01 |
| Defective B3GAT3 causes JDSSDHD | 11 | 9.69e-01 | -6.88e-03 | 9.76e-01 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | 31 | 9.50e-01 | 6.49e-03 | 9.67e-01 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 59 | 9.33e-01 | -6.36e-03 | 9.56e-01 |
| Diseases of glycosylation | 109 | 9.12e-01 | -6.11e-03 | 9.46e-01 |
| Metabolism of amino acids and derivatives | 326 | 8.50e-01 | -6.08e-03 | 9.02e-01 |
| Regulation of TP53 Degradation | 35 | 9.51e-01 | 6.03e-03 | 9.67e-01 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | 78 | 9.29e-01 | -5.87e-03 | 9.54e-01 |
| G1/S Transition | 130 | 9.10e-01 | 5.77e-03 | 9.44e-01 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | 13 | 9.72e-01 | 5.64e-03 | 9.79e-01 |
| Collagen chain trimerization | 27 | 9.60e-01 | 5.54e-03 | 9.70e-01 |
| Resolution of Sister Chromatid Cohesion | 104 | 9.23e-01 | -5.49e-03 | 9.52e-01 |
| Mitochondrial translation initiation | 91 | 9.42e-01 | -4.45e-03 | 9.61e-01 |
| Mitochondrial translation | 97 | 9.40e-01 | 4.40e-03 | 9.61e-01 |
| Kinesins | 39 | 9.64e-01 | 4.16e-03 | 9.73e-01 |
| Anti-inflammatory response favouring Leishmania parasite infection | 169 | 9.27e-01 | 4.07e-03 | 9.54e-01 |
| Leishmania parasite growth and survival | 169 | 9.27e-01 | 4.07e-03 | 9.54e-01 |
| SLC transporter disorders | 77 | 9.52e-01 | 3.97e-03 | 9.67e-01 |
| Synaptic adhesion-like molecules | 15 | 9.79e-01 | 3.89e-03 | 9.85e-01 |
| ATF4 activates genes in response to endoplasmic reticulum stress | 26 | 9.78e-01 | -3.15e-03 | 9.84e-01 |
| mRNA Splicing - Major Pathway | 179 | 9.58e-01 | -2.29e-03 | 9.68e-01 |
| DCC mediated attractive signaling | 13 | 9.92e-01 | 1.61e-03 | 9.96e-01 |
| Protein-protein interactions at synapses | 58 | 9.88e-01 | 1.16e-03 | 9.92e-01 |
| mRNA Splicing | 187 | 9.80e-01 | 1.05e-03 | 9.85e-01 |
| Glyoxylate metabolism and glycine degradation | 24 | 9.93e-01 | -1.02e-03 | 9.96e-01 |
| Nuclear Receptor transcription pathway | 38 | 9.93e-01 | -7.77e-04 | 9.96e-01 |
| Gene Silencing by RNA | 88 | 9.96e-01 | 3.02e-04 | 9.98e-01 |
| Glutathione synthesis and recycling | 10 | 9.99e-01 | -2.37e-04 | 1.00e+00 |
| Ion homeostasis | 41 | 1.00e+00 | -1.34e-05 | 1.00e+00 |
IRAK4 deficiency (TLR2/4)
| 513 | |
|---|---|
| set | IRAK4 deficiency (TLR2/4) |
| setSize | 10 |
| pANOVA | 8.37e-07 |
| s.dist | 0.899 |
| p.adjustANOVA | 1.05e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CD36 | 9444 |
| TLR2 | 9103 |
| CD14 | 9097 |
| TLR4 | 9016 |
| TLR1 | 8932 |
| TLR6 | 8840 |
| LY96 | 8795 |
| MYD88 | 8136 |
| BTK | 7206 |
| TIRAP | 5640 |
| GeneID | Gene Rank |
|---|---|
| CD36 | 9444 |
| TLR2 | 9103 |
| CD14 | 9097 |
| TLR4 | 9016 |
| TLR1 | 8932 |
| TLR6 | 8840 |
| LY96 | 8795 |
| MYD88 | 8136 |
| BTK | 7206 |
| TIRAP | 5640 |
MyD88 deficiency (TLR2/4)
| 686 | |
|---|---|
| set | MyD88 deficiency (TLR2/4) |
| setSize | 10 |
| pANOVA | 8.37e-07 |
| s.dist | 0.899 |
| p.adjustANOVA | 1.05e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CD36 | 9444 |
| TLR2 | 9103 |
| CD14 | 9097 |
| TLR4 | 9016 |
| TLR1 | 8932 |
| TLR6 | 8840 |
| LY96 | 8795 |
| MYD88 | 8136 |
| BTK | 7206 |
| TIRAP | 5640 |
| GeneID | Gene Rank |
|---|---|
| CD36 | 9444 |
| TLR2 | 9103 |
| CD14 | 9097 |
| TLR4 | 9016 |
| TLR1 | 8932 |
| TLR6 | 8840 |
| LY96 | 8795 |
| MYD88 | 8136 |
| BTK | 7206 |
| TIRAP | 5640 |
alpha-linolenic (omega3) and linoleic (omega6) acid metabolism
| 1331 | |
|---|---|
| set | alpha-linolenic (omega3) and linoleic (omega6) acid metabolism |
| setSize | 12 |
| pANOVA | 2.46e-06 |
| s.dist | 0.785 |
| p.adjustANOVA | 2.62e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ACSL1 | 9217 |
| ACOX1 | 8859 |
| HSD17B4 | 8858 |
| ELOVL3 | 8710 |
| ACAA1 | 8292 |
| ACOT8 | 8018 |
| FADS1 | 7699 |
| ABCD1 | 7346 |
| ELOVL1 | 7088 |
| ELOVL5 | 6011 |
| SCP2 | 4454 |
| FADS2 | 1486 |
| GeneID | Gene Rank |
|---|---|
| ACSL1 | 9217 |
| ACOX1 | 8859 |
| HSD17B4 | 8858 |
| ELOVL3 | 8710 |
| ACAA1 | 8292 |
| ACOT8 | 8018 |
| FADS1 | 7699 |
| ABCD1 | 7346 |
| ELOVL1 | 7088 |
| ELOVL5 | 6011 |
| SCP2 | 4454 |
| FADS2 | 1486 |
alpha-linolenic acid (ALA) metabolism
| 1332 | |
|---|---|
| set | alpha-linolenic acid (ALA) metabolism |
| setSize | 12 |
| pANOVA | 2.46e-06 |
| s.dist | 0.785 |
| p.adjustANOVA | 2.62e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ACSL1 | 9217 |
| ACOX1 | 8859 |
| HSD17B4 | 8858 |
| ELOVL3 | 8710 |
| ACAA1 | 8292 |
| ACOT8 | 8018 |
| FADS1 | 7699 |
| ABCD1 | 7346 |
| ELOVL1 | 7088 |
| ELOVL5 | 6011 |
| SCP2 | 4454 |
| FADS2 | 1486 |
| GeneID | Gene Rank |
|---|---|
| ACSL1 | 9217 |
| ACOX1 | 8859 |
| HSD17B4 | 8858 |
| ELOVL3 | 8710 |
| ACAA1 | 8292 |
| ACOT8 | 8018 |
| FADS1 | 7699 |
| ABCD1 | 7346 |
| ELOVL1 | 7088 |
| ELOVL5 | 6011 |
| SCP2 | 4454 |
| FADS2 | 1486 |
Regulation of TLR by endogenous ligand
| 968 | |
|---|---|
| set | Regulation of TLR by endogenous ligand |
| setSize | 11 |
| pANOVA | 1.93e-05 |
| s.dist | 0.744 |
| p.adjustANOVA | 0.000145 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| S100A9 | 9516 |
| S100A8 | 9503 |
| CD36 | 9444 |
| TLR2 | 9103 |
| CD14 | 9097 |
| TLR4 | 9016 |
| TLR1 | 8932 |
| TLR6 | 8840 |
| LY96 | 8795 |
| HMGB1 | -252 |
| S100A1 | -8108 |
| GeneID | Gene Rank |
|---|---|
| S100A9 | 9516 |
| S100A8 | 9503 |
| CD36 | 9444 |
| TLR2 | 9103 |
| CD14 | 9097 |
| TLR4 | 9016 |
| TLR1 | 8932 |
| TLR6 | 8840 |
| LY96 | 8795 |
| HMGB1 | -252 |
| S100A1 | -8108 |
Translocation of ZAP-70 to Immunological synapse
| 1278 | |
|---|---|
| set | Translocation of ZAP-70 to Immunological synapse |
| setSize | 24 |
| pANOVA | 2.81e-10 |
| s.dist | -0.744 |
| p.adjustANOVA | 8.52e-09 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CD247 | -12345 |
| HLA-DPA1 | -12316 |
| HLA-DPB1 | -12248 |
| HLA-DRA | -12009 |
| TRBC1 | -12006 |
| HLA-DQA1 | -11992 |
| ZAP70 | -11949 |
| LCK | -11838 |
| CD3G | -11526 |
| TRAC | -11482 |
| CD3D | -11401 |
| CD3E | -11302 |
| TRBV12-3 | -10436 |
| TRAV19 | -9915 |
| TRAV29DV5 | -9673 |
| TRBV7-9 | -9539 |
| HLA-DQB2 | -9401 |
| HLA-DRB1 | -8075 |
| TRAV8-4 | -7261 |
| HLA-DQB1 | -6416 |
| GeneID | Gene Rank |
|---|---|
| CD247 | -12345 |
| HLA-DPA1 | -12316 |
| HLA-DPB1 | -12248 |
| HLA-DRA | -12009 |
| TRBC1 | -12006 |
| HLA-DQA1 | -11992 |
| ZAP70 | -11949 |
| LCK | -11838 |
| CD3G | -11526 |
| TRAC | -11482 |
| CD3D | -11401 |
| CD3E | -11302 |
| TRBV12-3 | -10436 |
| TRAV19 | -9915 |
| TRAV29DV5 | -9673 |
| TRBV7-9 | -9539 |
| HLA-DQB2 | -9401 |
| HLA-DRB1 | -8075 |
| TRAV8-4 | -7261 |
| HLA-DQB1 | -6416 |
| CD4 | -5406 |
| HLA-DRB5 | -4971 |
| HLA-DQA2 | -4806 |
| PTPN22 | -1208 |
Hyaluronan uptake and degradation
| 505 | |
|---|---|
| set | Hyaluronan uptake and degradation |
| setSize | 12 |
| pANOVA | 8.85e-06 |
| s.dist | 0.741 |
| p.adjustANOVA | 7.23e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CHP1 | 9258 |
| HYAL2 | 9088 |
| LYVE1 | 8999 |
| HEXB | 8776 |
| CD44 | 8333 |
| SLC9A1 | 7969 |
| GUSB | 7723 |
| STAB2 | 5569 |
| HYAL3 | 5229 |
| HYAL1 | 4164 |
| HMMR | 3808 |
| HEXA | 1261 |
| GeneID | Gene Rank |
|---|---|
| CHP1 | 9258 |
| HYAL2 | 9088 |
| LYVE1 | 8999 |
| HEXB | 8776 |
| CD44 | 8333 |
| SLC9A1 | 7969 |
| GUSB | 7723 |
| STAB2 | 5569 |
| HYAL3 | 5229 |
| HYAL1 | 4164 |
| HMMR | 3808 |
| HEXA | 1261 |
Uptake and function of anthrax toxins
| 1306 | |
|---|---|
| set | Uptake and function of anthrax toxins |
| setSize | 10 |
| pANOVA | 0.000114 |
| s.dist | 0.705 |
| p.adjustANOVA | 0.000651 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| FURIN | 9075 |
| MAP2K1 | 9063 |
| MAP2K6 | 8887 |
| MAP2K3 | 8748 |
| ANTXR2 | 7331 |
| MAP2K4 | 6866 |
| MAP2K2 | 6794 |
| PDCD6IP | 6528 |
| MAP2K7 | 1654 |
| CALM1 | -2081 |
| GeneID | Gene Rank |
|---|---|
| FURIN | 9075 |
| MAP2K1 | 9063 |
| MAP2K6 | 8887 |
| MAP2K3 | 8748 |
| ANTXR2 | 7331 |
| MAP2K4 | 6866 |
| MAP2K2 | 6794 |
| PDCD6IP | 6528 |
| MAP2K7 | 1654 |
| CALM1 | -2081 |
Erythrocytes take up carbon dioxide and release oxygen
| 345 | |
|---|---|
| set | Erythrocytes take up carbon dioxide and release oxygen |
| setSize | 11 |
| pANOVA | 9.46e-05 |
| s.dist | 0.68 |
| p.adjustANOVA | 0.000553 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CYB5R1 | 9460 |
| CA1 | 9380 |
| SLC4A1 | 9141 |
| HBB | 9054 |
| HBA1 | 8990 |
| CYB5R2 | 8600 |
| CYB5R4 | 8421 |
| AQP1 | 7476 |
| CA2 | 3570 |
| CA4 | 2826 |
| CYB5RL | -10762 |
| GeneID | Gene Rank |
|---|---|
| CYB5R1 | 9460 |
| CA1 | 9380 |
| SLC4A1 | 9141 |
| HBB | 9054 |
| HBA1 | 8990 |
| CYB5R2 | 8600 |
| CYB5R4 | 8421 |
| AQP1 | 7476 |
| CA2 | 3570 |
| CA4 | 2826 |
| CYB5RL | -10762 |
O2/CO2 exchange in erythrocytes
| 765 | |
|---|---|
| set | O2/CO2 exchange in erythrocytes |
| setSize | 11 |
| pANOVA | 9.46e-05 |
| s.dist | 0.68 |
| p.adjustANOVA | 0.000553 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CYB5R1 | 9460 |
| CA1 | 9380 |
| SLC4A1 | 9141 |
| HBB | 9054 |
| HBA1 | 8990 |
| CYB5R2 | 8600 |
| CYB5R4 | 8421 |
| AQP1 | 7476 |
| CA2 | 3570 |
| CA4 | 2826 |
| CYB5RL | -10762 |
| GeneID | Gene Rank |
|---|---|
| CYB5R1 | 9460 |
| CA1 | 9380 |
| SLC4A1 | 9141 |
| HBB | 9054 |
| HBA1 | 8990 |
| CYB5R2 | 8600 |
| CYB5R4 | 8421 |
| AQP1 | 7476 |
| CA2 | 3570 |
| CA4 | 2826 |
| CYB5RL | -10762 |
WNT5A-dependent internalization of FZD2, FZD5 and ROR2
| 1324 | |
|---|---|
| set | WNT5A-dependent internalization of FZD2, FZD5 and ROR2 |
| setSize | 11 |
| pANOVA | 0.000117 |
| s.dist | 0.671 |
| p.adjustANOVA | 0.000657 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| FZD5 | 9513 |
| CLTC | 9000 |
| AP2M1 | 8627 |
| CLTA | 8376 |
| AP2S1 | 8026 |
| AP2A2 | 7257 |
| AP2A1 | 6832 |
| FZD2 | 6462 |
| CLTB | 6084 |
| ROR1 | -2376 |
| AP2B1 | -2709 |
| GeneID | Gene Rank |
|---|---|
| FZD5 | 9513 |
| CLTC | 9000 |
| AP2M1 | 8627 |
| CLTA | 8376 |
| AP2S1 | 8026 |
| AP2A2 | 7257 |
| AP2A1 | 6832 |
| FZD2 | 6462 |
| CLTB | 6084 |
| ROR1 | -2376 |
| AP2B1 | -2709 |
p130Cas linkage to MAPK signaling for integrins
| 1343 | |
|---|---|
| set | p130Cas linkage to MAPK signaling for integrins |
| setSize | 11 |
| pANOVA | 0.000132 |
| s.dist | 0.665 |
| p.adjustANOVA | 0.000721 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CRK | 8906 |
| ITGA2B | 8893 |
| APBB1IP | 8744 |
| TLN1 | 8525 |
| ITGB3 | 8291 |
| FN1 | 8284 |
| RAP1A | 7305 |
| VWF | 6641 |
| PTK2 | 4462 |
| RAP1B | 3206 |
| SRC | -8820 |
| GeneID | Gene Rank |
|---|---|
| CRK | 8906 |
| ITGA2B | 8893 |
| APBB1IP | 8744 |
| TLN1 | 8525 |
| ITGB3 | 8291 |
| FN1 | 8284 |
| RAP1A | 7305 |
| VWF | 6641 |
| PTK2 | 4462 |
| RAP1B | 3206 |
| SRC | -8820 |
Advanced glycosylation endproduct receptor signaling
| 61 | |
|---|---|
| set | Advanced glycosylation endproduct receptor signaling |
| setSize | 12 |
| pANOVA | 9.48e-05 |
| s.dist | 0.651 |
| p.adjustANOVA | 0.000553 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| S100A12 | 9515 |
| APP | 9177 |
| MAPK3 | 8953 |
| LGALS3 | 8752 |
| CAPZA2 | 8597 |
| CAPZA1 | 8135 |
| MAPK1 | 7493 |
| DDOST | 6931 |
| PRKCSH | 5220 |
| AGER | 1294 |
| HMGB1 | -252 |
| S100B | -5457 |
| GeneID | Gene Rank |
|---|---|
| S100A12 | 9515 |
| APP | 9177 |
| MAPK3 | 8953 |
| LGALS3 | 8752 |
| CAPZA2 | 8597 |
| CAPZA1 | 8135 |
| MAPK1 | 7493 |
| DDOST | 6931 |
| PRKCSH | 5220 |
| AGER | 1294 |
| HMGB1 | -252 |
| S100B | -5457 |
Unwinding of DNA
| 1304 | |
|---|---|
| set | Unwinding of DNA |
| setSize | 12 |
| pANOVA | 0.000132 |
| s.dist | -0.637 |
| p.adjustANOVA | 0.000721 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MCM3 | -12200 |
| MCM7 | -12129 |
| MCM8 | -10944 |
| GINS3 | -10508 |
| GINS4 | -10236 |
| MCM6 | -9715 |
| MCM4 | -8701 |
| MCM5 | -7292 |
| MCM2 | -7223 |
| GINS2 | -4815 |
| GINS1 | -4401 |
| CDC45 | -2659 |
| GeneID | Gene Rank |
|---|---|
| MCM3 | -12200 |
| MCM7 | -12129 |
| MCM8 | -10944 |
| GINS3 | -10508 |
| GINS4 | -10236 |
| MCM6 | -9715 |
| MCM4 | -8701 |
| MCM5 | -7292 |
| MCM2 | -7223 |
| GINS2 | -4815 |
| GINS1 | -4401 |
| CDC45 | -2659 |
RNA Polymerase I Promoter Opening
| 902 | |
|---|---|
| set | RNA Polymerase I Promoter Opening |
| setSize | 19 |
| pANOVA | 3.29e-06 |
| s.dist | 0.616 |
| p.adjustANOVA | 3.27e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| H2AJ | 9374.0 |
| H2BC21 | 9283.0 |
| H2BC12 | 9051.0 |
| MAPK3 | 8953.0 |
| H3-3A | 8661.0 |
| H2BC5 | 8003.0 |
| H2AC6 | 7934.0 |
| H2BC11 | 7912.0 |
| H2BC4 | 7389.0 |
| H2BC17 | 7285.0 |
| H3C15 | 6699.5 |
| MBD2 | 6581.0 |
| H2AZ1 | 6036.0 |
| H2BC9 | 5394.0 |
| H2BC15 | 5312.0 |
| H2AC20 | 4972.0 |
| H2AZ2 | -1209.0 |
| H2BU1 | -6555.0 |
| UBTF | -10033.0 |
| GeneID | Gene Rank |
|---|---|
| H2AJ | 9374.0 |
| H2BC21 | 9283.0 |
| H2BC12 | 9051.0 |
| MAPK3 | 8953.0 |
| H3-3A | 8661.0 |
| H2BC5 | 8003.0 |
| H2AC6 | 7934.0 |
| H2BC11 | 7912.0 |
| H2BC4 | 7389.0 |
| H2BC17 | 7285.0 |
| H3C15 | 6699.5 |
| MBD2 | 6581.0 |
| H2AZ1 | 6036.0 |
| H2BC9 | 5394.0 |
| H2BC15 | 5312.0 |
| H2AC20 | 4972.0 |
| H2AZ2 | -1209.0 |
| H2BU1 | -6555.0 |
| UBTF | -10033.0 |
RHO GTPases Activate WASPs and WAVEs
| 889 | |
|---|---|
| set | RHO GTPases Activate WASPs and WAVEs |
| setSize | 35 |
| pANOVA | 4.57e-10 |
| s.dist | 0.609 |
| p.adjustANOVA | 1.33e-08 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| WASF1 | 9520 |
| GRB2 | 9304 |
| CYFIP1 | 9265 |
| ARPC1B | 9259 |
| ACTB | 9011 |
| MAPK3 | 8953 |
| ARPC1A | 8894 |
| RAC1 | 8793 |
| ARPC5 | 8686 |
| ACTG1 | 8562 |
| WAS | 8560 |
| WASF2 | 8369 |
| ARPC3 | 8277 |
| ACTR2 | 7870 |
| ACTR3 | 7818 |
| NCKAP1L | 7673 |
| CDC42 | 7537 |
| ARPC4 | 7516 |
| MAPK1 | 7493 |
| NCKAP1 | 7462 |
| GeneID | Gene Rank |
|---|---|
| WASF1 | 9520 |
| GRB2 | 9304 |
| CYFIP1 | 9265 |
| ARPC1B | 9259 |
| ACTB | 9011 |
| MAPK3 | 8953 |
| ARPC1A | 8894 |
| RAC1 | 8793 |
| ARPC5 | 8686 |
| ACTG1 | 8562 |
| WAS | 8560 |
| WASF2 | 8369 |
| ARPC3 | 8277 |
| ACTR2 | 7870 |
| ACTR3 | 7818 |
| NCKAP1L | 7673 |
| CDC42 | 7537 |
| ARPC4 | 7516 |
| MAPK1 | 7493 |
| NCKAP1 | 7462 |
| ARPC2 | 7390 |
| BTK | 7206 |
| ABI1 | 7082 |
| BRK1 | 7032 |
| WASF3 | 6808 |
| WIPF2 | 5713 |
| PTK2 | 4462 |
| WIPF1 | 569 |
| NCKIPSD | 328 |
| WASL | 299 |
| ABL1 | 226 |
| BAIAP2 | -215 |
| CYFIP2 | -10367 |
| ABI2 | -10915 |
| NCK1 | -11454 |
ROS and RNS production in phagocytes
| 925 | |
|---|---|
| set | ROS and RNS production in phagocytes |
| setSize | 31 |
| pANOVA | 8.23e-09 |
| s.dist | 0.598 |
| p.adjustANOVA | 1.75e-07 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ATP6V0A1 | 9423 |
| ATP6V1A | 9302 |
| NCF4 | 9268 |
| ATP6V0D1 | 9245 |
| NCF2 | 9190 |
| SLC11A1 | 9169 |
| ATP6V0C | 9127 |
| ATP6V1B2 | 9057 |
| ATP6V1D | 9047 |
| CYBB | 9031 |
| ATP6V0B | 8598 |
| ATP6V0E1 | 8596 |
| ATP6V1C1 | 8539 |
| ATP6V1H | 8064 |
| ATP6V1E1 | 8035 |
| MPO | 7437 |
| NCF1 | 7334 |
| TCIRG1 | 7188 |
| CYBA | 6922 |
| LPO | 6502 |
| GeneID | Gene Rank |
|---|---|
| ATP6V0A1 | 9423 |
| ATP6V1A | 9302 |
| NCF4 | 9268 |
| ATP6V0D1 | 9245 |
| NCF2 | 9190 |
| SLC11A1 | 9169 |
| ATP6V0C | 9127 |
| ATP6V1B2 | 9057 |
| ATP6V1D | 9047 |
| CYBB | 9031 |
| ATP6V0B | 8598 |
| ATP6V0E1 | 8596 |
| ATP6V1C1 | 8539 |
| ATP6V1H | 8064 |
| ATP6V1E1 | 8035 |
| MPO | 7437 |
| NCF1 | 7334 |
| TCIRG1 | 7188 |
| CYBA | 6922 |
| LPO | 6502 |
| ATP6V1F | 5878 |
| ATP6V1E2 | 5730 |
| RAC2 | 5163 |
| HVCN1 | 4912 |
| ATP6V1G1 | 3931 |
| NOS1 | 1365 |
| NOS3 | -2059 |
| ATP6V1C2 | -2219 |
| ATP6V1G2 | -9515 |
| ATP6V0E2 | -11555 |
| ATP6V0A2 | -12211 |
Neutrophil degranulation
| 736 | |
|---|---|
| set | Neutrophil degranulation |
| setSize | 458 |
| pANOVA | 1.61e-103 |
| s.dist | 0.586 |
| p.adjustANOVA | 2.2e-100 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| S100A9 | 9516 |
| S100A12 | 9515 |
| CTSA | 9514 |
| SIRPA | 9510 |
| IDH1 | 9507 |
| RNASE2 | 9506 |
| MCEMP1 | 9504 |
| S100A8 | 9503 |
| CD93 | 9496 |
| CR1 | 9486 |
| CREG1 | 9483 |
| MGST1 | 9482 |
| BST1 | 9480 |
| TIMP2 | 9458 |
| HP | 9454 |
| CD36 | 9444 |
| GCA | 9436 |
| PGAM1 | 9435 |
| SERPINB1 | 9434 |
| CTSD | 9433 |
| GeneID | Gene Rank |
|---|---|
| S100A9 | 9516 |
| S100A12 | 9515 |
| CTSA | 9514 |
| SIRPA | 9510 |
| IDH1 | 9507 |
| RNASE2 | 9506 |
| MCEMP1 | 9504 |
| S100A8 | 9503 |
| CD93 | 9496 |
| CR1 | 9486 |
| CREG1 | 9483 |
| MGST1 | 9482 |
| BST1 | 9480 |
| TIMP2 | 9458 |
| HP | 9454 |
| CD36 | 9444 |
| GCA | 9436 |
| PGAM1 | 9435 |
| SERPINB1 | 9434 |
| CTSD | 9433 |
| ATP6V0A1 | 9423 |
| PYGL | 9417 |
| LAMTOR1 | 9411 |
| ITGAM | 9398 |
| PKM | 9391 |
| DOK3 | 9388 |
| HK3 | 9385 |
| SIGLEC9 | 9383 |
| CKAP4 | 9370 |
| CTSB | 9364 |
| GNS | 9360 |
| RAB31 | 9356 |
| PTAFR | 9355 |
| ANPEP | 9350 |
| PGM2 | 9344 |
| QPCT | 9327 |
| SDCBP | 9311 |
| CDA | 9310 |
| GRN | 9308 |
| PLD1 | 9306 |
| QSOX1 | 9298 |
| FPR1 | 9295 |
| IMPDH1 | 9294 |
| CD63 | 9287 |
| MNDA | 9277 |
| VAT1 | 9276 |
| CYFIP1 | 9265 |
| LTA4H | 9261 |
| PADI2 | 9257 |
| AGPAT2 | 9256 |
| ALDOA | 9249 |
| MMP8 | 9232 |
| RAB3D | 9207 |
| TOM1 | 9200 |
| NCSTN | 9186 |
| CLEC4D | 9185 |
| SLC11A1 | 9169 |
| SERPINA1 | 9168 |
| CD55 | 9145 |
| GPR84 | 9133 |
| C5AR1 | 9129 |
| ATP6V0C | 9127 |
| CAT | 9123 |
| FCN1 | 9113 |
| FCAR | 9111 |
| CRISPLD2 | 9106 |
| MAPK14 | 9104 |
| TLR2 | 9103 |
| TRPM2 | 9102 |
| CD14 | 9097 |
| FPR2 | 9095 |
| VNN1 | 9092 |
| NFAM1 | 9086 |
| CYSTM1 | 9077 |
| OSCAR | 9068 |
| GM2A | 9059 |
| HBB | 9054 |
| MGAM | 9050 |
| ATP6V1D | 9047 |
| VAPA | 9033 |
| CYBB | 9031 |
| NEU1 | 9029 |
| SLC2A3 | 9021 |
| BRI3 | 9017 |
| APAF1 | 9015 |
| GYG1 | 9013 |
| PRKCD | 9008 |
| ALOX5 | 9001 |
| RETN | 8998 |
| CTSZ | 8975 |
| S100A11 | 8946 |
| ITGB2 | 8942 |
| PRDX6 | 8937 |
| SERPINB10 | 8933 |
| RAB10 | 8926 |
| SELL | 8912 |
| CYB5R3 | 8903 |
| LILRB3 | 8871 |
| FCGR2A | 8845 |
| RAC1 | 8793 |
| ADAM10 | 8791 |
| LAMP2 | 8786 |
| HEXB | 8776 |
| ARG1 | 8759 |
| LGALS3 | 8752 |
| GSN | 8749 |
| RAB7A | 8742 |
| TNFAIP6 | 8738 |
| AMPD3 | 8732 |
| GLB1 | 8725 |
| OLFM4 | 8724 |
| ARPC5 | 8686 |
| DNAJC5 | 8679 |
| LRG1 | 8674 |
| FTL | 8665 |
| ALDH3B1 | 8663 |
| RAB5C | 8655 |
| PYCARD | 8638 |
| PDXK | 8635 |
| DNASE1L1 | 8632 |
| SNAP23 | 8628 |
| TOLLIP | 8572 |
| GLA | 8570 |
| CAPN1 | 8563 |
| ANXA2 | 8544 |
| CD68 | 8533 |
| ASAH1 | 8529 |
| MMP25 | 8515 |
| ALAD | 8514 |
| DERA | 8500 |
| RHOG | 8487 |
| PSMB7 | 8485 |
| FGR | 8478 |
| HPSE | 8476 |
| CLEC5A | 8473 |
| PLAC8 | 8452 |
| P2RX1 | 8436 |
| DNAJC3 | 8435 |
| CEACAM1 | 8429 |
| PLAUR | 8424 |
| PNP | 8419 |
| RAB27A | 8411 |
| HEBP2 | 8398 |
| ATP11A | 8394 |
| CTSS | 8372 |
| TMBIM1 | 8361 |
| CPPED1 | 8357 |
| CD44 | 8333 |
| S100P | 8331 |
| RHOA | 8319 |
| FUCA2 | 8304 |
| ACAA1 | 8292 |
| CAB39 | 8276 |
| DNAJC13 | 8263 |
| GMFG | 8259 |
| MOSPD2 | 8252 |
| ARL8A | 8249 |
| PRCP | 8218 |
| ADGRG3 | 8204 |
| SIGLEC5 | 8161 |
| IQGAP1 | 8152 |
| RAB6A | 8148 |
| ATG7 | 8134 |
| RAB3A | 8133 |
| FCER1G | 8131 |
| CAP1 | 8111 |
| HSPA1A | 8071 |
| CD33 | 8069 |
| PLEKHO2 | 8059 |
| LILRB2 | 8057 |
| ANO6 | 8048 |
| TMEM30A | 8036 |
| ATP6AP2 | 8034 |
| C3AR1 | 8012 |
| ORM1 | 7971 |
| GAA | 7968 |
| COMMD9 | 7967 |
| PSEN1 | 7961 |
| COTL1 | 7933 |
| PGLYRP1 | 7910 |
| CMTM6 | 7891 |
| CD53 | 7884 |
| ACTR2 | 7870 |
| KCMF1 | 7869 |
| PECAM1 | 7855 |
| PSMD6 | 7846 |
| SIRPB1 | 7843 |
| TRAPPC1 | 7806 |
| RAB18 | 7801 |
| PGRMC1 | 7795 |
| PTPRJ | 7783 |
| LCN2 | 7755 |
| DBNL | 7749 |
| GLIPR1 | 7739 |
| DOCK2 | 7725 |
| GUSB | 7723 |
| CANT1 | 7707 |
| NCKAP1L | 7673 |
| LAMP1 | 7631 |
| UNC13D | 7607 |
| ACTR10 | 7605 |
| LAMTOR3 | 7574 |
| ARSB | 7572 |
| LAMTOR2 | 7567 |
| CRISP3 | 7552 |
| TYROBP | 7539 |
| MAPK1 | 7493 |
| ROCK1 | 7489 |
| RNASE3 | 7471 |
| FOLR3 | 7451 |
| CFP | 7445 |
| MPO | 7437 |
| OSTF1 | 7426 |
| NAPRT | 7412 |
| PSMD2 | 7411 |
| FUCA1 | 7408 |
| MANBA | 7386 |
| ITGAX | 7337 |
| VCL | 7328 |
| COPB1 | 7321 |
| ELANE | 7320 |
| RAP1A | 7305 |
| GDI2 | 7282 |
| AP2A2 | 7257 |
| PSMD1 | 7241 |
| TUBB4B | 7240 |
| LYZ | 7213 |
| TCIRG1 | 7188 |
| LAIR1 | 7184 |
| IGF2R | 7149 |
| PSAP | 7145 |
| GALNS | 7102 |
| RAB14 | 7095 |
| NBEAL2 | 7086 |
| SURF4 | 7058 |
| MVP | 7053 |
| TSPAN14 | 6971 |
| ATP8B4 | 6970 |
| PAFAH1B2 | 6942 |
| DYNC1LI1 | 6941 |
| DDOST | 6931 |
| CYBA | 6922 |
| METTL7A | 6920 |
| ERP44 | 6905 |
| CSTB | 6904 |
| VCP | 6886 |
| MAN2B1 | 6878 |
| CXCR1 | 6864 |
| CEACAM3 | 6838 |
| PRTN3 | 6762 |
| AP1M1 | 6711 |
| STOM | 6704 |
| RAB5B | 6690 |
| YPEL5 | 6684 |
| BPI | 6666 |
| CD58 | 6647 |
| CNN2 | 6645 |
| DDX3X | 6614 |
| IQGAP2 | 6599 |
| PSMD12 | 6556 |
| CCT8 | 6552 |
| HSPA6 | 6514 |
| AOC1 | 6509 |
| HSPA1B | 6470 |
| ARMC8 | 6398 |
| SNAP29 | 6390 |
| CTSH | 6360 |
| TICAM2 | 6335 |
| SRP14 | 6320 |
| LTF | 6306 |
| GPI | 6284 |
| NFKB1 | 6277 |
| ARHGAP9 | 6256 |
| PSMD11 | 6231 |
| GGH | 6205 |
| C6orf120 | 6192 |
| TCN1 | 6182 |
| DEGS1 | 6169 |
| VPS35L | 6118 |
| ITGAV | 6106 |
| PTPN6 | 6096 |
| NDUFC2 | 6093 |
| ATP11B | 6064 |
| DEFA1 | 6061 |
| DEFA4 | 6057 |
| TNFRSF1B | 6045 |
| PPBP | 6042 |
| FABP5 | 6021 |
| CHIT1 | 6012 |
| PSMD7 | 5963 |
| DYNLL1 | 5952 |
| PSMD13 | 5948 |
| RNASET2 | 5922 |
| PDAP1 | 5908 |
| CPNE3 | 5872 |
| IST1 | 5862 |
| CXCR2 | 5861 |
| CD59 | 5859 |
| SERPINB6 | 5854 |
| PGM1 | 5843 |
| CXCL1 | 5824 |
| PTX3 | 5797 |
| BIN2 | 5745 |
| ADAM8 | 5634 |
| A1BG | 5559 |
| FAF2 | 5554 |
| STBD1 | 5544 |
| AZU1 | 5507 |
| NPC2 | 5458 |
| XRCC5 | 5384 |
| NRAS | 5363 |
| RAB24 | 5354 |
| PSMA2 | 5339 |
| TARM1 | 5307 |
| DGAT1 | 5306 |
| SLPI | 5298 |
| VAMP8 | 5218 |
| PTPRN2 | 5183 |
| ACLY | 5159 |
| CTSG | 5115 |
| SIGLEC14 | 5087 |
| CEACAM8 | 4956 |
| HVCN1 | 4912 |
| PLAU | 4903 |
| FTH1 | 4902 |
| STING1 | 4791 |
| CAMP | 4785 |
| ABCA13 | 4768 |
| PSMD3 | 4618 |
| RAP2C | 4599 |
| KRT1 | 4537 |
| CLEC12A | 4535 |
| CEACAM6 | 4509 |
| DYNLT1 | 4450 |
| FCGR3B | 4313 |
| B4GALT1 | 4292 |
| GHDC | 4158 |
| GOLGA7 | 4055 |
| CSNK2B | 3969 |
| SLC15A4 | 3724 |
| STK11IP | 3586 |
| ARSA | 3486 |
| PSMB1 | 3374 |
| SLCO4C1 | 3212 |
| RAP1B | 3206 |
| RAB4B | 3137 |
| SLC44A2 | 2700 |
| MAGT1 | 2613 |
| PSMD14 | 2611 |
| PSMC2 | 2598 |
| OLR1 | 2486 |
| CD177 | 2457 |
| KPNB1 | 2430 |
| MS4A3 | 2361 |
| CTSC | 2326 |
| MLEC | 2322 |
| PTPRC | 2240 |
| CST3 | 2206 |
| SLC2A5 | 2044 |
| SVIP | 2035 |
| CFD | 1984 |
| PSMC3 | 1976 |
| GSDMD | 1955 |
| SCAMP1 | 1868 |
| HGSNAT | 1867 |
| NME2 | 1850 |
| MMP9 | 1690 |
| HSP90AA1 | 1326 |
| NHLRC3 | 1276 |
| HLA-C | 1018 |
| APEH | 997 |
| MME | 916 |
| NFASC | 866 |
| FGL2 | 675 |
| HLA-B | 649 |
| RAB44 | 573 |
| PYGB | 492 |
| TMEM179B | 449 |
| LRMP | 441 |
| ADGRE3 | 408 |
| TXNDC5 | 393 |
| EEF2 | 306 |
| GSTP1 | 135 |
| FRK | -24 |
| KCNAB2 | -101 |
| PRDX4 | -144 |
| HMGB1 | -252 |
| PIGR | -487 |
| CHI3L1 | -650 |
| RAP2B | -771 |
| DIAPH1 | -854 |
| COMMD3 | -1363 |
| DSP | -1812 |
| LRRC7 | -1966 |
| ILF2 | -1979 |
| UBR4 | -2086 |
| CD300A | -2133 |
| ORM2 | -2564 |
| ADGRE5 | -2571 |
| HLA-A | -2573 |
| APRT | -2766 |
| AGL | -3136 |
| PFKL | -3277 |
| CPNE1 | -3397 |
| ALDOC | -3438 |
| SLC27A2 | -3831 |
| MIF | -3863 |
| HLA-H | -3889 |
| STK10 | -3898 |
| PA2G4 | -3916 |
| XRCC6 | -4471 |
| DPP7 | -4586 |
| SYNGR1 | -4629 |
| AGA | -4632 |
| EPX | -4838 |
| EEF1A1 | -5087 |
| JUP | -5353 |
| PSMA5 | -6053 |
| RAB9B | -6552 |
| CAND1 | -6554 |
| PPIA | -6766 |
| HSP90AB1 | -6863 |
| B2M | -6920 |
| PTGES2 | -6926 |
| DSC1 | -6927 |
| TUBB | -6956 |
| HRNR | -7349 |
| BST2 | -7385 |
| LPCAT1 | -7428 |
| PTPRB | -7607 |
| DYNC1H1 | -7685 |
| HUWE1 | -7977 |
| CDK13 | -8392 |
| CCT2 | -8825 |
| PPIE | -9002 |
| CRACR2A | -9069 |
| TMEM63A | -9137 |
| CEP290 | -9182 |
| ENPP4 | -9583 |
| IMPDH2 | -9916 |
| ORMDL3 | -9997 |
| ATAD3B | -10079 |
| ACTR1B | -10514 |
| TMC6 | -10606 |
| DSN1 | -10773 |
| ITGAL | -10847 |
| HSPA8 | -10922 |
| SPTAN1 | -11426 |
| FRMPD3 | -11469 |
| NIT2 | -11695 |
| RAB37 | -11793 |
| CLEC4C | -11809 |
| HMOX2 | -11819 |
| ATP8A1 | -11842 |
| TBC1D10C | -11861 |
| CD47 | -12114 |
| C3 | -12262 |
| RHOF | -12344 |
GRB2:SOS provides linkage to MAPK signaling for Integrins
| 434 | |
|---|---|
| set | GRB2:SOS provides linkage to MAPK signaling for Integrins |
| setSize | 12 |
| pANOVA | 0.000497 |
| s.dist | 0.58 |
| p.adjustANOVA | 0.00228 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| ITGA2B | 8893 |
| APBB1IP | 8744 |
| TLN1 | 8525 |
| ITGB3 | 8291 |
| FN1 | 8284 |
| RAP1A | 7305 |
| VWF | 6641 |
| PTK2 | 4462 |
| RAP1B | 3206 |
| SOS1 | -5700 |
| SRC | -8820 |
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| ITGA2B | 8893 |
| APBB1IP | 8744 |
| TLN1 | 8525 |
| ITGB3 | 8291 |
| FN1 | 8284 |
| RAP1A | 7305 |
| VWF | 6641 |
| PTK2 | 4462 |
| RAP1B | 3206 |
| SOS1 | -5700 |
| SRC | -8820 |
PD-1 signaling
| 779 | |
|---|---|
| set | PD-1 signaling |
| setSize | 28 |
| pANOVA | 1.11e-07 |
| s.dist | -0.579 |
| p.adjustANOVA | 1.87e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CD247 | -12345 |
| HLA-DPA1 | -12316 |
| HLA-DPB1 | -12248 |
| HLA-DRA | -12009 |
| TRBC1 | -12006 |
| HLA-DQA1 | -11992 |
| LCK | -11838 |
| CD3G | -11526 |
| TRAC | -11482 |
| CD3D | -11401 |
| CD3E | -11302 |
| TRBV12-3 | -10436 |
| TRAV19 | -9915 |
| TRAV29DV5 | -9673 |
| TRBV7-9 | -9539 |
| HLA-DQB2 | -9401 |
| HLA-DRB1 | -8075 |
| CD274 | -7563 |
| TRAV8-4 | -7261 |
| PDCD1 | -6792 |
| GeneID | Gene Rank |
|---|---|
| CD247 | -12345 |
| HLA-DPA1 | -12316 |
| HLA-DPB1 | -12248 |
| HLA-DRA | -12009 |
| TRBC1 | -12006 |
| HLA-DQA1 | -11992 |
| LCK | -11838 |
| CD3G | -11526 |
| TRAC | -11482 |
| CD3D | -11401 |
| CD3E | -11302 |
| TRBV12-3 | -10436 |
| TRAV19 | -9915 |
| TRAV29DV5 | -9673 |
| TRBV7-9 | -9539 |
| HLA-DQB2 | -9401 |
| HLA-DRB1 | -8075 |
| CD274 | -7563 |
| TRAV8-4 | -7261 |
| PDCD1 | -6792 |
| HLA-DQB1 | -6416 |
| CD4 | -5406 |
| HLA-DRB5 | -4971 |
| HLA-DQA2 | -4806 |
| PDCD1LG2 | -3326 |
| CSK | 5219 |
| PTPN11 | 5314 |
| PTPN6 | 6096 |
Insulin receptor recycling
| 540 | |
|---|---|
| set | Insulin receptor recycling |
| setSize | 21 |
| pANOVA | 6.43e-06 |
| s.dist | 0.569 |
| p.adjustANOVA | 5.69e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ATP6V0A1 | 9423 |
| ATP6V1A | 9302 |
| ATP6V0D1 | 9245 |
| ATP6V0C | 9127 |
| ATP6V1B2 | 9057 |
| ATP6V1D | 9047 |
| ATP6V0B | 8598 |
| ATP6V0E1 | 8596 |
| ATP6V1C1 | 8539 |
| INSR | 8282 |
| ATP6AP1 | 8160 |
| ATP6V1H | 8064 |
| ATP6V1E1 | 8035 |
| TCIRG1 | 7188 |
| ATP6V1F | 5878 |
| ATP6V1E2 | 5730 |
| ATP6V1G1 | 3931 |
| ATP6V1C2 | -2219 |
| ATP6V1G2 | -9515 |
| ATP6V0E2 | -11555 |
| GeneID | Gene Rank |
|---|---|
| ATP6V0A1 | 9423 |
| ATP6V1A | 9302 |
| ATP6V0D1 | 9245 |
| ATP6V0C | 9127 |
| ATP6V1B2 | 9057 |
| ATP6V1D | 9047 |
| ATP6V0B | 8598 |
| ATP6V0E1 | 8596 |
| ATP6V1C1 | 8539 |
| INSR | 8282 |
| ATP6AP1 | 8160 |
| ATP6V1H | 8064 |
| ATP6V1E1 | 8035 |
| TCIRG1 | 7188 |
| ATP6V1F | 5878 |
| ATP6V1E2 | 5730 |
| ATP6V1G1 | 3931 |
| ATP6V1C2 | -2219 |
| ATP6V1G2 | -9515 |
| ATP6V0E2 | -11555 |
| ATP6V0A2 | -12211 |
Dissolution of Fibrin Clot
| 301 | |
|---|---|
| set | Dissolution of Fibrin Clot |
| setSize | 12 |
| pANOVA | 0.00067 |
| s.dist | 0.567 |
| p.adjustANOVA | 0.00292 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| SERPINB2 | 9438 |
| SERPINB8 | 9205 |
| ANXA2 | 8544 |
| PLAUR | 8424 |
| SERPINE1 | 7483 |
| S100A10 | 6860 |
| SERPINE2 | 6451 |
| SERPINB6 | 5854 |
| PLAU | 4903 |
| PLAT | -1242 |
| PLG | -1977 |
| SERPINF2 | -6574 |
| GeneID | Gene Rank |
|---|---|
| SERPINB2 | 9438 |
| SERPINB8 | 9205 |
| ANXA2 | 8544 |
| PLAUR | 8424 |
| SERPINE1 | 7483 |
| S100A10 | 6860 |
| SERPINE2 | 6451 |
| SERPINB6 | 5854 |
| PLAU | 4903 |
| PLAT | -1242 |
| PLG | -1977 |
| SERPINF2 | -6574 |
Retrograde neurotrophin signalling
| 1012 | |
|---|---|
| set | Retrograde neurotrophin signalling |
| setSize | 12 |
| pANOVA | 0.000674 |
| s.dist | 0.567 |
| p.adjustANOVA | 0.00293 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CLTC | 9000 |
| AP2M1 | 8627 |
| CLTA | 8376 |
| AP2S1 | 8026 |
| AP2A2 | 7257 |
| DNM3 | 7045 |
| AP2A1 | 6832 |
| DNM2 | 6089 |
| DNM1 | 3587 |
| DNAL4 | 3398 |
| AP2B1 | -2709 |
| NTRK1 | -8193 |
| GeneID | Gene Rank |
|---|---|
| CLTC | 9000 |
| AP2M1 | 8627 |
| CLTA | 8376 |
| AP2S1 | 8026 |
| AP2A2 | 7257 |
| DNM3 | 7045 |
| AP2A1 | 6832 |
| DNM2 | 6089 |
| DNM1 | 3587 |
| DNAL4 | 3398 |
| AP2B1 | -2709 |
| NTRK1 | -8193 |
Signaling by Leptin
| 1104 | |
|---|---|
| set | Signaling by Leptin |
| setSize | 10 |
| pANOVA | 0.00197 |
| s.dist | 0.565 |
| p.adjustANOVA | 0.00706 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| SOCS3 | 9476 |
| IRS2 | 8569 |
| STAT3 | 8098 |
| STAT5A | 6965 |
| STAT5B | 6925 |
| LEPR | 6485 |
| PTPN11 | 5314 |
| JAK2 | 2691 |
| IRS1 | 1741 |
| SH2B1 | -8670 |
| GeneID | Gene Rank |
|---|---|
| SOCS3 | 9476 |
| IRS2 | 8569 |
| STAT3 | 8098 |
| STAT5A | 6965 |
| STAT5B | 6925 |
| LEPR | 6485 |
| PTPN11 | 5314 |
| JAK2 | 2691 |
| IRS1 | 1741 |
| SH2B1 | -8670 |
COPI-independent Golgi-to-ER retrograde traffic
| 133 | |
|---|---|
| set | COPI-independent Golgi-to-ER retrograde traffic |
| setSize | 33 |
| pANOVA | 2.11e-08 |
| s.dist | 0.563 |
| p.adjustANOVA | 4.3e-07 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PLA2G4A | 9180 |
| DCTN2 | 9157 |
| GALNT2 | 8843 |
| BICD2 | 8746 |
| CAPZA2 | 8597 |
| DCTN4 | 8387 |
| RAB6A | 8148 |
| CAPZA1 | 8135 |
| CAPZB | 8015 |
| RAB18 | 7801 |
| DYNC1I2 | 7735 |
| ACTR10 | 7605 |
| DCTN6 | 7300 |
| ACTR1A | 7002 |
| PAFAH1B2 | 6942 |
| DYNC1LI1 | 6941 |
| GALNT1 | 6508 |
| RAB6B | 6053 |
| DCTN3 | 5994 |
| DYNLL1 | 5952 |
| GeneID | Gene Rank |
|---|---|
| PLA2G4A | 9180 |
| DCTN2 | 9157 |
| GALNT2 | 8843 |
| BICD2 | 8746 |
| CAPZA2 | 8597 |
| DCTN4 | 8387 |
| RAB6A | 8148 |
| CAPZA1 | 8135 |
| CAPZB | 8015 |
| RAB18 | 7801 |
| DYNC1I2 | 7735 |
| ACTR10 | 7605 |
| DCTN6 | 7300 |
| ACTR1A | 7002 |
| PAFAH1B2 | 6942 |
| DYNC1LI1 | 6941 |
| GALNT1 | 6508 |
| RAB6B | 6053 |
| DCTN3 | 5994 |
| DYNLL1 | 5952 |
| RAB3GAP1 | 5768 |
| PAFAH1B1 | 5470 |
| DCTN1 | 5078 |
| AGPAT3 | 4809 |
| RAB3GAP2 | 4429 |
| PAFAH1B3 | 4417 |
| DYNC1LI2 | 4273 |
| DYNC1I1 | 4187 |
| DYNLL2 | -3980 |
| DCTN5 | -4086 |
| BICD1 | -7365 |
| DYNC1H1 | -7685 |
| PLA2G6 | -12122 |
Detoxification of Reactive Oxygen Species
| 279 | |
|---|---|
| set | Detoxification of Reactive Oxygen Species |
| setSize | 32 |
| pANOVA | 3.64e-08 |
| s.dist | 0.562 |
| p.adjustANOVA | 6.98e-07 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PRDX3 | 9366 |
| GPX1 | 9314 |
| NCF4 | 9268 |
| GSR | 9235 |
| NCF2 | 9190 |
| CAT | 9123 |
| CYBB | 9031 |
| ERO1A | 8943 |
| PRDX6 | 8937 |
| PRDX5 | 8531 |
| P4HB | 8440 |
| TXN | 8285 |
| TXNRD1 | 8192 |
| TXNRD2 | 7526 |
| NCF1 | 7334 |
| PRDX1 | 7030 |
| CYBA | 6922 |
| TXN2 | 4651 |
| SOD2 | 4390 |
| ATOX1 | 4338 |
| GeneID | Gene Rank |
|---|---|
| PRDX3 | 9366 |
| GPX1 | 9314 |
| NCF4 | 9268 |
| GSR | 9235 |
| NCF2 | 9190 |
| CAT | 9123 |
| CYBB | 9031 |
| ERO1A | 8943 |
| PRDX6 | 8937 |
| PRDX5 | 8531 |
| P4HB | 8440 |
| TXN | 8285 |
| TXNRD1 | 8192 |
| TXNRD2 | 7526 |
| NCF1 | 7334 |
| PRDX1 | 7030 |
| CYBA | 6922 |
| TXN2 | 4651 |
| SOD2 | 4390 |
| ATOX1 | 4338 |
| PRDX2 | 3428 |
| NUDT2 | 2988 |
| CCS | 1538 |
| NOX5 | 1175 |
| NOX4 | 1114 |
| ATP7A | 694 |
| GPX3 | 680 |
| GSTP1 | 135 |
| CYCS | -1334 |
| GPX2 | -3533 |
| SOD1 | -4862 |
| GPX7 | -8901 |
RHO GTPases Activate NADPH Oxidases
| 887 | |
|---|---|
| set | RHO GTPases Activate NADPH Oxidases |
| setSize | 21 |
| pANOVA | 9.01e-06 |
| s.dist | 0.56 |
| p.adjustANOVA | 7.32e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| S100A9 | 9516 |
| S100A8 | 9503 |
| NCF4 | 9268 |
| NCF2 | 9190 |
| MAPK14 | 9104 |
| CYBB | 9031 |
| PRKCD | 9008 |
| MAPK3 | 8953 |
| RAC1 | 8793 |
| MAPK1 | 7493 |
| NCF1 | 7334 |
| PRKCB | 7097 |
| CYBA | 6922 |
| RAC2 | 5163 |
| MAPK11 | 3826 |
| PIK3C3 | 1619 |
| PRKCA | 1132 |
| PIN1 | -3188 |
| PIK3R4 | -4062 |
| NOXA1 | -5464 |
| GeneID | Gene Rank |
|---|---|
| S100A9 | 9516 |
| S100A8 | 9503 |
| NCF4 | 9268 |
| NCF2 | 9190 |
| MAPK14 | 9104 |
| CYBB | 9031 |
| PRKCD | 9008 |
| MAPK3 | 8953 |
| RAC1 | 8793 |
| MAPK1 | 7493 |
| NCF1 | 7334 |
| PRKCB | 7097 |
| CYBA | 6922 |
| RAC2 | 5163 |
| MAPK11 | 3826 |
| PIK3C3 | 1619 |
| PRKCA | 1132 |
| PIN1 | -3188 |
| PIK3R4 | -4062 |
| NOXA1 | -5464 |
| PRKCZ | -11629 |
PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
| 801 | |
|---|---|
| set | PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases |
| setSize | 13 |
| pANOVA | 0.000515 |
| s.dist | 0.556 |
| p.adjustANOVA | 0.00235 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CRK | 8906 |
| RAC1 | 8793 |
| RHOA | 8319 |
| DOCK1 | 7314 |
| ELMO1 | 6258 |
| PXN | 6230 |
| PTK6 | 5956 |
| NRAS | 5363 |
| ELMO2 | 4397 |
| KRAS | 3702 |
| RASA1 | 2106 |
| ARHGAP35 | -3359 |
| HRAS | -3382 |
| GeneID | Gene Rank |
|---|---|
| CRK | 8906 |
| RAC1 | 8793 |
| RHOA | 8319 |
| DOCK1 | 7314 |
| ELMO1 | 6258 |
| PXN | 6230 |
| PTK6 | 5956 |
| NRAS | 5363 |
| ELMO2 | 4397 |
| KRAS | 3702 |
| RASA1 | 2106 |
| ARHGAP35 | -3359 |
| HRAS | -3382 |
Platelet sensitization by LDL
| 833 | |
|---|---|
| set | Platelet sensitization by LDL |
| setSize | 16 |
| pANOVA | 0.000128 |
| s.dist | 0.553 |
| p.adjustANOVA | 0.000707 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PLA2G4A | 9180 |
| MAPK14 | 9104 |
| FGR | 8478 |
| PPP2CA | 8234 |
| PECAM1 | 7855 |
| PPP2CB | 7712 |
| PPP2R5B | 6774 |
| PTPN6 | 6096 |
| PPP2R5A | 5897 |
| PTPN11 | 5314 |
| PPP2R1A | 4589 |
| LRP8 | 4568 |
| PPP2R5D | 2421 |
| PPP2R1B | -241 |
| PPP2R5E | -680 |
| PPP2R5C | -11265 |
| GeneID | Gene Rank |
|---|---|
| PLA2G4A | 9180 |
| MAPK14 | 9104 |
| FGR | 8478 |
| PPP2CA | 8234 |
| PECAM1 | 7855 |
| PPP2CB | 7712 |
| PPP2R5B | 6774 |
| PTPN6 | 6096 |
| PPP2R5A | 5897 |
| PTPN11 | 5314 |
| PPP2R1A | 4589 |
| LRP8 | 4568 |
| PPP2R5D | 2421 |
| PPP2R1B | -241 |
| PPP2R5E | -680 |
| PPP2R5C | -11265 |
Hyaluronan metabolism
| 504 | |
|---|---|
| set | Hyaluronan metabolism |
| setSize | 15 |
| pANOVA | 0.00022 |
| s.dist | 0.551 |
| p.adjustANOVA | 0.00113 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CHP1 | 9258 |
| HYAL2 | 9088 |
| LYVE1 | 8999 |
| HEXB | 8776 |
| CD44 | 8333 |
| SLC9A1 | 7969 |
| GUSB | 7723 |
| STAB2 | 5569 |
| HYAL3 | 5229 |
| HYAL1 | 4164 |
| HMMR | 3808 |
| ABCC5 | 2477 |
| HEXA | 1261 |
| HAS3 | -6197 |
| CEMIP | -7418 |
| GeneID | Gene Rank |
|---|---|
| CHP1 | 9258 |
| HYAL2 | 9088 |
| LYVE1 | 8999 |
| HEXB | 8776 |
| CD44 | 8333 |
| SLC9A1 | 7969 |
| GUSB | 7723 |
| STAB2 | 5569 |
| HYAL3 | 5229 |
| HYAL1 | 4164 |
| HMMR | 3808 |
| ABCC5 | 2477 |
| HEXA | 1261 |
| HAS3 | -6197 |
| CEMIP | -7418 |
Golgi Cisternae Pericentriolar Stack Reorganization
| 468 | |
|---|---|
| set | Golgi Cisternae Pericentriolar Stack Reorganization |
| setSize | 14 |
| pANOVA | 0.000365 |
| s.dist | 0.55 |
| p.adjustANOVA | 0.00176 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RAB1A | 9052 |
| MAPK3 | 8953 |
| RAB2A | 8604 |
| RAB1B | 8313 |
| MAPK1 | 7493 |
| GORASP1 | 6606 |
| GOLGA2 | 6203 |
| USO1 | 4154 |
| CCNB2 | 3683 |
| BLZF1 | 3281 |
| PLK1 | 3002 |
| CDK1 | 1540 |
| CCNB1 | 467 |
| GORASP2 | -7034 |
| GeneID | Gene Rank |
|---|---|
| RAB1A | 9052 |
| MAPK3 | 8953 |
| RAB2A | 8604 |
| RAB1B | 8313 |
| MAPK1 | 7493 |
| GORASP1 | 6606 |
| GOLGA2 | 6203 |
| USO1 | 4154 |
| CCNB2 | 3683 |
| BLZF1 | 3281 |
| PLK1 | 3002 |
| CDK1 | 1540 |
| CCNB1 | 467 |
| GORASP2 | -7034 |
RHO GTPases Activate ROCKs
| 888 | |
|---|---|
| set | RHO GTPases Activate ROCKs |
| setSize | 18 |
| pANOVA | 6.85e-05 |
| s.dist | 0.542 |
| p.adjustANOVA | 0.000423 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MYL6 | 8576 |
| RHOA | 8319 |
| PAK1 | 8230 |
| CFL1 | 8186 |
| LIMK2 | 8074 |
| MYL9 | 7703 |
| ROCK1 | 7489 |
| PPP1CB | 7064 |
| MYH9 | 6685 |
| ROCK2 | 6138 |
| PPP1R12A | 6050 |
| MYL12B | 5088 |
| LIMK1 | 4679 |
| PPP1R12B | 1775 |
| RHOB | 1254 |
| MYH10 | 653 |
| MYH11 | -3522 |
| RHOC | -11360 |
| GeneID | Gene Rank |
|---|---|
| MYL6 | 8576 |
| RHOA | 8319 |
| PAK1 | 8230 |
| CFL1 | 8186 |
| LIMK2 | 8074 |
| MYL9 | 7703 |
| ROCK1 | 7489 |
| PPP1CB | 7064 |
| MYH9 | 6685 |
| ROCK2 | 6138 |
| PPP1R12A | 6050 |
| MYL12B | 5088 |
| LIMK1 | 4679 |
| PPP1R12B | 1775 |
| RHOB | 1254 |
| MYH10 | 653 |
| MYH11 | -3522 |
| RHOC | -11360 |
Phosphorylation of CD3 and TCR zeta chains
| 821 | |
|---|---|
| set | Phosphorylation of CD3 and TCR zeta chains |
| setSize | 27 |
| pANOVA | 1.38e-06 |
| s.dist | -0.537 |
| p.adjustANOVA | 1.62e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CD247 | -12345 |
| HLA-DPA1 | -12316 |
| HLA-DPB1 | -12248 |
| HLA-DRA | -12009 |
| TRBC1 | -12006 |
| HLA-DQA1 | -11992 |
| LCK | -11838 |
| CD3G | -11526 |
| TRAC | -11482 |
| CD3D | -11401 |
| CD3E | -11302 |
| TRBV12-3 | -10436 |
| TRAV19 | -9915 |
| TRAV29DV5 | -9673 |
| TRBV7-9 | -9539 |
| HLA-DQB2 | -9401 |
| HLA-DRB1 | -8075 |
| TRAV8-4 | -7261 |
| HLA-DQB1 | -6416 |
| CD4 | -5406 |
| GeneID | Gene Rank |
|---|---|
| CD247 | -12345 |
| HLA-DPA1 | -12316 |
| HLA-DPB1 | -12248 |
| HLA-DRA | -12009 |
| TRBC1 | -12006 |
| HLA-DQA1 | -11992 |
| LCK | -11838 |
| CD3G | -11526 |
| TRAC | -11482 |
| CD3D | -11401 |
| CD3E | -11302 |
| TRBV12-3 | -10436 |
| TRAV19 | -9915 |
| TRAV29DV5 | -9673 |
| TRBV7-9 | -9539 |
| HLA-DQB2 | -9401 |
| HLA-DRB1 | -8075 |
| TRAV8-4 | -7261 |
| HLA-DQB1 | -6416 |
| CD4 | -5406 |
| HLA-DRB5 | -4971 |
| HLA-DQA2 | -4806 |
| PTPN22 | -1208 |
| PTPRC | 2240 |
| CSK | 5219 |
| PAG1 | 5268 |
| PTPRJ | 7783 |
Diseases associated with the TLR signaling cascade
| 289 | |
|---|---|
| set | Diseases associated with the TLR signaling cascade |
| setSize | 23 |
| pANOVA | 8.79e-06 |
| s.dist | 0.535 |
| p.adjustANOVA | 7.22e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CD36 | 9444 |
| TLR5 | 9201 |
| TLR2 | 9103 |
| CD14 | 9097 |
| TLR4 | 9016 |
| TLR1 | 8932 |
| TLR6 | 8840 |
| LY96 | 8795 |
| MYD88 | 8136 |
| CHUK | 7966 |
| BTK | 7206 |
| NFKBIA | 6807 |
| TICAM1 | 6307 |
| NFKB1 | 6277 |
| TIRAP | 5640 |
| IKBKG | 5377 |
| UNC93B1 | 4170 |
| NFKB2 | -1165 |
| RELA | -1803 |
| TLR10 | -2961 |
| GeneID | Gene Rank |
|---|---|
| CD36 | 9444 |
| TLR5 | 9201 |
| TLR2 | 9103 |
| CD14 | 9097 |
| TLR4 | 9016 |
| TLR1 | 8932 |
| TLR6 | 8840 |
| LY96 | 8795 |
| MYD88 | 8136 |
| CHUK | 7966 |
| BTK | 7206 |
| NFKBIA | 6807 |
| TICAM1 | 6307 |
| NFKB1 | 6277 |
| TIRAP | 5640 |
| IKBKG | 5377 |
| UNC93B1 | 4170 |
| NFKB2 | -1165 |
| RELA | -1803 |
| TLR10 | -2961 |
| IKBKB | -5386 |
| TRAF3 | -5576 |
| TLR3 | -11525 |
Diseases of Immune System
| 291 | |
|---|---|
| set | Diseases of Immune System |
| setSize | 23 |
| pANOVA | 8.79e-06 |
| s.dist | 0.535 |
| p.adjustANOVA | 7.22e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CD36 | 9444 |
| TLR5 | 9201 |
| TLR2 | 9103 |
| CD14 | 9097 |
| TLR4 | 9016 |
| TLR1 | 8932 |
| TLR6 | 8840 |
| LY96 | 8795 |
| MYD88 | 8136 |
| CHUK | 7966 |
| BTK | 7206 |
| NFKBIA | 6807 |
| TICAM1 | 6307 |
| NFKB1 | 6277 |
| TIRAP | 5640 |
| IKBKG | 5377 |
| UNC93B1 | 4170 |
| NFKB2 | -1165 |
| RELA | -1803 |
| TLR10 | -2961 |
| GeneID | Gene Rank |
|---|---|
| CD36 | 9444 |
| TLR5 | 9201 |
| TLR2 | 9103 |
| CD14 | 9097 |
| TLR4 | 9016 |
| TLR1 | 8932 |
| TLR6 | 8840 |
| LY96 | 8795 |
| MYD88 | 8136 |
| CHUK | 7966 |
| BTK | 7206 |
| NFKBIA | 6807 |
| TICAM1 | 6307 |
| NFKB1 | 6277 |
| TIRAP | 5640 |
| IKBKG | 5377 |
| UNC93B1 | 4170 |
| NFKB2 | -1165 |
| RELA | -1803 |
| TLR10 | -2961 |
| IKBKB | -5386 |
| TRAF3 | -5576 |
| TLR3 | -11525 |
IRAK1 recruits IKK complex
| 509 | |
|---|---|
| set | IRAK1 recruits IKK complex |
| setSize | 10 |
| pANOVA | 0.00346 |
| s.dist | 0.534 |
| p.adjustANOVA | 0.0114 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PELI2 | 8314 |
| CHUK | 7966 |
| PELI3 | 7716 |
| PELI1 | 6715 |
| IRAK1 | 6131 |
| UBE2V1 | 5637 |
| IKBKG | 5377 |
| UBE2N | 1936 |
| TRAF6 | -229 |
| IKBKB | -5386 |
| GeneID | Gene Rank |
|---|---|
| PELI2 | 8314 |
| CHUK | 7966 |
| PELI3 | 7716 |
| PELI1 | 6715 |
| IRAK1 | 6131 |
| UBE2V1 | 5637 |
| IKBKG | 5377 |
| UBE2N | 1936 |
| TRAF6 | -229 |
| IKBKB | -5386 |
IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
| 510 | |
|---|---|
| set | IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation |
| setSize | 10 |
| pANOVA | 0.00346 |
| s.dist | 0.534 |
| p.adjustANOVA | 0.0114 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PELI2 | 8314 |
| CHUK | 7966 |
| PELI3 | 7716 |
| PELI1 | 6715 |
| IRAK1 | 6131 |
| UBE2V1 | 5637 |
| IKBKG | 5377 |
| UBE2N | 1936 |
| TRAF6 | -229 |
| IKBKB | -5386 |
| GeneID | Gene Rank |
|---|---|
| PELI2 | 8314 |
| CHUK | 7966 |
| PELI3 | 7716 |
| PELI1 | 6715 |
| IRAK1 | 6131 |
| UBE2V1 | 5637 |
| IKBKG | 5377 |
| UBE2N | 1936 |
| TRAF6 | -229 |
| IKBKB | -5386 |
MET activates RAP1 and RAC1
| 620 | |
|---|---|
| set | MET activates RAP1 and RAC1 |
| setSize | 10 |
| pANOVA | 0.00366 |
| s.dist | 0.531 |
| p.adjustANOVA | 0.0118 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| CRK | 8906 |
| HGF | 8863 |
| RAC1 | 8793 |
| RAP1A | 7305 |
| GAB1 | 5679 |
| CRKL | 3966 |
| RAP1B | 3206 |
| DOCK7 | -2369 |
| RAPGEF1 | -9826 |
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| CRK | 8906 |
| HGF | 8863 |
| RAC1 | 8793 |
| RAP1A | 7305 |
| GAB1 | 5679 |
| CRKL | 3966 |
| RAP1B | 3206 |
| DOCK7 | -2369 |
| RAPGEF1 | -9826 |
NOTCH4 Activation and Transmission of Signal to the Nucleus
| 707 | |
|---|---|
| set | NOTCH4 Activation and Transmission of Signal to the Nucleus |
| setSize | 10 |
| pANOVA | 0.00385 |
| s.dist | 0.528 |
| p.adjustANOVA | 0.0123 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| NCSTN | 9186 |
| ADAM10 | 8791 |
| JAG1 | 8743 |
| PSEN1 | 7961 |
| APH1B | 6280 |
| PSENEN | 5735 |
| YWHAZ | 5624 |
| APH1A | 4133 |
| NOTCH4 | -5229 |
| PSEN2 | -7718 |
| GeneID | Gene Rank |
|---|---|
| NCSTN | 9186 |
| ADAM10 | 8791 |
| JAG1 | 8743 |
| PSEN1 | 7961 |
| APH1B | 6280 |
| PSENEN | 5735 |
| YWHAZ | 5624 |
| APH1A | 4133 |
| NOTCH4 | -5229 |
| PSEN2 | -7718 |
Negative regulation of MET activity
| 723 | |
|---|---|
| set | Negative regulation of MET activity |
| setSize | 18 |
| pANOVA | 0.000111 |
| s.dist | 0.526 |
| p.adjustANOVA | 0.000638 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| HGF | 8863 |
| PTPRJ | 7783 |
| SH3GL1 | 7625 |
| PTPN2 | 7615 |
| CBL | 7480 |
| UBB | 6639 |
| USP8 | 6418 |
| SH3KBP1 | 6173 |
| STAM2 | 6159 |
| PTPN1 | 5722 |
| HGS | 4513 |
| UBC | 4439 |
| EPS15 | 4138 |
| STAM | 1285 |
| UBA52 | 1121 |
| RPS27A | -6938 |
| LRIG1 | -10389 |
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| HGF | 8863 |
| PTPRJ | 7783 |
| SH3GL1 | 7625 |
| PTPN2 | 7615 |
| CBL | 7480 |
| UBB | 6639 |
| USP8 | 6418 |
| SH3KBP1 | 6173 |
| STAM2 | 6159 |
| PTPN1 | 5722 |
| HGS | 4513 |
| UBC | 4439 |
| EPS15 | 4138 |
| STAM | 1285 |
| UBA52 | 1121 |
| RPS27A | -6938 |
| LRIG1 | -10389 |
Budding and maturation of HIV virion
| 117 | |
|---|---|
| set | Budding and maturation of HIV virion |
| setSize | 26 |
| pANOVA | 3.45e-06 |
| s.dist | 0.526 |
| p.adjustANOVA | 3.41e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CHMP4B | 8866 |
| CHMP2A | 8780 |
| UBAP1 | 8701 |
| CHMP3 | 8349 |
| VPS37C | 8010 |
| NEDD4L | 7875 |
| TSG101 | 7786 |
| MVB12A | 7400 |
| UBB | 6639 |
| PDCD6IP | 6528 |
| VPS37A | 6467 |
| VTA1 | 6185 |
| CHMP2B | 5714 |
| CHMP6 | 5499 |
| VPS4B | 5212 |
| MVB12B | 5175 |
| CHMP5 | 4943 |
| UBC | 4439 |
| VPS28 | 4199 |
| VPS37B | 3908 |
| GeneID | Gene Rank |
|---|---|
| CHMP4B | 8866 |
| CHMP2A | 8780 |
| UBAP1 | 8701 |
| CHMP3 | 8349 |
| VPS37C | 8010 |
| NEDD4L | 7875 |
| TSG101 | 7786 |
| MVB12A | 7400 |
| UBB | 6639 |
| PDCD6IP | 6528 |
| VPS37A | 6467 |
| VTA1 | 6185 |
| CHMP2B | 5714 |
| CHMP6 | 5499 |
| VPS4B | 5212 |
| MVB12B | 5175 |
| CHMP5 | 4943 |
| UBC | 4439 |
| VPS28 | 4199 |
| VPS37B | 3908 |
| CHMP4A | 2400 |
| UBA52 | 1121 |
| VPS4A | 784 |
| PPIA | -6766 |
| RPS27A | -6938 |
| CHMP7 | -8802 |
InlB-mediated entry of Listeria monocytogenes into host cell
| 535 | |
|---|---|
| set | InlB-mediated entry of Listeria monocytogenes into host cell |
| setSize | 12 |
| pANOVA | 0.00161 |
| s.dist | 0.526 |
| p.adjustANOVA | 0.00606 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| SH3GL1 | 7625 |
| CBL | 7480 |
| UBB | 6639 |
| SH3KBP1 | 6173 |
| STAM2 | 6159 |
| HGS | 4513 |
| UBC | 4439 |
| EPS15 | 4138 |
| STAM | 1285 |
| UBA52 | 1121 |
| RPS27A | -6938 |
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| SH3GL1 | 7625 |
| CBL | 7480 |
| UBB | 6639 |
| SH3KBP1 | 6173 |
| STAM2 | 6159 |
| HGS | 4513 |
| UBC | 4439 |
| EPS15 | 4138 |
| STAM | 1285 |
| UBA52 | 1121 |
| RPS27A | -6938 |
DNA strand elongation
| 247 | |
|---|---|
| set | DNA strand elongation |
| setSize | 32 |
| pANOVA | 3.21e-07 |
| s.dist | -0.522 |
| p.adjustANOVA | 4.91e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MCM3 | -12200 |
| POLA1 | -12150 |
| MCM7 | -12129 |
| RPA1 | -12004 |
| RFC5 | -11712 |
| POLA2 | -11575 |
| LIG1 | -11053 |
| MCM8 | -10944 |
| RFC4 | -10702 |
| FEN1 | -10593 |
| GINS3 | -10508 |
| RFC3 | -10489 |
| POLD2 | -10351 |
| GINS4 | -10236 |
| PRIM1 | -10191 |
| MCM6 | -9715 |
| RPA3 | -8911 |
| MCM4 | -8701 |
| RFC1 | -7437 |
| MCM5 | -7292 |
| GeneID | Gene Rank |
|---|---|
| MCM3 | -12200 |
| POLA1 | -12150 |
| MCM7 | -12129 |
| RPA1 | -12004 |
| RFC5 | -11712 |
| POLA2 | -11575 |
| LIG1 | -11053 |
| MCM8 | -10944 |
| RFC4 | -10702 |
| FEN1 | -10593 |
| GINS3 | -10508 |
| RFC3 | -10489 |
| POLD2 | -10351 |
| GINS4 | -10236 |
| PRIM1 | -10191 |
| MCM6 | -9715 |
| RPA3 | -8911 |
| MCM4 | -8701 |
| RFC1 | -7437 |
| MCM5 | -7292 |
| MCM2 | -7223 |
| RPA2 | -6306 |
| PCNA | -5969 |
| PRIM2 | -5575 |
| GINS2 | -4815 |
| GINS1 | -4401 |
| DNA2 | -2858 |
| CDC45 | -2659 |
| POLD1 | 204 |
| RFC2 | 4948 |
| POLD4 | 6336 |
| POLD3 | 8885 |
Cargo concentration in the ER
| 147 | |
|---|---|
| set | Cargo concentration in the ER |
| setSize | 30 |
| pANOVA | 7.76e-07 |
| s.dist | 0.521 |
| p.adjustANOVA | 1.03e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| F5 | 9485 |
| SERPINA1 | 9168 |
| CTSZ | 8975 |
| TGFA | 8889 |
| SEC24D | 8115 |
| CNIH1 | 7779 |
| SEC24A | 7660 |
| SEC23A | 7335 |
| STX5 | 7166 |
| MCFD2 | 7099 |
| LMAN2 | 7080 |
| F8 | 7022 |
| LMAN2L | 6937 |
| SAR1B | 6479 |
| PREB | 6368 |
| COL7A1 | 6304 |
| TMED2 | 6052 |
| AREG | 5977 |
| SEC22B | 5873 |
| CD59 | 5859 |
| GeneID | Gene Rank |
|---|---|
| F5 | 9485 |
| SERPINA1 | 9168 |
| CTSZ | 8975 |
| TGFA | 8889 |
| SEC24D | 8115 |
| CNIH1 | 7779 |
| SEC24A | 7660 |
| SEC23A | 7335 |
| STX5 | 7166 |
| MCFD2 | 7099 |
| LMAN2 | 7080 |
| F8 | 7022 |
| LMAN2L | 6937 |
| SAR1B | 6479 |
| PREB | 6368 |
| COL7A1 | 6304 |
| TMED2 | 6052 |
| AREG | 5977 |
| SEC22B | 5873 |
| CD59 | 5859 |
| MIA2 | 5574 |
| SEC24B | 3608 |
| CTSC | 2326 |
| CNIH2 | 654 |
| TMED10 | 323 |
| GOSR2 | -1456 |
| SEC24C | -2569 |
| MIA3 | -6245 |
| CNIH3 | -9011 |
| LMAN1 | -10630 |
Endosomal Sorting Complex Required For Transport (ESCRT)
| 340 | |
|---|---|
| set | Endosomal Sorting Complex Required For Transport (ESCRT) |
| setSize | 29 |
| pANOVA | 1.25e-06 |
| s.dist | 0.52 |
| p.adjustANOVA | 1.49e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CHMP4B | 8866 |
| CHMP2A | 8780 |
| UBAP1 | 8701 |
| CHMP3 | 8349 |
| VPS37C | 8010 |
| TSG101 | 7786 |
| VPS25 | 7638 |
| MVB12A | 7400 |
| UBB | 6639 |
| VPS37A | 6467 |
| VTA1 | 6185 |
| STAM2 | 6159 |
| SNF8 | 5973 |
| CHMP2B | 5714 |
| CHMP6 | 5499 |
| VPS4B | 5212 |
| MVB12B | 5175 |
| CHMP5 | 4943 |
| HGS | 4513 |
| UBC | 4439 |
| GeneID | Gene Rank |
|---|---|
| CHMP4B | 8866 |
| CHMP2A | 8780 |
| UBAP1 | 8701 |
| CHMP3 | 8349 |
| VPS37C | 8010 |
| TSG101 | 7786 |
| VPS25 | 7638 |
| MVB12A | 7400 |
| UBB | 6639 |
| VPS37A | 6467 |
| VTA1 | 6185 |
| STAM2 | 6159 |
| SNF8 | 5973 |
| CHMP2B | 5714 |
| CHMP6 | 5499 |
| VPS4B | 5212 |
| MVB12B | 5175 |
| CHMP5 | 4943 |
| HGS | 4513 |
| UBC | 4439 |
| VPS28 | 4199 |
| VPS37B | 3908 |
| CHMP4A | 2400 |
| STAM | 1285 |
| UBA52 | 1121 |
| VPS4A | 784 |
| VPS36 | -6848 |
| RPS27A | -6938 |
| CHMP7 | -8802 |
DNA methylation
| 246 | |
|---|---|
| set | DNA methylation |
| setSize | 20 |
| pANOVA | 6.16e-05 |
| s.dist | 0.517 |
| p.adjustANOVA | 0.000385 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| H2AJ | 9374.0 |
| H2BC21 | 9283.0 |
| H2BC12 | 9051.0 |
| H3-3A | 8661.0 |
| H2BC5 | 8003.0 |
| H2AC6 | 7934.0 |
| H2BC11 | 7912.0 |
| H2BC4 | 7389.0 |
| H2BC17 | 7285.0 |
| H3C15 | 6699.5 |
| H2AZ1 | 6036.0 |
| H2BC9 | 5394.0 |
| H2BC15 | 5312.0 |
| H2AC20 | 4972.0 |
| DNMT3B | 4294.0 |
| UHRF1 | 170.0 |
| H2AZ2 | -1209.0 |
| DNMT3A | -3039.0 |
| H2BU1 | -6555.0 |
| DNMT1 | -12257.0 |
| GeneID | Gene Rank |
|---|---|
| H2AJ | 9374.0 |
| H2BC21 | 9283.0 |
| H2BC12 | 9051.0 |
| H3-3A | 8661.0 |
| H2BC5 | 8003.0 |
| H2AC6 | 7934.0 |
| H2BC11 | 7912.0 |
| H2BC4 | 7389.0 |
| H2BC17 | 7285.0 |
| H3C15 | 6699.5 |
| H2AZ1 | 6036.0 |
| H2BC9 | 5394.0 |
| H2BC15 | 5312.0 |
| H2AC20 | 4972.0 |
| DNMT3B | 4294.0 |
| UHRF1 | 170.0 |
| H2AZ2 | -1209.0 |
| DNMT3A | -3039.0 |
| H2BU1 | -6555.0 |
| DNMT1 | -12257.0 |
Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
| 278 | |
|---|---|
| set | Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models |
| setSize | 21 |
| pANOVA | 4.1e-05 |
| s.dist | 0.517 |
| p.adjustANOVA | 0.000274 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| LMNB1 | 9345 |
| APP | 9177 |
| YWHAE | 9045 |
| FOXO3 | 8682 |
| CDK5 | 8616 |
| CAPN1 | 8563 |
| CAST | 8164 |
| CAPNS1 | 7729 |
| BCL2L11 | 7384 |
| PRDX1 | 7030 |
| GOLGA2 | 6203 |
| CDC25C | 4969 |
| SOD2 | 4390 |
| LMNA | 3887 |
| JUN | 3722 |
| PRDX2 | 3428 |
| CDC25A | 2911 |
| CAPN2 | 1064 |
| CDK5R1 | -1089 |
| CDC25B | -12017 |
| GeneID | Gene Rank |
|---|---|
| LMNB1 | 9345 |
| APP | 9177 |
| YWHAE | 9045 |
| FOXO3 | 8682 |
| CDK5 | 8616 |
| CAPN1 | 8563 |
| CAST | 8164 |
| CAPNS1 | 7729 |
| BCL2L11 | 7384 |
| PRDX1 | 7030 |
| GOLGA2 | 6203 |
| CDC25C | 4969 |
| SOD2 | 4390 |
| LMNA | 3887 |
| JUN | 3722 |
| PRDX2 | 3428 |
| CDC25A | 2911 |
| CAPN2 | 1064 |
| CDK5R1 | -1089 |
| CDC25B | -12017 |
| FASLG | -12371 |
Neurodegenerative Diseases
| 732 | |
|---|---|
| set | Neurodegenerative Diseases |
| setSize | 21 |
| pANOVA | 4.1e-05 |
| s.dist | 0.517 |
| p.adjustANOVA | 0.000274 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| LMNB1 | 9345 |
| APP | 9177 |
| YWHAE | 9045 |
| FOXO3 | 8682 |
| CDK5 | 8616 |
| CAPN1 | 8563 |
| CAST | 8164 |
| CAPNS1 | 7729 |
| BCL2L11 | 7384 |
| PRDX1 | 7030 |
| GOLGA2 | 6203 |
| CDC25C | 4969 |
| SOD2 | 4390 |
| LMNA | 3887 |
| JUN | 3722 |
| PRDX2 | 3428 |
| CDC25A | 2911 |
| CAPN2 | 1064 |
| CDK5R1 | -1089 |
| CDC25B | -12017 |
| GeneID | Gene Rank |
|---|---|
| LMNB1 | 9345 |
| APP | 9177 |
| YWHAE | 9045 |
| FOXO3 | 8682 |
| CDK5 | 8616 |
| CAPN1 | 8563 |
| CAST | 8164 |
| CAPNS1 | 7729 |
| BCL2L11 | 7384 |
| PRDX1 | 7030 |
| GOLGA2 | 6203 |
| CDC25C | 4969 |
| SOD2 | 4390 |
| LMNA | 3887 |
| JUN | 3722 |
| PRDX2 | 3428 |
| CDC25A | 2911 |
| CAPN2 | 1064 |
| CDK5R1 | -1089 |
| CDC25B | -12017 |
| FASLG | -12371 |
MAP2K and MAPK activation
| 611 | |
|---|---|
| set | MAP2K and MAPK activation |
| setSize | 34 |
| pANOVA | 1.81e-07 |
| s.dist | 0.517 |
| p.adjustANOVA | 2.91e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MAP2K1 | 9063 |
| MAPK3 | 8953 |
| ITGA2B | 8893 |
| APBB1IP | 8744 |
| MARK3 | 8697 |
| TLN1 | 8525 |
| ARRB2 | 8490 |
| ITGB3 | 8291 |
| FN1 | 8284 |
| IQGAP1 | 8152 |
| RAF1 | 7879 |
| LAMTOR3 | 7574 |
| LAMTOR2 | 7567 |
| MAPK1 | 7493 |
| VCL | 7328 |
| RAP1A | 7305 |
| MAP2K2 | 6794 |
| VWF | 6641 |
| YWHAB | 6385 |
| NRAS | 5363 |
| GeneID | Gene Rank |
|---|---|
| MAP2K1 | 9063 |
| MAPK3 | 8953 |
| ITGA2B | 8893 |
| APBB1IP | 8744 |
| MARK3 | 8697 |
| TLN1 | 8525 |
| ARRB2 | 8490 |
| ITGB3 | 8291 |
| FN1 | 8284 |
| IQGAP1 | 8152 |
| RAF1 | 7879 |
| LAMTOR3 | 7574 |
| LAMTOR2 | 7567 |
| MAPK1 | 7493 |
| VCL | 7328 |
| RAP1A | 7305 |
| MAP2K2 | 6794 |
| VWF | 6641 |
| YWHAB | 6385 |
| NRAS | 5363 |
| CSK | 5219 |
| KSR1 | 4167 |
| WDR83 | 3718 |
| KRAS | 3702 |
| RAP1B | 3206 |
| ARAF | 2644 |
| ARRB1 | 1998 |
| BRAF | 1308 |
| KSR2 | -3361 |
| HRAS | -3382 |
| CNKSR2 | -4781 |
| CNKSR1 | -7089 |
| SRC | -8820 |
| PEBP1 | -11270 |
VLDLR internalisation and degradation
| 1310 | |
|---|---|
| set | VLDLR internalisation and degradation |
| setSize | 12 |
| pANOVA | 0.00216 |
| s.dist | 0.511 |
| p.adjustANOVA | 0.00758 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PCSK9 | 9208 |
| CLTC | 9000 |
| AP2M1 | 8627 |
| CLTA | 8376 |
| AP2S1 | 8026 |
| NR1H2 | 7415 |
| AP2A2 | 7257 |
| AP2A1 | 6832 |
| AP2B1 | -2709 |
| NR1H3 | -3597 |
| MYLIP | -3991 |
| VLDLR | -4385 |
| GeneID | Gene Rank |
|---|---|
| PCSK9 | 9208 |
| CLTC | 9000 |
| AP2M1 | 8627 |
| CLTA | 8376 |
| AP2S1 | 8026 |
| NR1H2 | 7415 |
| AP2A2 | 7257 |
| AP2A1 | 6832 |
| AP2B1 | -2709 |
| NR1H3 | -3597 |
| MYLIP | -3991 |
| VLDLR | -4385 |
Transferrin endocytosis and recycling
| 1267 | |
|---|---|
| set | Transferrin endocytosis and recycling |
| setSize | 26 |
| pANOVA | 6.92e-06 |
| s.dist | 0.509 |
| p.adjustANOVA | 5.97e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ATP6V0A1 | 9423 |
| ATP6V1A | 9302 |
| ATP6V0D1 | 9245 |
| ATP6V0C | 9127 |
| ATP6V1B2 | 9057 |
| ATP6V1D | 9047 |
| HFE | 8777 |
| ATP6V0B | 8598 |
| ATP6V0E1 | 8596 |
| ATP6V1C1 | 8539 |
| ATP6AP1 | 8160 |
| ATP6V1H | 8064 |
| ATP6V1E1 | 8035 |
| MCOLN1 | 7740 |
| TCIRG1 | 7188 |
| STEAP3 | 5996 |
| ATP6V1F | 5878 |
| ATP6V1E2 | 5730 |
| ATP6V1G1 | 3931 |
| TFRC | 1524 |
| GeneID | Gene Rank |
|---|---|
| ATP6V0A1 | 9423 |
| ATP6V1A | 9302 |
| ATP6V0D1 | 9245 |
| ATP6V0C | 9127 |
| ATP6V1B2 | 9057 |
| ATP6V1D | 9047 |
| HFE | 8777 |
| ATP6V0B | 8598 |
| ATP6V0E1 | 8596 |
| ATP6V1C1 | 8539 |
| ATP6AP1 | 8160 |
| ATP6V1H | 8064 |
| ATP6V1E1 | 8035 |
| MCOLN1 | 7740 |
| TCIRG1 | 7188 |
| STEAP3 | 5996 |
| ATP6V1F | 5878 |
| ATP6V1E2 | 5730 |
| ATP6V1G1 | 3931 |
| TFRC | 1524 |
| TF | 1102 |
| ATP6V1C2 | -2219 |
| ATP6V1G2 | -9515 |
| TFR2 | -9789 |
| ATP6V0E2 | -11555 |
| ATP6V0A2 | -12211 |
EPHB-mediated forward signaling
| 325 | |
|---|---|
| set | EPHB-mediated forward signaling |
| setSize | 32 |
| pANOVA | 7.98e-07 |
| s.dist | 0.504 |
| p.adjustANOVA | 1.03e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ITSN1 | 9289 |
| ARPC1B | 9259 |
| ACTB | 9011 |
| ARPC1A | 8894 |
| RAC1 | 8793 |
| ARPC5 | 8686 |
| ACTG1 | 8562 |
| RHOA | 8319 |
| ARPC3 | 8277 |
| PAK1 | 8230 |
| CFL1 | 8186 |
| LIMK2 | 8074 |
| ACTR2 | 7870 |
| ACTR3 | 7818 |
| LYN | 7809 |
| CDC42 | 7537 |
| ARPC4 | 7516 |
| ROCK1 | 7489 |
| ARPC2 | 7390 |
| ROCK2 | 6138 |
| GeneID | Gene Rank |
|---|---|
| ITSN1 | 9289 |
| ARPC1B | 9259 |
| ACTB | 9011 |
| ARPC1A | 8894 |
| RAC1 | 8793 |
| ARPC5 | 8686 |
| ACTG1 | 8562 |
| RHOA | 8319 |
| ARPC3 | 8277 |
| PAK1 | 8230 |
| CFL1 | 8186 |
| LIMK2 | 8074 |
| ACTR2 | 7870 |
| ACTR3 | 7818 |
| LYN | 7809 |
| CDC42 | 7537 |
| ARPC4 | 7516 |
| ROCK1 | 7489 |
| ARPC2 | 7390 |
| ROCK2 | 6138 |
| SDC2 | 5397 |
| LIMK1 | 4679 |
| PTK2 | 4462 |
| RASA1 | 2106 |
| TIAM1 | 651 |
| WASL | 299 |
| HRAS | -3382 |
| KALRN | -3692 |
| SRC | -8820 |
| ARHGEF28 | -10288 |
| FYN | -11675 |
| YES1 | -12142 |
Gap junction trafficking
| 437 | |
|---|---|
| set | Gap junction trafficking |
| setSize | 14 |
| pANOVA | 0.00116 |
| s.dist | 0.501 |
| p.adjustANOVA | 0.00459 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CLTC | 9000 |
| CLTCL1 | 8965 |
| AP2M1 | 8627 |
| CLTA | 8376 |
| DAB2 | 8112 |
| GJD3 | 7996 |
| DNM2 | 6089 |
| CLTB | 6084 |
| GJB6 | 4761 |
| DNM1 | 3587 |
| GJC2 | 1083 |
| GJC1 | 518 |
| GJA3 | -4935 |
| MYO6 | -11410 |
| GeneID | Gene Rank |
|---|---|
| CLTC | 9000 |
| CLTCL1 | 8965 |
| AP2M1 | 8627 |
| CLTA | 8376 |
| DAB2 | 8112 |
| GJD3 | 7996 |
| DNM2 | 6089 |
| CLTB | 6084 |
| GJB6 | 4761 |
| DNM1 | 3587 |
| GJC2 | 1083 |
| GJC1 | 518 |
| GJA3 | -4935 |
| MYO6 | -11410 |
Platelet Adhesion to exposed collagen
| 827 | |
|---|---|
| set | Platelet Adhesion to exposed collagen |
| setSize | 13 |
| pANOVA | 0.00176 |
| s.dist | 0.501 |
| p.adjustANOVA | 0.0065 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ITGA1 | 8729 |
| FCER1G | 8131 |
| LYN | 7809 |
| GP9 | 7506 |
| GP1BB | 7470 |
| GP6 | 6818 |
| VWF | 6641 |
| GP1BA | 6279 |
| ITGA2 | 4168 |
| GP5 | 1295 |
| ITGB1 | -94 |
| ITGA10 | -322 |
| FYN | -11675 |
| GeneID | Gene Rank |
|---|---|
| ITGA1 | 8729 |
| FCER1G | 8131 |
| LYN | 7809 |
| GP9 | 7506 |
| GP1BB | 7470 |
| GP6 | 6818 |
| VWF | 6641 |
| GP1BA | 6279 |
| ITGA2 | 4168 |
| GP5 | 1295 |
| ITGB1 | -94 |
| ITGA10 | -322 |
| FYN | -11675 |
Signaling by high-kinase activity BRAF mutants
| 1142 | |
|---|---|
| set | Signaling by high-kinase activity BRAF mutants |
| setSize | 31 |
| pANOVA | 1.54e-06 |
| s.dist | 0.499 |
| p.adjustANOVA | 1.77e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MAP2K1 | 9063 |
| MAPK3 | 8953 |
| ITGA2B | 8893 |
| APBB1IP | 8744 |
| MARK3 | 8697 |
| TLN1 | 8525 |
| ARRB2 | 8490 |
| ITGB3 | 8291 |
| FN1 | 8284 |
| IQGAP1 | 8152 |
| RAF1 | 7879 |
| MAPK1 | 7493 |
| VCL | 7328 |
| RAP1A | 7305 |
| MAP2K2 | 6794 |
| VWF | 6641 |
| YWHAB | 6385 |
| NRAS | 5363 |
| CSK | 5219 |
| KSR1 | 4167 |
| GeneID | Gene Rank |
|---|---|
| MAP2K1 | 9063 |
| MAPK3 | 8953 |
| ITGA2B | 8893 |
| APBB1IP | 8744 |
| MARK3 | 8697 |
| TLN1 | 8525 |
| ARRB2 | 8490 |
| ITGB3 | 8291 |
| FN1 | 8284 |
| IQGAP1 | 8152 |
| RAF1 | 7879 |
| MAPK1 | 7493 |
| VCL | 7328 |
| RAP1A | 7305 |
| MAP2K2 | 6794 |
| VWF | 6641 |
| YWHAB | 6385 |
| NRAS | 5363 |
| CSK | 5219 |
| KSR1 | 4167 |
| KRAS | 3702 |
| RAP1B | 3206 |
| ARAF | 2644 |
| ARRB1 | 1998 |
| BRAF | 1308 |
| KSR2 | -3361 |
| HRAS | -3382 |
| CNKSR2 | -4781 |
| CNKSR1 | -7089 |
| SRC | -8820 |
| PEBP1 | -11270 |
Smooth Muscle Contraction
| 1149 | |
|---|---|
| set | Smooth Muscle Contraction |
| setSize | 31 |
| pANOVA | 1.87e-06 |
| s.dist | 0.495 |
| p.adjustANOVA | 2.09e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| DYSF | 9464 |
| TPM4 | 9242 |
| ITGA1 | 8729 |
| MYL6 | 8576 |
| ANXA2 | 8544 |
| TLN1 | 8525 |
| PAK1 | 8230 |
| CALD1 | 8216 |
| PAK2 | 8185 |
| MYL6B | 8178 |
| TPM3 | 8051 |
| TPM1 | 8041 |
| ANXA1 | 7842 |
| MYL9 | 7703 |
| VCL | 7328 |
| ITGB5 | 6923 |
| MYL12A | 6899 |
| MYLK | 6618 |
| PXN | 6230 |
| MYL12B | 5088 |
| GeneID | Gene Rank |
|---|---|
| DYSF | 9464 |
| TPM4 | 9242 |
| ITGA1 | 8729 |
| MYL6 | 8576 |
| ANXA2 | 8544 |
| TLN1 | 8525 |
| PAK1 | 8230 |
| CALD1 | 8216 |
| PAK2 | 8185 |
| MYL6B | 8178 |
| TPM3 | 8051 |
| TPM1 | 8041 |
| ANXA1 | 7842 |
| MYL9 | 7703 |
| VCL | 7328 |
| ITGB5 | 6923 |
| MYL12A | 6899 |
| MYLK | 6618 |
| PXN | 6230 |
| MYL12B | 5088 |
| MYL5 | 3273 |
| TRIM72 | 1879 |
| SORBS1 | 1475 |
| ANXA6 | 327 |
| ACTA2 | -429 |
| CALM1 | -2081 |
| MYH11 | -3522 |
| GUCY1B2 | -5054 |
| MYLPF | -8871 |
| TPM2 | -9185 |
| SORBS3 | -10978 |
Pentose phosphate pathway
| 807 | |
|---|---|
| set | Pentose phosphate pathway |
| setSize | 13 |
| pANOVA | 0.00226 |
| s.dist | 0.489 |
| p.adjustANOVA | 0.00793 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PGD | 9481 |
| TALDO1 | 9456 |
| PGM2 | 9344 |
| TKT | 9342 |
| G6PD | 9004 |
| DERA | 8500 |
| PGLS | 6079 |
| PRPS2 | 3562 |
| RPE | 2589 |
| RPIA | 1441 |
| SHPK | -2528 |
| RBKS | -3142 |
| PRPS1 | -12077 |
| GeneID | Gene Rank |
|---|---|
| PGD | 9481 |
| TALDO1 | 9456 |
| PGM2 | 9344 |
| TKT | 9342 |
| G6PD | 9004 |
| DERA | 8500 |
| PGLS | 6079 |
| PRPS2 | 3562 |
| RPE | 2589 |
| RPIA | 1441 |
| SHPK | -2528 |
| RBKS | -3142 |
| PRPS1 | -12077 |
RHO GTPases activate PAKs
| 893 | |
|---|---|
| set | RHO GTPases activate PAKs |
| setSize | 20 |
| pANOVA | 0.00017 |
| s.dist | 0.486 |
| p.adjustANOVA | 0.000894 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RAC1 | 8793 |
| MYL6 | 8576 |
| PAK1 | 8230 |
| PAK2 | 8185 |
| MYL9 | 7703 |
| CDC42 | 7537 |
| PPP1CB | 7064 |
| MYH9 | 6685 |
| MYLK | 6618 |
| PPP1R12A | 6050 |
| CTTN | 5930 |
| MYL12B | 5088 |
| LIMK1 | 4679 |
| PPP1R12B | 1775 |
| MYH10 | 653 |
| FLNA | 483 |
| CALM1 | -2081 |
| MYH11 | -3522 |
| PAK3 | -4184 |
| NF2 | -6540 |
| GeneID | Gene Rank |
|---|---|
| RAC1 | 8793 |
| MYL6 | 8576 |
| PAK1 | 8230 |
| PAK2 | 8185 |
| MYL9 | 7703 |
| CDC42 | 7537 |
| PPP1CB | 7064 |
| MYH9 | 6685 |
| MYLK | 6618 |
| PPP1R12A | 6050 |
| CTTN | 5930 |
| MYL12B | 5088 |
| LIMK1 | 4679 |
| PPP1R12B | 1775 |
| MYH10 | 653 |
| FLNA | 483 |
| CALM1 | -2081 |
| MYH11 | -3522 |
| PAK3 | -4184 |
| NF2 | -6540 |
RHO GTPases activate PKNs
| 894 | |
|---|---|
| set | RHO GTPases activate PKNs |
| setSize | 48 |
| pANOVA | 6.95e-09 |
| s.dist | 0.483 |
| p.adjustANOVA | 1.56e-07 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| H2AJ | 9374.0 |
| H2BC21 | 9283.0 |
| YWHAG | 9264.0 |
| H2BC12 | 9051.0 |
| YWHAE | 9045.0 |
| RAC1 | 8793.0 |
| H3-3A | 8661.0 |
| YWHAH | 8649.0 |
| MYL6 | 8576.0 |
| RHOA | 8319.0 |
| PAK1 | 8230.0 |
| H2BC5 | 8003.0 |
| H2AC6 | 7934.0 |
| H2BC11 | 7912.0 |
| MYL9 | 7703.0 |
| H2BC4 | 7389.0 |
| H2BC17 | 7285.0 |
| PPP1CB | 7064.0 |
| PPP1R14A | 6839.0 |
| H3C15 | 6699.5 |
| GeneID | Gene Rank |
|---|---|
| H2AJ | 9374.0 |
| H2BC21 | 9283.0 |
| YWHAG | 9264.0 |
| H2BC12 | 9051.0 |
| YWHAE | 9045.0 |
| RAC1 | 8793.0 |
| H3-3A | 8661.0 |
| YWHAH | 8649.0 |
| MYL6 | 8576.0 |
| RHOA | 8319.0 |
| PAK1 | 8230.0 |
| H2BC5 | 8003.0 |
| H2AC6 | 7934.0 |
| H2BC11 | 7912.0 |
| MYL9 | 7703.0 |
| H2BC4 | 7389.0 |
| H2BC17 | 7285.0 |
| PPP1CB | 7064.0 |
| PPP1R14A | 6839.0 |
| H3C15 | 6699.5 |
| MYH9 | 6685.0 |
| YWHAB | 6385.0 |
| PDPK1 | 6136.0 |
| PPP1R12A | 6050.0 |
| H2AZ1 | 6036.0 |
| YWHAZ | 5624.0 |
| H2BC9 | 5394.0 |
| H2BC15 | 5312.0 |
| MYL12B | 5088.0 |
| H2AC20 | 4972.0 |
| CDC25C | 4969.0 |
| AR | 4840.0 |
| KLK2 | 3029.0 |
| PPP1R12B | 1775.0 |
| SFN | 1615.0 |
| RHOB | 1254.0 |
| NCOA2 | 1092.0 |
| MYH10 | 653.0 |
| PKN2 | 98.0 |
| H2AZ2 | -1209.0 |
| PKN1 | -2208.0 |
| MYH11 | -3522.0 |
| PKN3 | -3793.0 |
| H2BU1 | -6555.0 |
| YWHAQ | -7340.0 |
| KDM1A | -9430.0 |
| KDM4C | -10749.0 |
| RHOC | -11360.0 |
Amyloid fiber formation
| 70 | |
|---|---|
| set | Amyloid fiber formation |
| setSize | 51 |
| pANOVA | 2.44e-09 |
| s.dist | 0.483 |
| p.adjustANOVA | 5.64e-08 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| SNCA | 9354.0 |
| H2BC21 | 9283.0 |
| NCSTN | 9186.0 |
| APP | 9177.0 |
| FURIN | 9075.0 |
| H2BC12 | 9051.0 |
| ADAM10 | 8791.0 |
| GSN | 8749.0 |
| H3-3A | 8661.0 |
| SIAH2 | 8578.0 |
| TGFBI | 8211.0 |
| H2BC5 | 8003.0 |
| H2AC6 | 7934.0 |
| H2BC11 | 7912.0 |
| H2BC4 | 7389.0 |
| H2BC17 | 7285.0 |
| LYZ | 7213.0 |
| TSPAN14 | 6971.0 |
| H3C15 | 6699.5 |
| UBB | 6639.0 |
| GeneID | Gene Rank |
|---|---|
| SNCA | 9354.0 |
| H2BC21 | 9283.0 |
| NCSTN | 9186.0 |
| APP | 9177.0 |
| FURIN | 9075.0 |
| H2BC12 | 9051.0 |
| ADAM10 | 8791.0 |
| GSN | 8749.0 |
| H3-3A | 8661.0 |
| SIAH2 | 8578.0 |
| TGFBI | 8211.0 |
| H2BC5 | 8003.0 |
| H2AC6 | 7934.0 |
| H2BC11 | 7912.0 |
| H2BC4 | 7389.0 |
| H2BC17 | 7285.0 |
| LYZ | 7213.0 |
| TSPAN14 | 6971.0 |
| H3C15 | 6699.5 |
| UBB | 6639.0 |
| SORL1 | 6530.0 |
| LTF | 6306.0 |
| APH1B | 6280.0 |
| TSPAN33 | 6170.0 |
| H2AZ1 | 6036.0 |
| ITM2B | 5982.0 |
| PSENEN | 5735.0 |
| USP9X | 5464.0 |
| H2BC9 | 5394.0 |
| H2BC15 | 5312.0 |
| H2AC20 | 4972.0 |
| UBC | 4439.0 |
| APH1A | 4133.0 |
| GGA3 | 3816.0 |
| BACE1 | 3609.0 |
| MFGE8 | 3534.0 |
| GGA1 | 2310.0 |
| CST3 | 2206.0 |
| UBA52 | 1121.0 |
| TSPAN5 | 1028.0 |
| NPPA | -584.0 |
| TSPAN15 | -1876.0 |
| CALB1 | -2832.0 |
| SIAH1 | -3000.0 |
| NAT8B | -3939.0 |
| H2BU1 | -6555.0 |
| GGA2 | -6587.0 |
| B2M | -6920.0 |
| RPS27A | -6938.0 |
| HSPG2 | -7779.0 |
| UBE2L6 | -11293.0 |
Activation of the pre-replicative complex
| 51 | |
|---|---|
| set | Activation of the pre-replicative complex |
| setSize | 32 |
| pANOVA | 2.43e-06 |
| s.dist | -0.481 |
| p.adjustANOVA | 2.62e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MCM3 | -12200 |
| POLA1 | -12150 |
| MCM7 | -12129 |
| RPA1 | -12004 |
| POLE3 | -11581 |
| POLA2 | -11575 |
| MCM8 | -10944 |
| DBF4 | -10925 |
| ORC3 | -10713 |
| PRIM1 | -10191 |
| POLE2 | -9941 |
| ORC2 | -9922 |
| MCM6 | -9715 |
| ORC5 | -9479 |
| RPA3 | -8911 |
| MCM4 | -8701 |
| CDC7 | -7855 |
| POLE | -7579 |
| MCM5 | -7292 |
| MCM2 | -7223 |
| GeneID | Gene Rank |
|---|---|
| MCM3 | -12200 |
| POLA1 | -12150 |
| MCM7 | -12129 |
| RPA1 | -12004 |
| POLE3 | -11581 |
| POLA2 | -11575 |
| MCM8 | -10944 |
| DBF4 | -10925 |
| ORC3 | -10713 |
| PRIM1 | -10191 |
| POLE2 | -9941 |
| ORC2 | -9922 |
| MCM6 | -9715 |
| ORC5 | -9479 |
| RPA3 | -8911 |
| MCM4 | -8701 |
| CDC7 | -7855 |
| POLE | -7579 |
| MCM5 | -7292 |
| MCM2 | -7223 |
| RPA2 | -6306 |
| PRIM2 | -5575 |
| CDK2 | -5006 |
| CDC45 | -2659 |
| ORC1 | -2520 |
| ORC4 | -2028 |
| CDT1 | -287 |
| MCM10 | 776 |
| ORC6 | 1184 |
| GMNN | 1422 |
| CDC6 | 2370 |
| POLE4 | 5518 |
SHC1 events in EGFR signaling
| 1031 | |
|---|---|
| set | SHC1 events in EGFR signaling |
| setSize | 12 |
| pANOVA | 0.00392 |
| s.dist | 0.481 |
| p.adjustANOVA | 0.0125 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| TGFA | 8889 |
| EGF | 8179 |
| AREG | 5977 |
| NRAS | 5363 |
| HBEGF | 5013 |
| SHC1 | 4161 |
| KRAS | 3702 |
| EPGN | 2662 |
| EREG | 1888 |
| HRAS | -3382 |
| SOS1 | -5700 |
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| TGFA | 8889 |
| EGF | 8179 |
| AREG | 5977 |
| NRAS | 5363 |
| HBEGF | 5013 |
| SHC1 | 4161 |
| KRAS | 3702 |
| EPGN | 2662 |
| EREG | 1888 |
| HRAS | -3382 |
| SOS1 | -5700 |
Defects of contact activation system (CAS) and kallikrein/kinin system (KKS)
| 266 | |
|---|---|
| set | Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) |
| setSize | 12 |
| pANOVA | 0.00412 |
| s.dist | 0.478 |
| p.adjustANOVA | 0.013 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| F12 | 9492 |
| TPST1 | 9251 |
| GP9 | 7506 |
| GP1BB | 7470 |
| F8 | 7022 |
| VWF | 6641 |
| GP1BA | 6279 |
| TPST2 | 5725 |
| GGCX | 5237 |
| GP5 | 1295 |
| KLKB1 | -9019 |
| SERPING1 | -11197 |
| GeneID | Gene Rank |
|---|---|
| F12 | 9492 |
| TPST1 | 9251 |
| GP9 | 7506 |
| GP1BB | 7470 |
| F8 | 7022 |
| VWF | 6641 |
| GP1BA | 6279 |
| TPST2 | 5725 |
| GGCX | 5237 |
| GP5 | 1295 |
| KLKB1 | -9019 |
| SERPING1 | -11197 |
Diseases of hemostasis
| 294 | |
|---|---|
| set | Diseases of hemostasis |
| setSize | 12 |
| pANOVA | 0.00412 |
| s.dist | 0.478 |
| p.adjustANOVA | 0.013 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| F12 | 9492 |
| TPST1 | 9251 |
| GP9 | 7506 |
| GP1BB | 7470 |
| F8 | 7022 |
| VWF | 6641 |
| GP1BA | 6279 |
| TPST2 | 5725 |
| GGCX | 5237 |
| GP5 | 1295 |
| KLKB1 | -9019 |
| SERPING1 | -11197 |
| GeneID | Gene Rank |
|---|---|
| F12 | 9492 |
| TPST1 | 9251 |
| GP9 | 7506 |
| GP1BB | 7470 |
| F8 | 7022 |
| VWF | 6641 |
| GP1BA | 6279 |
| TPST2 | 5725 |
| GGCX | 5237 |
| GP5 | 1295 |
| KLKB1 | -9019 |
| SERPING1 | -11197 |
GRB2 events in EGFR signaling
| 432 | |
|---|---|
| set | GRB2 events in EGFR signaling |
| setSize | 11 |
| pANOVA | 0.00602 |
| s.dist | 0.478 |
| p.adjustANOVA | 0.0177 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| TGFA | 8889 |
| EGF | 8179 |
| AREG | 5977 |
| NRAS | 5363 |
| HBEGF | 5013 |
| KRAS | 3702 |
| EPGN | 2662 |
| EREG | 1888 |
| HRAS | -3382 |
| SOS1 | -5700 |
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| TGFA | 8889 |
| EGF | 8179 |
| AREG | 5977 |
| NRAS | 5363 |
| HBEGF | 5013 |
| KRAS | 3702 |
| EPGN | 2662 |
| EREG | 1888 |
| HRAS | -3382 |
| SOS1 | -5700 |
Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
| 346 | |
|---|---|
| set | Erythropoietin activates Phosphoinositide-3-kinase (PI3K) |
| setSize | 11 |
| pANOVA | 0.00619 |
| s.dist | 0.477 |
| p.adjustANOVA | 0.0181 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PIK3CB | 9038 |
| IRS2 | 8569 |
| LYN | 7809 |
| EPOR | 7223 |
| PIK3CD | 6046 |
| GAB1 | 5679 |
| PIK3CA | 4629 |
| JAK2 | 2691 |
| PIK3CG | 1833 |
| PIK3R5 | -2304 |
| PIK3R1 | -9505 |
| GeneID | Gene Rank |
|---|---|
| PIK3CB | 9038 |
| IRS2 | 8569 |
| LYN | 7809 |
| EPOR | 7223 |
| PIK3CD | 6046 |
| GAB1 | 5679 |
| PIK3CA | 4629 |
| JAK2 | 2691 |
| PIK3CG | 1833 |
| PIK3R5 | -2304 |
| PIK3R1 | -9505 |
Platelet Aggregation (Plug Formation)
| 828 | |
|---|---|
| set | Platelet Aggregation (Plug Formation) |
| setSize | 28 |
| pANOVA | 1.27e-05 |
| s.dist | 0.477 |
| p.adjustANOVA | 1e-04 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| SYK | 9076 |
| CRK | 8906 |
| ITGA2B | 8893 |
| APBB1IP | 8744 |
| TLN1 | 8525 |
| ITGB3 | 8291 |
| FN1 | 8284 |
| GP9 | 7506 |
| GP1BB | 7470 |
| RAP1A | 7305 |
| VWF | 6641 |
| GP1BA | 6279 |
| PDPK1 | 6136 |
| PTPN1 | 5722 |
| CSK | 5219 |
| PTK2 | 4462 |
| SHC1 | 4161 |
| AKT1 | 3614 |
| RAP1B | 3206 |
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| SYK | 9076 |
| CRK | 8906 |
| ITGA2B | 8893 |
| APBB1IP | 8744 |
| TLN1 | 8525 |
| ITGB3 | 8291 |
| FN1 | 8284 |
| GP9 | 7506 |
| GP1BB | 7470 |
| RAP1A | 7305 |
| VWF | 6641 |
| GP1BA | 6279 |
| PDPK1 | 6136 |
| PTPN1 | 5722 |
| CSK | 5219 |
| PTK2 | 4462 |
| SHC1 | 4161 |
| AKT1 | 3614 |
| RAP1B | 3206 |
| MPL | 2634 |
| ADRA2A | 2271 |
| GP5 | 1295 |
| RAPGEF3 | -2911 |
| SOS1 | -5700 |
| RASGRP2 | -8529 |
| SRC | -8820 |
| RASGRP1 | -11974 |
Spry regulation of FGF signaling
| 1152 | |
|---|---|
| set | Spry regulation of FGF signaling |
| setSize | 16 |
| pANOVA | 0.000996 |
| s.dist | 0.475 |
| p.adjustANOVA | 0.00406 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| MAPK3 | 8953 |
| PPP2CA | 8234 |
| MKNK1 | 8170 |
| PPP2CB | 7712 |
| MAPK1 | 7493 |
| CBL | 7480 |
| UBB | 6639 |
| PTPN11 | 5314 |
| PPP2R1A | 4589 |
| UBC | 4439 |
| BRAF | 1308 |
| UBA52 | 1121 |
| SPRY2 | -4603 |
| RPS27A | -6938 |
| SRC | -8820 |
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| MAPK3 | 8953 |
| PPP2CA | 8234 |
| MKNK1 | 8170 |
| PPP2CB | 7712 |
| MAPK1 | 7493 |
| CBL | 7480 |
| UBB | 6639 |
| PTPN11 | 5314 |
| PPP2R1A | 4589 |
| UBC | 4439 |
| BRAF | 1308 |
| UBA52 | 1121 |
| SPRY2 | -4603 |
| RPS27A | -6938 |
| SRC | -8820 |
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3
| 32 | |
|---|---|
| set | Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 |
| setSize | 22 |
| pANOVA | 0.000129 |
| s.dist | 0.472 |
| p.adjustANOVA | 0.000707 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| H2AJ | 9374.0 |
| H2BC21 | 9283.0 |
| H2BC12 | 9051.0 |
| H3-3A | 8661.0 |
| H2BC5 | 8003.0 |
| H2AC6 | 7934.0 |
| H2BC11 | 7912.0 |
| H2BC4 | 7389.0 |
| H2BC17 | 7285.0 |
| H3C15 | 6699.5 |
| H2AZ1 | 6036.0 |
| H2BC9 | 5394.0 |
| H2BC15 | 5312.0 |
| H2AC20 | 4972.0 |
| AR | 4840.0 |
| KLK2 | 3029.0 |
| NCOA2 | 1092.0 |
| H2AZ2 | -1209.0 |
| PKN1 | -2208.0 |
| H2BU1 | -6555.0 |
| GeneID | Gene Rank |
|---|---|
| H2AJ | 9374.0 |
| H2BC21 | 9283.0 |
| H2BC12 | 9051.0 |
| H3-3A | 8661.0 |
| H2BC5 | 8003.0 |
| H2AC6 | 7934.0 |
| H2BC11 | 7912.0 |
| H2BC4 | 7389.0 |
| H2BC17 | 7285.0 |
| H3C15 | 6699.5 |
| H2AZ1 | 6036.0 |
| H2BC9 | 5394.0 |
| H2BC15 | 5312.0 |
| H2AC20 | 4972.0 |
| AR | 4840.0 |
| KLK2 | 3029.0 |
| NCOA2 | 1092.0 |
| H2AZ2 | -1209.0 |
| PKN1 | -2208.0 |
| H2BU1 | -6555.0 |
| KDM1A | -9430.0 |
| KDM4C | -10749.0 |
Signaling by RAF1 mutants
| 1128 | |
|---|---|
| set | Signaling by RAF1 mutants |
| setSize | 34 |
| pANOVA | 1.94e-06 |
| s.dist | 0.472 |
| p.adjustANOVA | 2.16e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MAP2K1 | 9063 |
| MAPK3 | 8953 |
| ITGA2B | 8893 |
| APBB1IP | 8744 |
| MARK3 | 8697 |
| TLN1 | 8525 |
| ARRB2 | 8490 |
| ITGB3 | 8291 |
| FN1 | 8284 |
| IQGAP1 | 8152 |
| RAF1 | 7879 |
| MAPK1 | 7493 |
| VCL | 7328 |
| RAP1A | 7305 |
| MAP2K2 | 6794 |
| VWF | 6641 |
| YWHAB | 6385 |
| NRAS | 5363 |
| CSK | 5219 |
| KSR1 | 4167 |
| GeneID | Gene Rank |
|---|---|
| MAP2K1 | 9063 |
| MAPK3 | 8953 |
| ITGA2B | 8893 |
| APBB1IP | 8744 |
| MARK3 | 8697 |
| TLN1 | 8525 |
| ARRB2 | 8490 |
| ITGB3 | 8291 |
| FN1 | 8284 |
| IQGAP1 | 8152 |
| RAF1 | 7879 |
| MAPK1 | 7493 |
| VCL | 7328 |
| RAP1A | 7305 |
| MAP2K2 | 6794 |
| VWF | 6641 |
| YWHAB | 6385 |
| NRAS | 5363 |
| CSK | 5219 |
| KSR1 | 4167 |
| KRAS | 3702 |
| RAP1B | 3206 |
| JAK2 | 2691 |
| ARAF | 2644 |
| ARRB1 | 1998 |
| CAMK2G | 1921 |
| BRAF | 1308 |
| CALM1 | -2081 |
| KSR2 | -3361 |
| HRAS | -3382 |
| CNKSR2 | -4781 |
| CNKSR1 | -7089 |
| SRC | -8820 |
| CAMK2D | -11816 |
Josephin domain DUBs
| 583 | |
|---|---|
| set | Josephin domain DUBs |
| setSize | 10 |
| pANOVA | 0.00989 |
| s.dist | 0.471 |
| p.adjustANOVA | 0.0261 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RAD23B | 8886 |
| JOSD2 | 7931 |
| VCP | 6886 |
| UBB | 6639 |
| RAD23A | 6512 |
| UBC | 4439 |
| ATXN3 | 1601 |
| UBA52 | 1121 |
| JOSD1 | 227 |
| RPS27A | -6938 |
| GeneID | Gene Rank |
|---|---|
| RAD23B | 8886 |
| JOSD2 | 7931 |
| VCP | 6886 |
| UBB | 6639 |
| RAD23A | 6512 |
| UBC | 4439 |
| ATXN3 | 1601 |
| UBA52 | 1121 |
| JOSD1 | 227 |
| RPS27A | -6938 |
GAB1 signalosome
| 423 | |
|---|---|
| set | GAB1 signalosome |
| setSize | 15 |
| pANOVA | 0.00159 |
| s.dist | 0.471 |
| p.adjustANOVA | 0.00597 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| TGFA | 8889 |
| EGF | 8179 |
| PXN | 6230 |
| AREG | 5977 |
| GAB1 | 5679 |
| PTPN11 | 5314 |
| PAG1 | 5268 |
| CSK | 5219 |
| HBEGF | 5013 |
| PIK3CA | 4629 |
| EPGN | 2662 |
| EREG | 1888 |
| SRC | -8820 |
| PIK3R1 | -9505 |
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| TGFA | 8889 |
| EGF | 8179 |
| PXN | 6230 |
| AREG | 5977 |
| GAB1 | 5679 |
| PTPN11 | 5314 |
| PAG1 | 5268 |
| CSK | 5219 |
| HBEGF | 5013 |
| PIK3CA | 4629 |
| EPGN | 2662 |
| EREG | 1888 |
| SRC | -8820 |
| PIK3R1 | -9505 |
Trafficking of GluR2-containing AMPA receptors
| 1248 | |
|---|---|
| set | Trafficking of GluR2-containing AMPA receptors |
| setSize | 12 |
| pANOVA | 0.00479 |
| s.dist | 0.47 |
| p.adjustANOVA | 0.0147 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| NSF | 8829 |
| AP2M1 | 8627 |
| AP2S1 | 8026 |
| AP2A2 | 7257 |
| PRKCB | 7097 |
| AP2A1 | 6832 |
| TSPAN7 | 6469 |
| PICK1 | 3594 |
| PRKCA | 1132 |
| GRIA4 | -97 |
| AP2B1 | -2709 |
| GRIP1 | -10411 |
| GeneID | Gene Rank |
|---|---|
| NSF | 8829 |
| AP2M1 | 8627 |
| AP2S1 | 8026 |
| AP2A2 | 7257 |
| PRKCB | 7097 |
| AP2A1 | 6832 |
| TSPAN7 | 6469 |
| PICK1 | 3594 |
| PRKCA | 1132 |
| GRIA4 | -97 |
| AP2B1 | -2709 |
| GRIP1 | -10411 |
Generation of second messenger molecules
| 445 | |
|---|---|
| set | Generation of second messenger molecules |
| setSize | 38 |
| pANOVA | 7.2e-07 |
| s.dist | -0.464 |
| p.adjustANOVA | 9.72e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CD247 | -12345 |
| HLA-DPA1 | -12316 |
| HLA-DPB1 | -12248 |
| EVL | -12207 |
| HLA-DRA | -12009 |
| TRBC1 | -12006 |
| HLA-DQA1 | -11992 |
| ZAP70 | -11949 |
| LCK | -11838 |
| LAT | -11694 |
| CD3G | -11526 |
| TRAC | -11482 |
| NCK1 | -11454 |
| CD3D | -11401 |
| CD3E | -11302 |
| ITK | -11223 |
| PLCG1 | -11120 |
| TRBV12-3 | -10436 |
| TRAV19 | -9915 |
| TRAV29DV5 | -9673 |
| GeneID | Gene Rank |
|---|---|
| CD247 | -12345 |
| HLA-DPA1 | -12316 |
| HLA-DPB1 | -12248 |
| EVL | -12207 |
| HLA-DRA | -12009 |
| TRBC1 | -12006 |
| HLA-DQA1 | -11992 |
| ZAP70 | -11949 |
| LCK | -11838 |
| LAT | -11694 |
| CD3G | -11526 |
| TRAC | -11482 |
| NCK1 | -11454 |
| CD3D | -11401 |
| CD3E | -11302 |
| ITK | -11223 |
| PLCG1 | -11120 |
| TRBV12-3 | -10436 |
| TRAV19 | -9915 |
| TRAV29DV5 | -9673 |
| TRBV7-9 | -9539 |
| HLA-DQB2 | -9401 |
| HLA-DRB1 | -8075 |
| TRAV8-4 | -7261 |
| HLA-DQB1 | -6416 |
| CD4 | -5406 |
| HLA-DRB5 | -4971 |
| HLA-DQA2 | -4806 |
| PAK3 | -4184 |
| ENAH | -2707 |
| LCP2 | -1156 |
| CD101 | 4146 |
| GRAP2 | 4690 |
| PLCG2 | 5006 |
| VASP | 8027 |
| PAK2 | 8185 |
| PAK1 | 8230 |
| WAS | 8560 |
EGFR downregulation
| 319 | |
|---|---|
| set | EGFR downregulation |
| setSize | 27 |
| pANOVA | 3.34e-05 |
| s.dist | 0.461 |
| p.adjustANOVA | 0.000228 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| TGFA | 8889 |
| EGF | 8179 |
| PTPN12 | 8151 |
| EPN1 | 8045 |
| SH3GL1 | 7625 |
| CDC42 | 7537 |
| CBL | 7480 |
| UBB | 6639 |
| SH3KBP1 | 6173 |
| STAM2 | 6159 |
| AREG | 5977 |
| HBEGF | 5013 |
| HGS | 4513 |
| UBC | 4439 |
| EPS15 | 4138 |
| EPS15L1 | 3655 |
| EPGN | 2662 |
| SPRY1 | 2302 |
| EREG | 1888 |
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| TGFA | 8889 |
| EGF | 8179 |
| PTPN12 | 8151 |
| EPN1 | 8045 |
| SH3GL1 | 7625 |
| CDC42 | 7537 |
| CBL | 7480 |
| UBB | 6639 |
| SH3KBP1 | 6173 |
| STAM2 | 6159 |
| AREG | 5977 |
| HBEGF | 5013 |
| HGS | 4513 |
| UBC | 4439 |
| EPS15 | 4138 |
| EPS15L1 | 3655 |
| EPGN | 2662 |
| SPRY1 | 2302 |
| EREG | 1888 |
| STAM | 1285 |
| UBA52 | 1121 |
| PTPN3 | -85 |
| ARHGEF7 | -4583 |
| SPRY2 | -4603 |
| RPS27A | -6938 |
| PTPRK | -7262 |
Response of Mtb to phagocytosis
| 1009 | |
|---|---|
| set | Response of Mtb to phagocytosis |
| setSize | 22 |
| pANOVA | 0.000191 |
| s.dist | 0.459 |
| p.adjustANOVA | 0.000985 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MAPK3 | 8953 |
| ENO1 | 8890 |
| RAB7A | 8742 |
| PGK1 | 8672 |
| TRIM27 | 8142 |
| ATP6V1H | 8064 |
| GSK3A | 7760 |
| MAPK1 | 7493 |
| RAB5A | 7103 |
| UBB | 6639 |
| CORO1A | 5178 |
| CTSG | 5115 |
| HGS | 4513 |
| UBC | 4439 |
| KPNB1 | 2430 |
| SFPQ | 2253 |
| KPNA1 | 1296 |
| UBA52 | 1121 |
| VPS33B | -2091 |
| DUSP16 | -6655 |
| GeneID | Gene Rank |
|---|---|
| MAPK3 | 8953 |
| ENO1 | 8890 |
| RAB7A | 8742 |
| PGK1 | 8672 |
| TRIM27 | 8142 |
| ATP6V1H | 8064 |
| GSK3A | 7760 |
| MAPK1 | 7493 |
| RAB5A | 7103 |
| UBB | 6639 |
| CORO1A | 5178 |
| CTSG | 5115 |
| HGS | 4513 |
| UBC | 4439 |
| KPNB1 | 2430 |
| SFPQ | 2253 |
| KPNA1 | 1296 |
| UBA52 | 1121 |
| VPS33B | -2091 |
| DUSP16 | -6655 |
| RPS27A | -6938 |
| RNF213 | -11905 |
Antimicrobial peptides
| 77 | |
|---|---|
| set | Antimicrobial peptides |
| setSize | 33 |
| pANOVA | 4.93e-06 |
| s.dist | 0.459 |
| p.adjustANOVA | 4.51e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| S100A9 | 9516 |
| S100A8 | 9503 |
| CCR2 | 9449 |
| CLU | 9371 |
| SLC11A1 | 9169 |
| TLR2 | 9103 |
| TLR1 | 8932 |
| PGLYRP1 | 7910 |
| LCN2 | 7755 |
| RNASE3 | 7471 |
| ELANE | 7320 |
| LYZ | 7213 |
| RNASE6 | 6837 |
| PRTN3 | 6762 |
| BPI | 6666 |
| LTF | 6306 |
| DEFA1 | 6061 |
| DEFA4 | 6057 |
| DEFA3 | 5385 |
| CTSG | 5115 |
| GeneID | Gene Rank |
|---|---|
| S100A9 | 9516 |
| S100A8 | 9503 |
| CCR2 | 9449 |
| CLU | 9371 |
| SLC11A1 | 9169 |
| TLR2 | 9103 |
| TLR1 | 8932 |
| PGLYRP1 | 7910 |
| LCN2 | 7755 |
| RNASE3 | 7471 |
| ELANE | 7320 |
| LYZ | 7213 |
| RNASE6 | 6837 |
| PRTN3 | 6762 |
| BPI | 6666 |
| LTF | 6306 |
| DEFA1 | 6061 |
| DEFA4 | 6057 |
| DEFA3 | 5385 |
| CTSG | 5115 |
| CAMP | 4785 |
| ATOX1 | 4338 |
| PI3 | 3023 |
| EPPIN | 2251 |
| ATP7A | 694 |
| PGLYRP2 | -2281 |
| HTN1 | -3453 |
| LEAP2 | -4703 |
| CD4 | -5406 |
| PDZD11 | -6288 |
| ITLN1 | -6873 |
| CCR6 | -7862 |
| GNLY | -11428 |
Diseases of programmed cell death
| 297 | |
|---|---|
| set | Diseases of programmed cell death |
| setSize | 23 |
| pANOVA | 0.000137 |
| s.dist | 0.459 |
| p.adjustANOVA | 0.000735 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| LMNB1 | 9345 |
| APP | 9177 |
| YWHAE | 9045 |
| FOXO3 | 8682 |
| CDK5 | 8616 |
| CAPN1 | 8563 |
| CAST | 8164 |
| CAPNS1 | 7729 |
| BCL2L11 | 7384 |
| PRDX1 | 7030 |
| GOLGA2 | 6203 |
| CDC25C | 4969 |
| SOD2 | 4390 |
| LMNA | 3887 |
| JUN | 3722 |
| PRDX2 | 3428 |
| CDC25A | 2911 |
| CAPN2 | 1064 |
| C1QBP | -822 |
| CDK5R1 | -1089 |
| GeneID | Gene Rank |
|---|---|
| LMNB1 | 9345 |
| APP | 9177 |
| YWHAE | 9045 |
| FOXO3 | 8682 |
| CDK5 | 8616 |
| CAPN1 | 8563 |
| CAST | 8164 |
| CAPNS1 | 7729 |
| BCL2L11 | 7384 |
| PRDX1 | 7030 |
| GOLGA2 | 6203 |
| CDC25C | 4969 |
| SOD2 | 4390 |
| LMNA | 3887 |
| JUN | 3722 |
| PRDX2 | 3428 |
| CDC25A | 2911 |
| CAPN2 | 1064 |
| C1QBP | -822 |
| CDK5R1 | -1089 |
| CDKN2A | -5236 |
| CDC25B | -12017 |
| FASLG | -12371 |
The NLRP3 inflammasome
| 1226 | |
|---|---|
| set | The NLRP3 inflammasome |
| setSize | 15 |
| pANOVA | 0.00213 |
| s.dist | 0.458 |
| p.adjustANOVA | 0.0075 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| APP | 9177 |
| NLRP3 | 8901 |
| PYCARD | 8638 |
| MEFV | 8605 |
| TXN | 8285 |
| PSTPIP1 | 7841 |
| NFKB1 | 6277 |
| PANX1 | 6267 |
| CASP1 | 4224 |
| P2RX7 | 3475 |
| SUGT1 | 1544 |
| NFKB2 | -1165 |
| RELA | -1803 |
| HSP90AB1 | -6863 |
| TXNIP | -9600 |
| GeneID | Gene Rank |
|---|---|
| APP | 9177 |
| NLRP3 | 8901 |
| PYCARD | 8638 |
| MEFV | 8605 |
| TXN | 8285 |
| PSTPIP1 | 7841 |
| NFKB1 | 6277 |
| PANX1 | 6267 |
| CASP1 | 4224 |
| P2RX7 | 3475 |
| SUGT1 | 1544 |
| NFKB2 | -1165 |
| RELA | -1803 |
| HSP90AB1 | -6863 |
| TXNIP | -9600 |
Integrin signaling
| 544 | |
|---|---|
| set | Integrin signaling |
| setSize | 22 |
| pANOVA | 0.000208 |
| s.dist | 0.457 |
| p.adjustANOVA | 0.00107 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| SYK | 9076 |
| CRK | 8906 |
| ITGA2B | 8893 |
| APBB1IP | 8744 |
| TLN1 | 8525 |
| ITGB3 | 8291 |
| FN1 | 8284 |
| RAP1A | 7305 |
| VWF | 6641 |
| PDPK1 | 6136 |
| PTPN1 | 5722 |
| CSK | 5219 |
| PTK2 | 4462 |
| SHC1 | 4161 |
| AKT1 | 3614 |
| RAP1B | 3206 |
| RAPGEF3 | -2911 |
| SOS1 | -5700 |
| RASGRP2 | -8529 |
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| SYK | 9076 |
| CRK | 8906 |
| ITGA2B | 8893 |
| APBB1IP | 8744 |
| TLN1 | 8525 |
| ITGB3 | 8291 |
| FN1 | 8284 |
| RAP1A | 7305 |
| VWF | 6641 |
| PDPK1 | 6136 |
| PTPN1 | 5722 |
| CSK | 5219 |
| PTK2 | 4462 |
| SHC1 | 4161 |
| AKT1 | 3614 |
| RAP1B | 3206 |
| RAPGEF3 | -2911 |
| SOS1 | -5700 |
| RASGRP2 | -8529 |
| SRC | -8820 |
| RASGRP1 | -11974 |
Response to elevated platelet cytosolic Ca2+
| 1010 | |
|---|---|
| set | Response to elevated platelet cytosolic Ca2+ |
| setSize | 110 |
| pANOVA | 1.25e-16 |
| s.dist | 0.457 |
| p.adjustANOVA | 1.22e-14 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| F5 | 9485 |
| CYB5R1 | 9460 |
| CD36 | 9444 |
| CLU | 9371 |
| APLP2 | 9347 |
| QSOX1 | 9298 |
| CD63 | 9287 |
| ALDOA | 9249 |
| LHFPL2 | 9224 |
| FERMT3 | 9223 |
| APP | 9177 |
| SERPINA1 | 9168 |
| ACTN1 | 9094 |
| STXBP2 | 9035 |
| ITGA2B | 8893 |
| F13A1 | 8876 |
| HGF | 8863 |
| TOR4A | 8861 |
| VTI1B | 8850 |
| LAMP2 | 8786 |
| GeneID | Gene Rank |
|---|---|
| F5 | 9485 |
| CYB5R1 | 9460 |
| CD36 | 9444 |
| CLU | 9371 |
| APLP2 | 9347 |
| QSOX1 | 9298 |
| CD63 | 9287 |
| ALDOA | 9249 |
| LHFPL2 | 9224 |
| FERMT3 | 9223 |
| APP | 9177 |
| SERPINA1 | 9168 |
| ACTN1 | 9094 |
| STXBP2 | 9035 |
| ITGA2B | 8893 |
| F13A1 | 8876 |
| HGF | 8863 |
| TOR4A | 8861 |
| VTI1B | 8850 |
| LAMP2 | 8786 |
| SRGN | 8761 |
| TIMP1 | 8677 |
| TLN1 | 8525 |
| CLEC3B | 8480 |
| SELP | 8457 |
| ITGB3 | 8291 |
| FN1 | 8284 |
| SYTL4 | 8256 |
| ANXA5 | 8210 |
| CFL1 | 8186 |
| EGF | 8179 |
| CAP1 | 8111 |
| GAS6 | 8063 |
| LY6G6F | 8023 |
| ORM1 | 7971 |
| CALU | 7894 |
| PECAM1 | 7855 |
| SCCPDH | 7787 |
| PROS1 | 7758 |
| MMRN1 | 7714 |
| SERPINE1 | 7483 |
| VEGFA | 7467 |
| ABCC4 | 7434 |
| STXBP3 | 7424 |
| TAGLN2 | 7367 |
| SPARC | 7339 |
| VCL | 7328 |
| PSAP | 7145 |
| PRKCB | 7097 |
| HSPA5 | 7029 |
| F8 | 7022 |
| WDR1 | 6976 |
| VEGFC | 6906 |
| VWF | 6641 |
| TUBA4A | 6484 |
| GTPBP2 | 6331 |
| TMSB4X | 6295 |
| PPBP | 6042 |
| THBS1 | 5951 |
| CD9 | 5940 |
| PF4 | 5707 |
| A1BG | 5559 |
| PFN1 | 5459 |
| PHACTR2 | 5410 |
| PDGFA | 5293 |
| ECM1 | 5176 |
| TGFB1 | 5153 |
| ACTN4 | 5049 |
| OLA1 | 4914 |
| CD109 | 4316 |
| ALB | 3668 |
| RAB27B | 3386 |
| ENDOD1 | 3361 |
| TIMP3 | 3296 |
| CHID1 | 2811 |
| MANF | 2550 |
| PLEK | 1999 |
| CFD | 1984 |
| APOOL | 1609 |
| TTN | 1195 |
| PRKCA | 1132 |
| TF | 1102 |
| STX4 | 606 |
| FLNA | 483 |
| TMX3 | -775 |
| PLG | -1977 |
| PCYOX1L | -2009 |
| CALM1 | -2081 |
| ORM2 | -2564 |
| MAGED2 | -2687 |
| ITIH3 | -3017 |
| SOD1 | -4862 |
| ITIH4 | -6208 |
| SERPINF2 | -6574 |
| BRPF3 | -6615 |
| PPIA | -6766 |
| TGFB2 | -7492 |
| SELENOP | -7771 |
| NHLRC2 | -7835 |
| TGFB3 | -7891 |
| VEGFB | -7929 |
| TEX264 | -8366 |
| CDC37L1 | -8470 |
| PDGFB | -8577 |
| A2M | -9870 |
| FAM3C | -10062 |
| HABP4 | -10921 |
| CTSW | -11117 |
| SERPING1 | -11197 |
| LGALS3BP | -11459 |
activated TAK1 mediates p38 MAPK activation
| 1330 | |
|---|---|
| set | activated TAK1 mediates p38 MAPK activation |
| setSize | 19 |
| pANOVA | 0.000578 |
| s.dist | 0.456 |
| p.adjustANOVA | 0.00259 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MAPK14 | 9104 |
| MAP2K6 | 8887 |
| MAP2K3 | 8748 |
| NOD2 | 8442 |
| MAPKAPK3 | 8382 |
| TAB2 | 6964 |
| IRAK1 | 6131 |
| TAB1 | 5681 |
| UBE2V1 | 5637 |
| IKBKG | 5377 |
| MAPKAPK2 | 4054 |
| MAPK11 | 3826 |
| TAB3 | 3160 |
| MAP3K7 | 2395 |
| UBE2N | 1936 |
| RIPK2 | 1025 |
| TRAF6 | -229 |
| IRAK2 | -9548 |
| NOD1 | -12263 |
| GeneID | Gene Rank |
|---|---|
| MAPK14 | 9104 |
| MAP2K6 | 8887 |
| MAP2K3 | 8748 |
| NOD2 | 8442 |
| MAPKAPK3 | 8382 |
| TAB2 | 6964 |
| IRAK1 | 6131 |
| TAB1 | 5681 |
| UBE2V1 | 5637 |
| IKBKG | 5377 |
| MAPKAPK2 | 4054 |
| MAPK11 | 3826 |
| TAB3 | 3160 |
| MAP3K7 | 2395 |
| UBE2N | 1936 |
| RIPK2 | 1025 |
| TRAF6 | -229 |
| IRAK2 | -9548 |
| NOD1 | -12263 |
Mucopolysaccharidoses
| 683 | |
|---|---|
| set | Mucopolysaccharidoses |
| setSize | 11 |
| pANOVA | 0.00883 |
| s.dist | 0.456 |
| p.adjustANOVA | 0.024 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GNS | 9360 |
| GLB1 | 8725 |
| GUSB | 7723 |
| ARSB | 7572 |
| GALNS | 7102 |
| SGSH | 5912 |
| HYAL1 | 4164 |
| HGSNAT | 1867 |
| IDS | -2621 |
| NAGLU | -4761 |
| IDUA | -5830 |
| GeneID | Gene Rank |
|---|---|
| GNS | 9360 |
| GLB1 | 8725 |
| GUSB | 7723 |
| ARSB | 7572 |
| GALNS | 7102 |
| SGSH | 5912 |
| HYAL1 | 4164 |
| HGSNAT | 1867 |
| IDS | -2621 |
| NAGLU | -4761 |
| IDUA | -5830 |
Platelet degranulation
| 831 | |
|---|---|
| set | Platelet degranulation |
| setSize | 106 |
| pANOVA | 5.81e-16 |
| s.dist | 0.455 |
| p.adjustANOVA | 5.29e-14 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| F5 | 9485 |
| CYB5R1 | 9460 |
| CD36 | 9444 |
| CLU | 9371 |
| APLP2 | 9347 |
| QSOX1 | 9298 |
| CD63 | 9287 |
| ALDOA | 9249 |
| LHFPL2 | 9224 |
| FERMT3 | 9223 |
| APP | 9177 |
| SERPINA1 | 9168 |
| ACTN1 | 9094 |
| STXBP2 | 9035 |
| ITGA2B | 8893 |
| F13A1 | 8876 |
| HGF | 8863 |
| TOR4A | 8861 |
| VTI1B | 8850 |
| LAMP2 | 8786 |
| GeneID | Gene Rank |
|---|---|
| F5 | 9485 |
| CYB5R1 | 9460 |
| CD36 | 9444 |
| CLU | 9371 |
| APLP2 | 9347 |
| QSOX1 | 9298 |
| CD63 | 9287 |
| ALDOA | 9249 |
| LHFPL2 | 9224 |
| FERMT3 | 9223 |
| APP | 9177 |
| SERPINA1 | 9168 |
| ACTN1 | 9094 |
| STXBP2 | 9035 |
| ITGA2B | 8893 |
| F13A1 | 8876 |
| HGF | 8863 |
| TOR4A | 8861 |
| VTI1B | 8850 |
| LAMP2 | 8786 |
| SRGN | 8761 |
| TIMP1 | 8677 |
| TLN1 | 8525 |
| CLEC3B | 8480 |
| SELP | 8457 |
| ITGB3 | 8291 |
| FN1 | 8284 |
| SYTL4 | 8256 |
| ANXA5 | 8210 |
| CFL1 | 8186 |
| EGF | 8179 |
| CAP1 | 8111 |
| GAS6 | 8063 |
| LY6G6F | 8023 |
| ORM1 | 7971 |
| CALU | 7894 |
| PECAM1 | 7855 |
| SCCPDH | 7787 |
| PROS1 | 7758 |
| MMRN1 | 7714 |
| SERPINE1 | 7483 |
| VEGFA | 7467 |
| ABCC4 | 7434 |
| TAGLN2 | 7367 |
| SPARC | 7339 |
| VCL | 7328 |
| PSAP | 7145 |
| HSPA5 | 7029 |
| F8 | 7022 |
| WDR1 | 6976 |
| VEGFC | 6906 |
| VWF | 6641 |
| TUBA4A | 6484 |
| GTPBP2 | 6331 |
| TMSB4X | 6295 |
| PPBP | 6042 |
| THBS1 | 5951 |
| CD9 | 5940 |
| PF4 | 5707 |
| A1BG | 5559 |
| PFN1 | 5459 |
| PHACTR2 | 5410 |
| PDGFA | 5293 |
| ECM1 | 5176 |
| TGFB1 | 5153 |
| ACTN4 | 5049 |
| OLA1 | 4914 |
| CD109 | 4316 |
| ALB | 3668 |
| RAB27B | 3386 |
| ENDOD1 | 3361 |
| TIMP3 | 3296 |
| CHID1 | 2811 |
| MANF | 2550 |
| PLEK | 1999 |
| CFD | 1984 |
| APOOL | 1609 |
| TTN | 1195 |
| TF | 1102 |
| FLNA | 483 |
| TMX3 | -775 |
| PLG | -1977 |
| PCYOX1L | -2009 |
| CALM1 | -2081 |
| ORM2 | -2564 |
| MAGED2 | -2687 |
| ITIH3 | -3017 |
| SOD1 | -4862 |
| ITIH4 | -6208 |
| SERPINF2 | -6574 |
| BRPF3 | -6615 |
| PPIA | -6766 |
| TGFB2 | -7492 |
| SELENOP | -7771 |
| NHLRC2 | -7835 |
| TGFB3 | -7891 |
| VEGFB | -7929 |
| TEX264 | -8366 |
| CDC37L1 | -8470 |
| PDGFB | -8577 |
| A2M | -9870 |
| FAM3C | -10062 |
| HABP4 | -10921 |
| CTSW | -11117 |
| SERPING1 | -11197 |
| LGALS3BP | -11459 |
IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation
| 512 | |
|---|---|
| set | IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation |
| setSize | 15 |
| pANOVA | 0.0023 |
| s.dist | 0.455 |
| p.adjustANOVA | 0.00804 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CD14 | 9097 |
| TLR4 | 9016 |
| LY96 | 8795 |
| TAB2 | 6964 |
| UBB | 6639 |
| TICAM2 | 6335 |
| TICAM1 | 6307 |
| TAB1 | 5681 |
| UBC | 4439 |
| TAB3 | 3160 |
| MAP3K7 | 2395 |
| UBA52 | 1121 |
| TRAF6 | -229 |
| RPS27A | -6938 |
| IRAK2 | -9548 |
| GeneID | Gene Rank |
|---|---|
| CD14 | 9097 |
| TLR4 | 9016 |
| LY96 | 8795 |
| TAB2 | 6964 |
| UBB | 6639 |
| TICAM2 | 6335 |
| TICAM1 | 6307 |
| TAB1 | 5681 |
| UBC | 4439 |
| TAB3 | 3160 |
| MAP3K7 | 2395 |
| UBA52 | 1121 |
| TRAF6 | -229 |
| RPS27A | -6938 |
| IRAK2 | -9548 |
Lagging Strand Synthesis
| 592 | |
|---|---|
| set | Lagging Strand Synthesis |
| setSize | 20 |
| pANOVA | 0.000463 |
| s.dist | -0.452 |
| p.adjustANOVA | 0.00215 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| POLA1 | -12150 |
| RPA1 | -12004 |
| RFC5 | -11712 |
| POLA2 | -11575 |
| LIG1 | -11053 |
| RFC4 | -10702 |
| FEN1 | -10593 |
| RFC3 | -10489 |
| POLD2 | -10351 |
| PRIM1 | -10191 |
| RPA3 | -8911 |
| RFC1 | -7437 |
| RPA2 | -6306 |
| PCNA | -5969 |
| PRIM2 | -5575 |
| DNA2 | -2858 |
| POLD1 | 204 |
| RFC2 | 4948 |
| POLD4 | 6336 |
| POLD3 | 8885 |
| GeneID | Gene Rank |
|---|---|
| POLA1 | -12150 |
| RPA1 | -12004 |
| RFC5 | -11712 |
| POLA2 | -11575 |
| LIG1 | -11053 |
| RFC4 | -10702 |
| FEN1 | -10593 |
| RFC3 | -10489 |
| POLD2 | -10351 |
| PRIM1 | -10191 |
| RPA3 | -8911 |
| RFC1 | -7437 |
| RPA2 | -6306 |
| PCNA | -5969 |
| PRIM2 | -5575 |
| DNA2 | -2858 |
| POLD1 | 204 |
| RFC2 | 4948 |
| POLD4 | 6336 |
| POLD3 | 8885 |
Prolonged ERK activation events
| 863 | |
|---|---|
| set | Prolonged ERK activation events |
| setSize | 13 |
| pANOVA | 0.00476 |
| s.dist | 0.452 |
| p.adjustANOVA | 0.0147 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MAP2K1 | 9063 |
| MAPK3 | 8953 |
| CRK | 8906 |
| MAPK1 | 7493 |
| RAP1A | 7305 |
| KIDINS220 | 7069 |
| MAP2K2 | 6794 |
| YWHAB | 6385 |
| CRKL | 3966 |
| BRAF | 1308 |
| FRS2 | -3433 |
| NTRK1 | -8193 |
| RAPGEF1 | -9826 |
| GeneID | Gene Rank |
|---|---|
| MAP2K1 | 9063 |
| MAPK3 | 8953 |
| CRK | 8906 |
| MAPK1 | 7493 |
| RAP1A | 7305 |
| KIDINS220 | 7069 |
| MAP2K2 | 6794 |
| YWHAB | 6385 |
| CRKL | 3966 |
| BRAF | 1308 |
| FRS2 | -3433 |
| NTRK1 | -8193 |
| RAPGEF1 | -9826 |
Infection with Mycobacterium tuberculosis
| 524 | |
|---|---|
| set | Infection with Mycobacterium tuberculosis |
| setSize | 26 |
| pANOVA | 7.2e-05 |
| s.dist | 0.45 |
| p.adjustANOVA | 0.000442 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| TLR2 | 9103 |
| MAPK3 | 8953 |
| ENO1 | 8890 |
| RAB7A | 8742 |
| PGK1 | 8672 |
| TRIM27 | 8142 |
| ATP6V1H | 8064 |
| GSK3A | 7760 |
| MAPK1 | 7493 |
| RAB5A | 7103 |
| UBB | 6639 |
| LTF | 6306 |
| CORO1A | 5178 |
| CTSG | 5115 |
| HGS | 4513 |
| UBC | 4439 |
| MRC1 | 3109 |
| KPNB1 | 2430 |
| SFPQ | 2253 |
| KPNA1 | 1296 |
| GeneID | Gene Rank |
|---|---|
| TLR2 | 9103 |
| MAPK3 | 8953 |
| ENO1 | 8890 |
| RAB7A | 8742 |
| PGK1 | 8672 |
| TRIM27 | 8142 |
| ATP6V1H | 8064 |
| GSK3A | 7760 |
| MAPK1 | 7493 |
| RAB5A | 7103 |
| UBB | 6639 |
| LTF | 6306 |
| CORO1A | 5178 |
| CTSG | 5115 |
| HGS | 4513 |
| UBC | 4439 |
| MRC1 | 3109 |
| KPNB1 | 2430 |
| SFPQ | 2253 |
| KPNA1 | 1296 |
| UBA52 | 1121 |
| VPS33B | -2091 |
| DUSP16 | -6655 |
| B2M | -6920 |
| RPS27A | -6938 |
| RNF213 | -11905 |
WNT5A-dependent internalization of FZD4
| 1325 | |
|---|---|
| set | WNT5A-dependent internalization of FZD4 |
| setSize | 13 |
| pANOVA | 0.00502 |
| s.dist | 0.449 |
| p.adjustANOVA | 0.0153 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CLTC | 9000 |
| AP2M1 | 8627 |
| ARRB2 | 8490 |
| CLTA | 8376 |
| AP2S1 | 8026 |
| AP2A2 | 7257 |
| PRKCB | 7097 |
| AP2A1 | 6832 |
| CLTB | 6084 |
| PRKCA | 1132 |
| AP2B1 | -2709 |
| DVL2 | -11152 |
| FZD4 | -11650 |
| GeneID | Gene Rank |
|---|---|
| CLTC | 9000 |
| AP2M1 | 8627 |
| ARRB2 | 8490 |
| CLTA | 8376 |
| AP2S1 | 8026 |
| AP2A2 | 7257 |
| PRKCB | 7097 |
| AP2A1 | 6832 |
| CLTB | 6084 |
| PRKCA | 1132 |
| AP2B1 | -2709 |
| DVL2 | -11152 |
| FZD4 | -11650 |
Packaging Of Telomere Ends
| 802 | |
|---|---|
| set | Packaging Of Telomere Ends |
| setSize | 20 |
| pANOVA | 0.000517 |
| s.dist | 0.448 |
| p.adjustANOVA | 0.00235 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| H2AJ | 9374 |
| H2BC21 | 9283 |
| H2BC12 | 9051 |
| H2BC5 | 8003 |
| H2AC6 | 7934 |
| H2BC11 | 7912 |
| H2BC4 | 7389 |
| H2BC17 | 7285 |
| H2AZ1 | 6036 |
| H2BC9 | 5394 |
| H2BC15 | 5312 |
| TERF2IP | 5040 |
| H2AC20 | 4972 |
| TINF2 | 4592 |
| H2AZ2 | -1209 |
| TERF1 | -3601 |
| POT1 | -4355 |
| TERF2 | -4464 |
| H2BU1 | -6555 |
| ACD | -7800 |
| GeneID | Gene Rank |
|---|---|
| H2AJ | 9374 |
| H2BC21 | 9283 |
| H2BC12 | 9051 |
| H2BC5 | 8003 |
| H2AC6 | 7934 |
| H2BC11 | 7912 |
| H2BC4 | 7389 |
| H2BC17 | 7285 |
| H2AZ1 | 6036 |
| H2BC9 | 5394 |
| H2BC15 | 5312 |
| TERF2IP | 5040 |
| H2AC20 | 4972 |
| TINF2 | 4592 |
| H2AZ2 | -1209 |
| TERF1 | -3601 |
| POT1 | -4355 |
| TERF2 | -4464 |
| H2BU1 | -6555 |
| ACD | -7800 |
ATF6 (ATF6-alpha) activates chaperone genes
| 20 | |
|---|---|
| set | ATF6 (ATF6-alpha) activates chaperone genes |
| setSize | 10 |
| pANOVA | 0.0144 |
| s.dist | 0.447 |
| p.adjustANOVA | 0.0352 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ATF6 | 8464 |
| NFYC | 7653 |
| HSPA5 | 7029 |
| CALR | 6340 |
| ATF4 | 6237 |
| DDIT3 | 4906 |
| NFYA | 3506 |
| HSP90B1 | 2059 |
| XBP1 | -1579 |
| NFYB | -9964 |
| GeneID | Gene Rank |
|---|---|
| ATF6 | 8464 |
| NFYC | 7653 |
| HSPA5 | 7029 |
| CALR | 6340 |
| ATF4 | 6237 |
| DDIT3 | 4906 |
| NFYA | 3506 |
| HSP90B1 | 2059 |
| XBP1 | -1579 |
| NFYB | -9964 |
Membrane binding and targetting of GAG proteins
| 632 | |
|---|---|
| set | Membrane binding and targetting of GAG proteins |
| setSize | 13 |
| pANOVA | 0.0054 |
| s.dist | 0.446 |
| p.adjustANOVA | 0.0162 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| UBAP1 | 8701 |
| VPS37C | 8010 |
| TSG101 | 7786 |
| MVB12A | 7400 |
| UBB | 6639 |
| VPS37A | 6467 |
| MVB12B | 5175 |
| UBC | 4439 |
| VPS28 | 4199 |
| VPS37B | 3908 |
| UBA52 | 1121 |
| RPS27A | -6938 |
| NMT2 | -12035 |
| GeneID | Gene Rank |
|---|---|
| UBAP1 | 8701 |
| VPS37C | 8010 |
| TSG101 | 7786 |
| MVB12A | 7400 |
| UBB | 6639 |
| VPS37A | 6467 |
| MVB12B | 5175 |
| UBC | 4439 |
| VPS28 | 4199 |
| VPS37B | 3908 |
| UBA52 | 1121 |
| RPS27A | -6938 |
| NMT2 | -12035 |
Synthesis And Processing Of GAG, GAGPOL Polyproteins
| 1162 | |
|---|---|
| set | Synthesis And Processing Of GAG, GAGPOL Polyproteins |
| setSize | 13 |
| pANOVA | 0.0054 |
| s.dist | 0.446 |
| p.adjustANOVA | 0.0162 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| UBAP1 | 8701 |
| VPS37C | 8010 |
| TSG101 | 7786 |
| MVB12A | 7400 |
| UBB | 6639 |
| VPS37A | 6467 |
| MVB12B | 5175 |
| UBC | 4439 |
| VPS28 | 4199 |
| VPS37B | 3908 |
| UBA52 | 1121 |
| RPS27A | -6938 |
| NMT2 | -12035 |
| GeneID | Gene Rank |
|---|---|
| UBAP1 | 8701 |
| VPS37C | 8010 |
| TSG101 | 7786 |
| MVB12A | 7400 |
| UBB | 6639 |
| VPS37A | 6467 |
| MVB12B | 5175 |
| UBC | 4439 |
| VPS28 | 4199 |
| VPS37B | 3908 |
| UBA52 | 1121 |
| RPS27A | -6938 |
| NMT2 | -12035 |
Resolution of AP sites via the multiple-nucleotide patch replacement pathway
| 999 | |
|---|---|
| set | Resolution of AP sites via the multiple-nucleotide patch replacement pathway |
| setSize | 24 |
| pANOVA | 0.000157 |
| s.dist | -0.446 |
| p.adjustANOVA | 0.000836 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PARP2 | -12221 |
| RPA1 | -12004 |
| PARP1 | -11764 |
| RFC5 | -11712 |
| POLE3 | -11581 |
| LIG1 | -11053 |
| RFC4 | -10702 |
| FEN1 | -10593 |
| RFC3 | -10489 |
| POLD2 | -10351 |
| APEX1 | -10332 |
| POLE2 | -9941 |
| RPA3 | -8911 |
| POLE | -7579 |
| POLB | -7537 |
| RFC1 | -7437 |
| RPA2 | -6306 |
| PCNA | -5969 |
| PARG | -658 |
| POLD1 | 204 |
| GeneID | Gene Rank |
|---|---|
| PARP2 | -12221 |
| RPA1 | -12004 |
| PARP1 | -11764 |
| RFC5 | -11712 |
| POLE3 | -11581 |
| LIG1 | -11053 |
| RFC4 | -10702 |
| FEN1 | -10593 |
| RFC3 | -10489 |
| POLD2 | -10351 |
| APEX1 | -10332 |
| POLE2 | -9941 |
| RPA3 | -8911 |
| POLE | -7579 |
| POLB | -7537 |
| RFC1 | -7437 |
| RPA2 | -6306 |
| PCNA | -5969 |
| PARG | -658 |
| POLD1 | 204 |
| RFC2 | 4948 |
| POLE4 | 5518 |
| POLD4 | 6336 |
| POLD3 | 8885 |
Regulation of glycolysis by fructose 2,6-bisphosphate metabolism
| 983 | |
|---|---|
| set | Regulation of glycolysis by fructose 2,6-bisphosphate metabolism |
| setSize | 11 |
| pANOVA | 0.0109 |
| s.dist | 0.443 |
| p.adjustANOVA | 0.0279 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PRKACA | 9429 |
| PFKFB4 | 9271 |
| PFKFB3 | 8656 |
| PPP2CA | 8234 |
| PFKFB2 | 7946 |
| PPP2CB | 7712 |
| PPP2R1A | 4589 |
| PPP2R5D | 2421 |
| PPP2R1B | -241 |
| PFKFB1 | -8393 |
| PRKACB | -11959 |
| GeneID | Gene Rank |
|---|---|
| PRKACA | 9429 |
| PFKFB4 | 9271 |
| PFKFB3 | 8656 |
| PPP2CA | 8234 |
| PFKFB2 | 7946 |
| PPP2CB | 7712 |
| PPP2R1A | 4589 |
| PPP2R5D | 2421 |
| PPP2R1B | -241 |
| PFKFB1 | -8393 |
| PRKACB | -11959 |
Signal amplification
| 1070 | |
|---|---|
| set | Signal amplification |
| setSize | 28 |
| pANOVA | 5.41e-05 |
| s.dist | 0.441 |
| p.adjustANOVA | 0.000346 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GNA15 | 9452 |
| GNG10 | 9349 |
| PLA2G4A | 9180 |
| MAPK14 | 9104 |
| GNAQ | 8993 |
| GNG5 | 8815 |
| GNB1 | 8294 |
| GNB2 | 8141 |
| GNAI2 | 8075 |
| GNAI3 | 7953 |
| P2RY1 | 7852 |
| GNB4 | 7336 |
| GNG11 | 6495 |
| GNA13 | 5836 |
| TBXA2R | 5148 |
| P2RY12 | 4821 |
| GNG8 | 4296 |
| GNAI1 | 3329 |
| GNA11 | 3259 |
| GNG3 | 890 |
| GeneID | Gene Rank |
|---|---|
| GNA15 | 9452 |
| GNG10 | 9349 |
| PLA2G4A | 9180 |
| MAPK14 | 9104 |
| GNAQ | 8993 |
| GNG5 | 8815 |
| GNB1 | 8294 |
| GNB2 | 8141 |
| GNAI2 | 8075 |
| GNAI3 | 7953 |
| P2RY1 | 7852 |
| GNB4 | 7336 |
| GNG11 | 6495 |
| GNA13 | 5836 |
| TBXA2R | 5148 |
| P2RY12 | 4821 |
| GNG8 | 4296 |
| GNAI1 | 3329 |
| GNA11 | 3259 |
| GNG3 | 890 |
| GNB5 | 512 |
| GNG4 | -2154 |
| GNB3 | -2397 |
| AAMP | -3636 |
| GNG7 | -5198 |
| GNG2 | -7795 |
| SRC | -8820 |
| GNGT2 | -12086 |
Biotin transport and metabolism
| 114 | |
|---|---|
| set | Biotin transport and metabolism |
| setSize | 11 |
| pANOVA | 0.0116 |
| s.dist | -0.44 |
| p.adjustANOVA | 0.0291 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| BTD | -12170 |
| MCCC2 | -11857 |
| HLCS | -11710 |
| ACACB | -9957 |
| MCCC1 | -8976 |
| PCCA | -8664 |
| PCCB | -7976 |
| PDZD11 | -6288 |
| SLC5A6 | -5629 |
| ACACA | 5315 |
| PC | 9263 |
| GeneID | Gene Rank |
|---|---|
| BTD | -12170 |
| MCCC2 | -11857 |
| HLCS | -11710 |
| ACACB | -9957 |
| MCCC1 | -8976 |
| PCCA | -8664 |
| PCCB | -7976 |
| PDZD11 | -6288 |
| SLC5A6 | -5629 |
| ACACA | 5315 |
| PC | 9263 |
MyD88:MAL(TIRAP) cascade initiated on plasma membrane
| 689 | |
|---|---|
| set | MyD88:MAL(TIRAP) cascade initiated on plasma membrane |
| setSize | 92 |
| pANOVA | 3.03e-13 |
| s.dist | 0.44 |
| p.adjustANOVA | 1.53e-11 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| S100A12 | 9515 |
| CD36 | 9444 |
| NKIRAS2 | 9353 |
| DUSP3 | 9280 |
| APP | 9177 |
| IRAK3 | 9107 |
| MAPK14 | 9104 |
| TLR2 | 9103 |
| CD14 | 9097 |
| MAP2K1 | 9063 |
| TLR4 | 9016 |
| MAPK3 | 8953 |
| TLR1 | 8932 |
| MAP2K6 | 8887 |
| TLR6 | 8840 |
| LY96 | 8795 |
| MAP2K3 | 8748 |
| NOD2 | 8442 |
| MAPKAPK3 | 8382 |
| PELI2 | 8314 |
| GeneID | Gene Rank |
|---|---|
| S100A12 | 9515 |
| CD36 | 9444 |
| NKIRAS2 | 9353 |
| DUSP3 | 9280 |
| APP | 9177 |
| IRAK3 | 9107 |
| MAPK14 | 9104 |
| TLR2 | 9103 |
| CD14 | 9097 |
| MAP2K1 | 9063 |
| TLR4 | 9016 |
| MAPK3 | 8953 |
| TLR1 | 8932 |
| MAP2K6 | 8887 |
| TLR6 | 8840 |
| LY96 | 8795 |
| MAP2K3 | 8748 |
| NOD2 | 8442 |
| MAPKAPK3 | 8382 |
| PELI2 | 8314 |
| PPP2CA | 8234 |
| MYD88 | 8136 |
| MEF2A | 8009 |
| CHUK | 7966 |
| PELI3 | 7716 |
| PPP2CB | 7712 |
| RPS6KA1 | 7695 |
| MAPK1 | 7493 |
| BTK | 7206 |
| TAB2 | 6964 |
| MAP2K4 | 6866 |
| NFKBIA | 6807 |
| PELI1 | 6715 |
| UBB | 6639 |
| NFKB1 | 6277 |
| FBXW11 | 6196 |
| MAP3K8 | 6160 |
| IRAK1 | 6131 |
| ATF1 | 5706 |
| TAB1 | 5681 |
| TIRAP | 5640 |
| UBE2V1 | 5637 |
| TNIP2 | 5552 |
| FOS | 5460 |
| IKBKG | 5377 |
| MAP3K1 | 5121 |
| ECSIT | 4918 |
| PPP2R1A | 4589 |
| UBC | 4439 |
| DUSP6 | 4357 |
| MAPK10 | 4325 |
| SKP1 | 4287 |
| MAPKAPK2 | 4054 |
| SOCS1 | 3947 |
| MAPK11 | 3826 |
| JUN | 3722 |
| TAB3 | 3160 |
| RPS6KA2 | 3087 |
| RPS6KA3 | 2973 |
| PPP2R5D | 2421 |
| MAP3K7 | 2395 |
| ATF2 | 2085 |
| UBE2N | 1936 |
| MAP2K7 | 1654 |
| AGER | 1294 |
| VRK3 | 1281 |
| UBA52 | 1121 |
| ELK1 | 1040 |
| RIPK2 | 1025 |
| NKIRAS1 | 375 |
| NFKBIB | -152 |
| TRAF6 | -229 |
| PPP2R1B | -241 |
| HMGB1 | -252 |
| MEF2C | -293 |
| NFKB2 | -1165 |
| MAPK7 | -1337 |
| CREB1 | -1378 |
| RELA | -1803 |
| DUSP7 | -3211 |
| BTRC | -4924 |
| IKBKB | -5386 |
| S100B | -5457 |
| DUSP4 | -6287 |
| RPS27A | -6938 |
| MAPK9 | -7068 |
| MAPK8 | -9428 |
| IRAK2 | -9548 |
| SIGIRR | -10752 |
| CUL1 | -11330 |
| RPS6KA5 | -11594 |
| NOD1 | -12263 |
Toll Like Receptor 2 (TLR2) Cascade
| 1237 | |
|---|---|
| set | Toll Like Receptor 2 (TLR2) Cascade |
| setSize | 92 |
| pANOVA | 3.03e-13 |
| s.dist | 0.44 |
| p.adjustANOVA | 1.53e-11 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| S100A12 | 9515 |
| CD36 | 9444 |
| NKIRAS2 | 9353 |
| DUSP3 | 9280 |
| APP | 9177 |
| IRAK3 | 9107 |
| MAPK14 | 9104 |
| TLR2 | 9103 |
| CD14 | 9097 |
| MAP2K1 | 9063 |
| TLR4 | 9016 |
| MAPK3 | 8953 |
| TLR1 | 8932 |
| MAP2K6 | 8887 |
| TLR6 | 8840 |
| LY96 | 8795 |
| MAP2K3 | 8748 |
| NOD2 | 8442 |
| MAPKAPK3 | 8382 |
| PELI2 | 8314 |
| GeneID | Gene Rank |
|---|---|
| S100A12 | 9515 |
| CD36 | 9444 |
| NKIRAS2 | 9353 |
| DUSP3 | 9280 |
| APP | 9177 |
| IRAK3 | 9107 |
| MAPK14 | 9104 |
| TLR2 | 9103 |
| CD14 | 9097 |
| MAP2K1 | 9063 |
| TLR4 | 9016 |
| MAPK3 | 8953 |
| TLR1 | 8932 |
| MAP2K6 | 8887 |
| TLR6 | 8840 |
| LY96 | 8795 |
| MAP2K3 | 8748 |
| NOD2 | 8442 |
| MAPKAPK3 | 8382 |
| PELI2 | 8314 |
| PPP2CA | 8234 |
| MYD88 | 8136 |
| MEF2A | 8009 |
| CHUK | 7966 |
| PELI3 | 7716 |
| PPP2CB | 7712 |
| RPS6KA1 | 7695 |
| MAPK1 | 7493 |
| BTK | 7206 |
| TAB2 | 6964 |
| MAP2K4 | 6866 |
| NFKBIA | 6807 |
| PELI1 | 6715 |
| UBB | 6639 |
| NFKB1 | 6277 |
| FBXW11 | 6196 |
| MAP3K8 | 6160 |
| IRAK1 | 6131 |
| ATF1 | 5706 |
| TAB1 | 5681 |
| TIRAP | 5640 |
| UBE2V1 | 5637 |
| TNIP2 | 5552 |
| FOS | 5460 |
| IKBKG | 5377 |
| MAP3K1 | 5121 |
| ECSIT | 4918 |
| PPP2R1A | 4589 |
| UBC | 4439 |
| DUSP6 | 4357 |
| MAPK10 | 4325 |
| SKP1 | 4287 |
| MAPKAPK2 | 4054 |
| SOCS1 | 3947 |
| MAPK11 | 3826 |
| JUN | 3722 |
| TAB3 | 3160 |
| RPS6KA2 | 3087 |
| RPS6KA3 | 2973 |
| PPP2R5D | 2421 |
| MAP3K7 | 2395 |
| ATF2 | 2085 |
| UBE2N | 1936 |
| MAP2K7 | 1654 |
| AGER | 1294 |
| VRK3 | 1281 |
| UBA52 | 1121 |
| ELK1 | 1040 |
| RIPK2 | 1025 |
| NKIRAS1 | 375 |
| NFKBIB | -152 |
| TRAF6 | -229 |
| PPP2R1B | -241 |
| HMGB1 | -252 |
| MEF2C | -293 |
| NFKB2 | -1165 |
| MAPK7 | -1337 |
| CREB1 | -1378 |
| RELA | -1803 |
| DUSP7 | -3211 |
| BTRC | -4924 |
| IKBKB | -5386 |
| S100B | -5457 |
| DUSP4 | -6287 |
| RPS27A | -6938 |
| MAPK9 | -7068 |
| MAPK8 | -9428 |
| IRAK2 | -9548 |
| SIGIRR | -10752 |
| CUL1 | -11330 |
| RPS6KA5 | -11594 |
| NOD1 | -12263 |
Toll Like Receptor TLR1:TLR2 Cascade
| 1243 | |
|---|---|
| set | Toll Like Receptor TLR1:TLR2 Cascade |
| setSize | 92 |
| pANOVA | 3.03e-13 |
| s.dist | 0.44 |
| p.adjustANOVA | 1.53e-11 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| S100A12 | 9515 |
| CD36 | 9444 |
| NKIRAS2 | 9353 |
| DUSP3 | 9280 |
| APP | 9177 |
| IRAK3 | 9107 |
| MAPK14 | 9104 |
| TLR2 | 9103 |
| CD14 | 9097 |
| MAP2K1 | 9063 |
| TLR4 | 9016 |
| MAPK3 | 8953 |
| TLR1 | 8932 |
| MAP2K6 | 8887 |
| TLR6 | 8840 |
| LY96 | 8795 |
| MAP2K3 | 8748 |
| NOD2 | 8442 |
| MAPKAPK3 | 8382 |
| PELI2 | 8314 |
| GeneID | Gene Rank |
|---|---|
| S100A12 | 9515 |
| CD36 | 9444 |
| NKIRAS2 | 9353 |
| DUSP3 | 9280 |
| APP | 9177 |
| IRAK3 | 9107 |
| MAPK14 | 9104 |
| TLR2 | 9103 |
| CD14 | 9097 |
| MAP2K1 | 9063 |
| TLR4 | 9016 |
| MAPK3 | 8953 |
| TLR1 | 8932 |
| MAP2K6 | 8887 |
| TLR6 | 8840 |
| LY96 | 8795 |
| MAP2K3 | 8748 |
| NOD2 | 8442 |
| MAPKAPK3 | 8382 |
| PELI2 | 8314 |
| PPP2CA | 8234 |
| MYD88 | 8136 |
| MEF2A | 8009 |
| CHUK | 7966 |
| PELI3 | 7716 |
| PPP2CB | 7712 |
| RPS6KA1 | 7695 |
| MAPK1 | 7493 |
| BTK | 7206 |
| TAB2 | 6964 |
| MAP2K4 | 6866 |
| NFKBIA | 6807 |
| PELI1 | 6715 |
| UBB | 6639 |
| NFKB1 | 6277 |
| FBXW11 | 6196 |
| MAP3K8 | 6160 |
| IRAK1 | 6131 |
| ATF1 | 5706 |
| TAB1 | 5681 |
| TIRAP | 5640 |
| UBE2V1 | 5637 |
| TNIP2 | 5552 |
| FOS | 5460 |
| IKBKG | 5377 |
| MAP3K1 | 5121 |
| ECSIT | 4918 |
| PPP2R1A | 4589 |
| UBC | 4439 |
| DUSP6 | 4357 |
| MAPK10 | 4325 |
| SKP1 | 4287 |
| MAPKAPK2 | 4054 |
| SOCS1 | 3947 |
| MAPK11 | 3826 |
| JUN | 3722 |
| TAB3 | 3160 |
| RPS6KA2 | 3087 |
| RPS6KA3 | 2973 |
| PPP2R5D | 2421 |
| MAP3K7 | 2395 |
| ATF2 | 2085 |
| UBE2N | 1936 |
| MAP2K7 | 1654 |
| AGER | 1294 |
| VRK3 | 1281 |
| UBA52 | 1121 |
| ELK1 | 1040 |
| RIPK2 | 1025 |
| NKIRAS1 | 375 |
| NFKBIB | -152 |
| TRAF6 | -229 |
| PPP2R1B | -241 |
| HMGB1 | -252 |
| MEF2C | -293 |
| NFKB2 | -1165 |
| MAPK7 | -1337 |
| CREB1 | -1378 |
| RELA | -1803 |
| DUSP7 | -3211 |
| BTRC | -4924 |
| IKBKB | -5386 |
| S100B | -5457 |
| DUSP4 | -6287 |
| RPS27A | -6938 |
| MAPK9 | -7068 |
| MAPK8 | -9428 |
| IRAK2 | -9548 |
| SIGIRR | -10752 |
| CUL1 | -11330 |
| RPS6KA5 | -11594 |
| NOD1 | -12263 |
Here is the session info with all the versions of packages used.
sessionInfo()
## R version 4.0.2 (2020-06-22)
## Platform: x86_64-pc-linux-gnu (64-bit)
## Running under: Ubuntu 18.04.5 LTS
##
## Matrix products: default
## BLAS: /usr/lib/x86_64-linux-gnu/blas/libblas.so.3.7.1
## LAPACK: /usr/lib/x86_64-linux-gnu/lapack/liblapack.so.3.7.1
##
## locale:
## [1] LC_CTYPE=en_US.UTF-8 LC_NUMERIC=C
## [3] LC_TIME=en_US.UTF-8 LC_COLLATE=en_US.UTF-8
## [5] LC_MONETARY=en_US.UTF-8 LC_MESSAGES=en_US.UTF-8
## [7] LC_PAPER=en_US.UTF-8 LC_NAME=C
## [9] LC_ADDRESS=C LC_TELEPHONE=C
## [11] LC_MEASUREMENT=en_US.UTF-8 LC_IDENTIFICATION=C
##
## attached base packages:
## [1] parallel stats4 stats graphics grDevices utils datasets
## [8] methods base
##
## other attached packages:
## [1] pkgload_1.1.0 GGally_2.0.0
## [3] beeswarm_0.2.3 gtools_3.8.2
## [5] echarts4r_0.3.2 mitch_1.0.6
## [7] MASS_7.3-52 fgsea_1.14.0
## [9] gplots_3.0.3 DESeq2_1.28.1
## [11] SummarizedExperiment_1.18.1 DelayedArray_0.14.0
## [13] matrixStats_0.56.0 Biobase_2.48.0
## [15] GenomicRanges_1.40.0 GenomeInfoDb_1.24.2
## [17] IRanges_2.22.2 S4Vectors_0.26.1
## [19] BiocGenerics_0.34.0 reshape2_1.4.4
## [21] forcats_0.5.0 stringr_1.4.0
## [23] dplyr_1.0.0 purrr_0.3.4
## [25] readr_1.3.1 tidyr_1.1.0
## [27] tibble_3.0.1 ggplot2_3.3.2
## [29] tidyverse_1.3.0
##
## loaded via a namespace (and not attached):
## [1] colorspace_1.4-1 ellipsis_0.3.1 rprojroot_1.3-2
## [4] XVector_0.28.0 fs_1.4.2 rstudioapi_0.11
## [7] bit64_0.9-7 AnnotationDbi_1.50.1 fansi_0.4.1
## [10] lubridate_1.7.9 xml2_1.3.2 splines_4.0.2
## [13] geneplotter_1.66.0 knitr_1.29 jsonlite_1.7.0
## [16] broom_0.5.6 annotate_1.66.0 dbplyr_1.4.4
## [19] shiny_1.5.0 compiler_4.0.2 httr_1.4.1
## [22] backports_1.1.8 assertthat_0.2.1 Matrix_1.2-18
## [25] fastmap_1.0.1 cli_2.0.2 later_1.1.0.1
## [28] htmltools_0.5.0 tools_4.0.2 gtable_0.3.0
## [31] glue_1.4.1 GenomeInfoDbData_1.2.3 fastmatch_1.1-0
## [34] Rcpp_1.0.4.6 cellranger_1.1.0 vctrs_0.3.1
## [37] gdata_2.18.0 nlme_3.1-148 xfun_0.15
## [40] testthat_2.3.2 rvest_0.3.5 mime_0.9
## [43] lifecycle_0.2.0 XML_3.99-0.3 zlibbioc_1.34.0
## [46] scales_1.1.1 hms_0.5.3 promises_1.1.1
## [49] RColorBrewer_1.1-2 yaml_2.2.1 memoise_1.1.0
## [52] gridExtra_2.3 reshape_0.8.8 stringi_1.4.6
## [55] RSQLite_2.2.0 highr_0.8 genefilter_1.70.0
## [58] desc_1.2.0 caTools_1.18.0 BiocParallel_1.22.0
## [61] rlang_0.4.6 pkgconfig_2.0.3 bitops_1.0-6
## [64] evaluate_0.14 lattice_0.20-41 htmlwidgets_1.5.1
## [67] bit_1.1-15.2 tidyselect_1.1.0 plyr_1.8.6
## [70] magrittr_1.5 R6_2.4.1 generics_0.0.2
## [73] DBI_1.1.0 pillar_1.4.4 haven_2.3.1
## [76] withr_2.2.0 survival_3.2-3 RCurl_1.98-1.2
## [79] modelr_0.1.8 crayon_1.3.4 KernSmooth_2.23-17
## [82] rmarkdown_2.3 locfit_1.5-9.4 grid_4.0.2
## [85] readxl_1.3.1 data.table_1.12.8 blob_1.2.1
## [88] reprex_0.3.0 digest_0.6.25 pbmcapply_1.5.0
## [91] xtable_1.8-4 httpuv_1.5.4 munsell_0.5.0
END of report